head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel g sk changing registered number printed uk paper used annual report production document made post consumer waste pulp bleached using totally chlorine free process feel better live longer glaxosmithkline annual report wwwgskcomavailable online year significant change gsk review progress visit wwwgskcomannualreport website glaxosmithklines website wwwgskcom gives additional information group notwithstanding references make annual report glaxosmithklines website none information made available website constitutes part annual report shall deemed incorporated reference herein cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report contents business review performance overview business review financial trends discusses financial products intellectual property competition nonfinancial activities resources global manufacturing supply development performance research development outlines employees factors including trends responsibility principal risks uncertainties regulation likely affect future world market economy outlook development financial review financial position resources risk factors governance remuneration financial review discusses management structures governance governance remuneration procedures also sets board remuneration policies operated corporate executive team directors corporate governance policy executive team members dialogue shareholders internal control framework committee reports financial statements remuneration policy director terms conditions financial statements provide summary groups financial director senior management remuneration performance throughout directors interests position st december directors interests contracts consolidated financial statements prepared accordance ifrs adopted european union also financial statements ifrs issued international directors statement responsibilities accounting standards board independent auditors report financial statements notes financial statements shareholder information financial statements glaxosmithkline plc includes full product prepared uk gaap development pipeline discusses shareholder return form dividends share price movements shareholder information quarterly trend five year record product development pipeline share price dividends nature trading market annual general meeting investor relations registrar taxation information shareholders glossary terms index gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notice regarding limitations director liability english law uk companies act safe harbour limits liability directors respect statements omissions report directors contained pages english law directors would liable company third party report directors contains errors result recklessness knowing misstatement dishonest concealment material fact would otherwise liable report directors pages inclusive comprise report directors drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law chairman ceo summary strategy delivering believe gsk moving position deliver longterm financial performance sustainable basis shareholders sir christopher gent andrew witty chairman chief executive officer gsk annual report chairman ceo summary dear shareholder continue look make better decisions around pipeline progression maintain strategy increase level since last annual report gsk made significant progress externally sourced compounds pipeline transform business model optionbased agreements strategy delivering believe gsk moving addition reducing rd investment associated position deliver longterm financial performance infrastructure therapy areas believe prospects sustainable basis shareholders successful registration launch differentiated medicines low return sales growth saw gsk return sales growth strategic based investment made late stage pipeline priority diversify drive growth key investment areas longterm sales expectation estimate projected rate rd emerging markets consumer healthcare vaccines return around believe improvement supported growth industry average last ten years longterm goal go realise aspirational rate return gsks developed many engines growth rd around company increased diversification helping reduce risk lower sales volatility evident responsive flexible open gsk absorbed impact losing billion equally important gsks financial social responsibilities sales genericisation us market ensure longterm success sustainability business course sales influenza products governments determined make company responsive responding hn pandemic also contributed sales flexible open societys expectations many years invested developing influenza continue make progress many areas improving capabilities five months declared hn global access medicines enhancing research opportunities flu pandemic gsk able supply approved vaccine neglected tropical diseases raising ethical standards governments across world continuing work conducting research commercial activities closely respond needs transparent way run business new product momentum sustained progressive dividend remain focused broadening strengthening one ftse top dividend payers strongly believe product portfolio last year gsk received product approvals importance returning funds shareholders line completed new filings gsks progressive dividend policy board approved total dividend year pence increase last last years gsk obtained fda approvals years dividend new medicines vaccines company improving longterm prospects next months potential launch conclusion making progress strategic number brand new medicines vaccines including benlysta priorities seen good progress sales performance would first new treatment systemic lupus maintaining strong focus cost reduction years delivering new medicines vaccines consumer momentum set continued goal maintaining healthcare products continue take new initiatives around assets late stage pipeline build societys trust accomplishing would like recognise enormous contribution employees improving return investment wide network partners remain mindful need improve demonstrate better returns investment across entire business doubt operating challenging continue implement restructuring programme simplify environment however successful execution operations reduce costs programme delivered strategy believe gsks longterm prospects improving billion annual savings enhance position leadingedge healthcare company particular research development strongly focused allocating capital areas get best return investment sir christopher gent andrew witty chairman chief executive officer gsk annual report strategy focused delivering three strategic priorities transform gsk company delivers growth less risk improved longterm financial performance successful sustainable business must also fulfil social responsibilities making company responsive flexible open strategic priorities grow diversified global business diversifying business create balanced product portfolio move away reliance traditional white pill western markets investing key growth areas emerging markets japan vaccines consumer healthcare business deliver products value aim sustain industryleading pipeline products ensuring demonstrate value healthcare providers rd strategy built around focusing best science diversifying externalisation research improving returns investment simplify operating model gsk large complex organisation transforming operating model reduce complexities improve efficiency reduce costs updates progress priorities measures operate responsibility integrity please visit website wwwgskcomannualreport gsk annual report discover world gsk online chosen twelve case studies demonstrate progress strategic priorities show gsk changing stories viewed online wwwgskcomannualreport gsk annual report performance overview cer growth earnings per share major restructuring cer growth free cash flow total shareholder return gsk annual report pp weiver ssenisub key performance indicators strategies focused business around delivery three strategic priorities turnover bn grow diversified global business broadening balancing portfolio diversifying new product areas capturing opportunities exist beyond established geographic footprint pence deliver products value transforming rd ensure deliver current pipeline also able sustain flow products years come glaxosmithkline total return index glaxosmithkline pharma peers return index ftse total return index calculation cer growth described calculation results major restructuring described note financial statements presentation financial statements simplifying operating model calculation free cash flow described simplifying operating model ensure fit purpose able support business cost efficient way performance overview measures progress use number measures track progress made good progress year number strategic priorities medium long notable successes term include following performance core pharmaceuticals core pharmaceuticals vaccines businesses vaccines businesses delivered sales billion grew year excludes genericised products avandia influenza products including pandemic products sales billion diversification sales sales white pillwestern markets fell turnover contribution emerging markets overall sales emerging markets pharmaceutical sales growth business grew nearly billion representing group turnover completed bolton acquisitions growth consumer healthcare market share consumer healthcare market share gains delivered otc oral healthcare businesses share declined nutritional healthcare consumer healthcare sales grew billion growth categories otc oral healthcare nutritional healthcare expansion japanese business sales reached billion driven adoair relenza products launched last three years contributed around million sales build biopharmaceutical portfolio arzerra launched usa positive opinion received prolia positive phase iii data announced benlysta around pipeline comprises biopharmaceutical assets contribution sales new products new pharmaceutical products launched since contributed sales billion billion including hn pandemic vaccine number reimbursable product approvals received product approvals completed filings new filings last three years obtained fda approvals new molecular entities vaccines company sustaining latestage pipeline maintained around assets phase iii registration five new programmes entering phase iii enhanced rd productivity increased projected rate return based investment externalisation drug discovery made late stage pipeline expected future longterm sales performance around longterm goal improve rate return rd around externalised approximately discovery research external partners delivery major restructuring programme annual cost savings billion already achieved programme expanded deliver annual savings billion gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp gsk annual report pp weiver ssenisub report directors report directors performance overview provides users financial financial trends products intellectual property competition statements complete global manufacturing supply picture gsk supplements research development employees information financial responsibility statements discussion regulation aspects activities world market economy outlook financial review future environment financial position resources operate risk factors financial review board corporate executive team governance policy dialogue shareholders share capital control business review donations political organisations discusses financial nonfinancial political expenditure activities resources development performance annual general meeting outlines factors including internal control framework trends principal risks uncertainties committee reports likely affect future development combined code us law regulation corporate governance discusses management structures governance procedures includes disclosures letter chairman remuneration compliance combined code corporate committee governance financial reporting council remuneration policy combined code us laws regulation executive director terms conditions nonexecutive director terms conditions fees remuneration report directors senior management remuneration annual remuneration sets remuneration policies operated nonexecutive directors remuneration directors corporate executive directors interests team cet members disclosures incentive plans directors remuneration including required pension benefits large mediumsized companies directors senior management groups accounts reports regulations directors interests contracts pp noitarenumer dna ecnanrevog pp stnemetats laicnanif pp noitamrofni redloherahsgsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial trends growth growth total results cer cer turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p results major restructuring turnover cost sales selling general administration research development operating income operating profit profit taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p research development total pharmaceuticals consumer healthcare total net finance cost cover total net finance costs cover times times times net finance cost cover profit tax plus net finance costs divided net finance costs tax rate total tax rate major restructuring borrowings net debt gearing gearing ratio calculated net debt percentage total equity cer represents growth constant exchange rates sterling represents growth actual exchange rates see calculation results major restructuring described note financial statements presentation financial statements gsk annual report pp weiver ssenisub history development company results major restructuring glaxosmithkline plc public limited company incorporated october board approved implementation th december english law shares listed detailed formal plan gsk announced significant new london stock exchange new york stock exchange operational excellence programme improve effectiveness th december company acquired glaxo wellcome productivity operations second formal plan representing plc smithkline beecham plc english public limited significant expansion operational excellence programme companies way scheme arrange ment merger approved board announced february two companies gsk subsidiary associated expansion approved board announced undertakings constitute major global healthcare group engaged february total costs implementation creation discovery development manufacture marketing expanded programme expected increase billion pharma ceutical consumer healthrelated products approximately billion incurred period programme expected deliver total gsk corporate head office london us annual pretax savings approximately billion headquarters research triangle park north carolina savings realised across business gsk presents restructuring operations countries products sold costs incurred solely direct result operational excellence countries programme separate column income statement titled annual report summary major restructuring addition restructuring costs operational excellence programme major restructuring column report annual report glaxosmithkline plc year income statement includes restructuring costs incurred solely ended st december prepared accordance united direct result restructuring programmes follow kingdom requirements approved board directors relate material acquisitions operations acquired th february published th february business overlap extensively gsks existing operations summary year intended shareholder needing billion million acquisition reliant pharmaceuticals full detail annual report produced separate december billion billion acquisition document issued shareholders summary stiefel laboratories july acquisitions since constitute set summary financial statements defined october meet criteria section companies act annual report groups results costs operational excellence issued shareholders elected receive programme acquisitionrelated restructuring programmes documents available gsks website meeting criteria described described results report glaxosmithkline group gsk means major restructuring presentation gsk intends glaxosmithkline plc subsidiary undertakings company apply consistently future major restructuring programmes means glaxo smithkline plc glaxosmithkline share means material impact gsks operating results ordinary share glaxosmithkline plc p american depositary manner gsks business conducted adopted shares ads represent two glaxosmithkline shares show clearly groups results costs restructuring programmes management believes brand names presentation assists shareholders gaining clearer understanding brand names appearing italics throughout report groups financial performance making projections trademarks either owned andor licensed glaxosmithkline future financial performance results include costs associated companies exception baycol levitra virtue size nature limited comparative value trademarks bayer benlysta trademark human genome presentation also consistent way management science bonivabonviva trademark roche citrucel trademark assesses groups financial performance merrell pharmaceuticals volibris trademark gilead nicoderm trademark elan johnson johnson merrell novartis cer growth sanofiaventis glaxosmithkline prolia trademark amgen order illustrate underlying performance groups vesicare trademark astellas pharmaceuticals many countries practice discuss results terms constant exchange rate yamanouchi pharmaceuticals certain countries cer growth represents growth calculated exchange used certain countries licence group rates used determine results overseas companies sterling remained unchanged used previous currencies year cer represents growth constant exchange rates currencies influence groups results remain represents growth actual exchange rates us dollar euro yen sterling details exchange rates used group given note exchange commentaries report presented terms cer rates unless otherwise stated average sterling exchange rates weaker exchange rates us dollar euro yen compared group operates many countries earns revenues however result significant currency movements incurs costs many currencies results group seen q year end sterling exchange rates actually reported sterling affected movements exchange rates stronger three currencies compared sterling currencies average exchange rates st december prevailing period used translate results cash flows overseas subsidiaries associates joint ventures sterling period end rates used translate net assets entities gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp products intellectual property competition pharmaceutical products within pharmaceutical industry introduction new gsks principal pharmaceutical products currently directed products processes competitors may affect pricing nine main therapeutic areas including dermatologicals following result changing patterns product use assurance acquisition stiefel laboratories july description products become outmoded notwithstanding patent products pages analysis sales therapeutic trademark protection addition increased government area pressures physicians patients use generic pharmaceuticals rather brandname medicines may increase competition competition products longer protected patent principal pharmaceutical competitors range small large intellectual property pharmaceutical companies often substantial resources companies intellectual property key business asset company effective legal protection intellectual property via abbott laboratories patents trademarks registered designs copyrights domain amgen name registrations critical ensuring reasonable return investment rd astrazeneca bristolmyers squibb patents eli lilly policy try obtain patents commercially important protectable inventions discovered developed rd johnson johnson activities patent protection new active ingredients available merck major markets patents also obtained new drug novartis formulations manufacturing processes medical uses devices pfizer administering products although may obtain patents products prevent challenged roche holdings expire grant patent mean sanofiaventis issued patent necessarily held valid enforceable pharmaceuticals may subject competition court court determines patent hold invalid products period patent protection non infringed unenforceable protect market patent generic versions manufacturers third party entry prior patent expiry significant litigation generic products typically incur significant research concerning challenges summarised note development education marketing development costs financial statements legal proceedings consequently able offer products considerably life patent countries years filing lower prices branded competitors research date however long development time pharmaceutical development based company normally seek achieve products may result substantial amount patent life sufficiently high profit margin sales volume period used launch markets including usa patent protection repay original investment europe possible lost time restored generally substantial generate profits fund research leads variations amount patent life actually future competition generic products generally occurs available product market certain countries patents major markets expire increasingly patent challenges provide period data market exclusivity prevents third made prior patent expiry claiming innovator patent party company relying clinical trial data enter valid andor infringed generic product market copy period exclusivity following loss patent protection generic products rapidly capture large share market particularly usa patent expiry dates significant products following table dates provided expiry patents believe remaining competitive dependent upon usa major european markets active ingredient unless discovery development new products together otherwise indicated include extensions patent term including effective marketing existing products paediatric use usa available gsk annual report pp weiver ssenisub products intellectual property competition products compounds indications major patent expiry dates competitor brands usa eu respiratory seretideadvair salmeterol xinafoate asthmacopd singulair symbicort fluticasone propionate spiriva asmanex pulmicort combination combination foster diskus device diskus device flixotideflovent fluticasone propionate asthmacopd qvar singulair devices devices serevent salmeterol xinafoate asthmacopd foradil spiriva diskus device devices veramyst fluticasone furoate rhinitis nasacort antivirals epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination combivir lamivudine zidovudine hivaids truvada atripla combination combination trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination agenerase amprenavir hivaids prezista kaletra reyataz lexiva fosamprenavir hivaids prezista kaletra reyataz epivir lamivudine hivaids truvada atripla ziagen abacavir hivaids truvada atripla valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffix lamivudine chronic hepatitis b hepsera relenza zanamivir influenza tamiflu central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro wellbutrin sr bupropion depression effexor cymbalta expired expired lexapro requip ropinirole parkinsons disease mirapex expired restless legs syndrome use treating parkinsons disease treximet sumatriptan naproxen migraine zomig maxalt relpax na combination use cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride lovaza omega acid ethyl esters high triglycerides tricor na formulation coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep arixtra fondaparinux deep vein thrombosis lovenox fragmin expired expired pulmonary embolism innohep vesicare solifenacin overactive bladder detrol detrol la enablex na sanctura uk irish patents revoked courts generic competition possible following conclusion patent proceedings gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp products intellectual property competition products compounds indications major patent expiry dates competitor brands usa eu metabolic avandia rosiglitazone maleate type diabetes actos januvia avandamet rosiglitazone maleate type diabetes competact janumet metformin hci actoplus met antibacterials augmentin amoxicillinclavulanate common infections expired expired potassium altabax retapamulin skin infections oncology emesis arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patients votrient pazopanib metastatic renal cell carcinoma sutent nexavar vaccines infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentavac pentaxim polio hepatitis b hepb polio hepatitis b hepb pediacel pentacel inactivated antigens fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtypes type b antigens influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone none none subtypes type b antigens influvac aggripal fluad cervarix hpv virus like particles human papilloma virus gardasil silgard vlps adjuvant mpl type aluminium hydroxide synflorix conjugated pneumococcal invasive pneumococcal prevenar na polysaccharide disease rotarix live attenuated rotavirus rotavirus gastroenteritis rotateq strain gip trademarks gsks commercial products protected registered trademarks major markets may local variations example usa trademark advair covers product sold eu seretide trademark protection may generally extended long trademark used renewing necessary gsks trademarks important maintaining brand identity products gsk enforces trademark rights prevent infringements consumer healthcare products portfolio comprises three main categories overthecounter otc medicines oral healthcare nutritional healthcare sales key consumer healthcare products shown leading consumer healthcare products include following otc medicines alli first licenced weight loss medicine available without prescription launched usa across europe panadol global paracetamolacetaminophen analgesic smoking control products nicoderm niquitin cq nicabate usa nicorette brands include breathe right nasal strips tums citrucel contac fiberchoice gsk annual report pp weiver ssenisub products intellectual property competition oral healthcare global manufacturing supply gms aquafresh range toothpastes toothbrushes people work gms across network mouthwashes sites countries gms supports commercial ambition sensodyne range toothpastes toothbrushes gsk delivering quality medicines consumer products mouthwashes including pronamel protect patients customers around world acid erosion scale manufacturing gsk huge manufacture b iotene acquired late leading treatment billion packs per year different presentations dry mouth including tablets creamsointments inhalers injections liquids polident poligrip corega denture care cleansers steriles supplied markets adhesives billion spent gms production ther brands include odol macleans dr best gms operates procurement operation behalf group spend billion annually external suppliers nutritional healthcare purchasing active ingredients chemical intermediates packaging lucozade range energy sports drinks components partfinished finished products h orlicks range milkbased malted food internal customers sought every opportunity chocolate drinks grow businesses focused costcompetitive ribena blackcurrant juicebased drink supply quality product meet ambitions worked consumer healthcare competition diligently leverage network sites contractors give us builtin flexibility sustain future growth adapt emerging gsk holds leading global positions key consumer product commercial business models increasingly rigorous external areas worldwide second largest otc medicines regulatory environment continued leverage technology third largest oral healthcare nutritional healthcare holds support process understanding control capability leading position uk india ireland primary supply sites supply high quality competitively priced environment consumer healthcare business bulk actives focus improvements primary technologies operates become ever challenging processes new product global supply sites work consumers demanding better quality better value closely rds development teams ensure right improved performance technical competencies place support rapid successful r etailers consolidated globalised new product introduction sites serve focal point strengthened negotiation power developing introducing new secondary manufacturing technologies sites regional pharma supply division focus cycle times innovation reduced reducing costs allowing gsk compete effectively main competitors include major international companies markets consumer healthcare sites deliver highquality colgatepalmolive johnson johnson procter gamble unilever competitively priced products support rapid new product pfizer addition many smaller companies introduction highly innovative competitive business compete gsk certain markets new technologies become fundamental platform driving innovation lowering costs providing flexibility operations major competitor products otc medicines embedding new ways working simplifying n usa metamucil laxative pepcid indigestion business achieving greater efficiencies focus private label smoking control products customer service including support new product launches n uk lemsip cold remedy nurofen anadin strong compliance culture commitment health safety analgesics nicorette nicotinell smoking control environment commitment developing people treatments delivered strong results gsk even external oral healthcare major competitors colgatepalmolives environment become demanding colgate procter gambles crest vaccine manufacturing managed integral part nutritional healthcare major competitors horlicks biologicals business particularly complex requires use ovaltine milo malted food chocolate drinks competitors innovative technologies living microorganisms sophisticated ribena primarily local fruit juice products lucozade quality assurance quality control procedures place competes energy drinks ensure vaccines quality safety includes animal use according health authorities requirements due biological nature individual health authorities may subject vaccines second control guarantee highest quality standards gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp research development research development pharmaceuticals delivering medicines patients gsk rd built one strongest pipelines potential progression latestage development consists optimising new medicines industry pharmaceutical rd physical product properties medicine ie actively managing projects human clinical trials across chemical steps formulation required manufacture globe delivering pipeline patients safely efficiently deliver well much larger scale studies humans number one goal confirming efficacy safety combination results two steps regulatory file submission discovering potential medicines regulatory agencies approval patient use ur early research identifies biological targets interfering responsibility regulatory team particular disease creates small molecules biopharmaceuticals interact disease targets medicines development organised therapy areas medicine development centres mdcs cardiovascular refocus best science led us create metabolic infectious diseases neurosciences respiratory entrepreneurial environment discovery building mdc ultimate accountability developing success existing model centres excellence drug experimental drugs regulatoryapproved medicines discovery cedds groups focused around defined therapy patients mdcs responsible creating value areas taking cedd model one step created execution full product development plans ensuring number smaller discovery performance units dpus strong partnerships rest rd gsk particular within cedd small integrated groups cedds preclinical development regulatory scientists focus particular disease pathway commercial groups manufacturing dpus gsk number dpus cedd varies according science standalone dpus emphasis put simplification clinical created explore new therapy areas ophthalmology development organisation focusing investment new ways working academic dpu forms project spend versus infrastructure reflects increased drug discovery collaborations academia focus rd return investment cedds one year year business plan adapting structure maximise chance succeed defining overall budget clear objectives business rds units oncology biopharmaceuticals plans reviewed end year integrating discovery late stage development discovery organisation track deliver gsks objectives group allows us build critical mass two growth areas gsk focus delivering strong pipeline w e continue identify compounds companies integrated units fully set would enhance portfolio create innovative successful progressing pipeline see collaborations ensure seen partner pipeline chart choice large small companies internal rd expertise allows us strong position business china discovery team focused neurodegeneration development makes us able complement internal neuroinflammation celebrated second anniversary pipeline acquisitions inlicensing comarketing grown approximately employees copromotion deals future options collaborations developed impressive early stage portfolio products enter clinic team establishing clinical capabilities gsk annual report pp weiver ssenisub research development governance vaccines rd key projects reaching significant milestones reviewed gsk active fields vaccine research development month product management board responsible production portfolio vaccines approved determining medicine met criteria passing marketing scientists devoted discovering next phase development innovative vaccines contribute health wellbeing people generations around world discovery gsks chief medical officer working global safety development new vaccine complex process requiring board ultimately accountable oversight major decisions longterm investment vaccines clinical regarding patient safety global safety board responsible development one strongest vaccine pipelines internally approving pivotal studies investigating issues industry although vaccines traditionally used ward related patient safety arising development programme illness gsks vaccine division working develop therapeutic postlaunch information gsk clinical trials widely immunotherapeutics aimed educating patients immune easily available clinical study register gsks website system identify attack cancer cells highly specific manner oversight strategic issues budget management across vaccine discovery involves many collaborations academia rd owned rd executive team radex biotech industry identify new vaccine antigens diseases developing world expressed yeast bacteria mammalian cells purified continued investment research diseases developing high level followed formulation clinical world essential longterm improvement lots vaccine may involve mixing antigens selected health people live regions part gsk novel proprietary adjuvant systems combinations response challenge operate drug discovery unit selected adjuvants designed elicit appropriate immune based tres cantos spain focuses malaria response specific antigen right combination antigen tuberculosis additional rd sites usa uk adjuvant system help body mobilise effective focused development new medicines treat hivaids immunological pathway designed provide maximum drug resistant bacteria vaccine research conducted protection specific diseases targeted populations rixensart belgium formulated candidate vaccine evaluated safety rd efforts addressing prevention efficacy perspective different phases preclinical treatment three world health organizations testing clinical trials involving healthy individuals priority infectious diseases range safety analysis small group volunteers phase dose adjustment proof concept phase ii largescale safety efficacy analysis phase iii results obtained clinical trials data regarding development quality largescale production process facilities combined regulatory file submitted authorities countries vaccine made available launch post marketing studies considerable size set assess vaccination programmes monitor vaccine safety gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp research development animals research ethical regulatory scientific reasons research using animals remains small vital part research development new medicines vaccines use animals alternative constantly strive reduce numbers used committed maintaining high standards humane care treatment laboratory animals undertake internal external review assure standards vast majority experimental methods use animals actively engaged research develop validate tests either avoid use animals research reduce numbers needed animals used research due measures taken prevent minimise pain distress decided initiate funding studies using great apes th october voluntary decision provides tangible demonstration commitment rs animal research advocates replacement reduction animals research refining experiments improve animal welfare understand use animals research purposes commands high level public interest public policy position care ethical use animals research information reports available website research development consumer healthcare continuous creation development innovative products keeps brands relevant vibrant valuable portfolio spans three major categories otc medicines oral healthcare nutritional healthcare major brands dedicated rd teams including regulatory partner work alongside commercial brand team colleagues officefree hub environments foster collaboration fast decisionmaking hubs quickly become preferred way working innovation centres weybridge uk parsippany usa expanding model rapidly key consumer healthcare territories including china india gsk annual report pp weiver ssenisub research development full diverse product development pipeline therapeutic compound key late stage projects highlighted comprising biopharmaceuticals arzerra ofatumumab new chemical entities new combinations formulations existing assets advanced status arzerra ofatumumab shown includes approvals arzerra ofatumumab benlysta belimumab key ofatumumab phase iii otelixizumab large comparative study compound versus placebo andor prolia denosumab established treatment patients establish clinical benefit syncria safety cardiovascular metabolic arixtra filed following successful phase iii trials file product avandamet xr approval regulatory authorities avandia simvastatin approval darapladib approval granted begin market neurosciences almorexant medicine vaccine horizant full pipeline pages website retigabine oncology avodart duodart avodart alpha blocker votrient pazopanib tyverbtykerb revoladepromacta revoladepromacta revoladepromacta tyverbtykerb tyverbtykerb tyverbtykerb tyverbtykerb votrient pazopanib votrient pazopanib votrient pazopanib respiratory relovair vaccines cervarix magea asci magea asci menhibrix hibmencytt mosquirix new generation flu vaccine nimenrix menacwytt simplirix find visit us inlicense alliance relationship third party wwwgskcom see note financial statements post balance sheet events asci antigen specific cancer therapeutic gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp research development indication phase filed approved chronic lymphocytic leukaemia refractory patients diffuse large b cell lymphoma relapsed patients follicular lymphoma refractory patients systemic lupus erythematosus rheumatoid arthritis type diabetes postmenopausal osteoporosis type diabetes treatment acute coronary syndrome type diabetes extended release type diabetes atherosclerosis insomnia restless legs syndrome epilepsy partial seizures reduction risk prostate cancer benign prostatic hyperplasia fixed dose combination inflammatory breast cancer idiopathic thrombocytopaenic purpura chronic liver disease induced thrombocytopaenia hepatitis c induced thrombocytopaenia breast cancer first line therapy breast cancer adjuvant therapy gastric cancer head neck squamous cell carcinomas resectable disease renal cell cancer ovarian cancer maintenance therapy sarcoma copd copd cervical dysplasia cancer prophylaxis caused hpv treatment melanoma treatment nonsmall cell lung cancer neisseria meningitis groups c disease haemophilus influenzae type b disease prophylaxis malaria prophylaxis plasmodium falciparum seasonal influenza prophylaxis elderly neisseria meningitis groups c w disease prophylaxis genital herpes prophylaxis gsk annual report pp weiver ssenisub employees gsk values behaviours employee numbers region changes healthcare market past decade necessitate usa transformation business model one europe customercentric innovative perform collective organisation determine success order effective rest world growing complexity exponential speed change external environment gsk needs create internal learning culture embodied gsk values behaviours details gsk values behaviours see corporate responsibility report recruitment talent management leadership inclusion diversity development committed employment policies free discrimination like every year recruiting retaining developing existing potential employees grounds age employees critical enhancing sustaining race ethnic national origin gender sexual orientation faith performance reputation proactive talent acquisition initiatives disability gsk committed offering people disabilities underpin ability attract specialist leadership talent access full range recruitment career opportunities externally assessment process aligned core set every effort made retain support employees become competencies ethics integrity central disabled working gsk details diversity global view talent strategic capabilities required looking measures see corporate responsibility report quality depth breadth talent across world healthy safe high performance need good succession plans senior roles critical positions across organisation maintain meet mission strategy employee health robust leadership strategy identify develop highly skilled performance initiatives focus health factors enable leadership cadre use systematic disciplined approach employees perform highest level sustaining energy leadership development providing tools programmes help engagement programmes developed deliver leaders master skills needed meet customer employees health strategy range traditional immunisations investor expectations launched first line leader smoking control weight management cuttingedge programme new leaders whether new gsk new programmes areas team personal resilience managing people also launched gskwide mentoring ergonomics energy performance programmes scheme senior leader mentor least one available many languages designed address root individual causes excessive work pressure low energy engagement work home complimented commitment performance reward flexible working enables employees best work performance development planning pdp process means environment helps integrate work employees businessaligned objectives behavioural personal lives details scope impact goals reward systems support high performance help programmes see corporate responsibility report attract retain best people performancebased pay bonuses sharebased equity plans align employee interests business targets communication employee involvement communication channels designed keep employees informed engaged involved activities across areas organisation encourage twoway open honest communication employees improvements web usage technology engaged employees feedback monitoring mechanisms part every major communication event qa feedback facilities core feature web communications channels broader processes include internal online opinion survey employees invited provide feedback individual empowerment employee engagement company values business evolves changes affect employees remain committed consulting changes via number internal consultation forums discussions european employee consultation forum similar bodies countries national practice gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsibility commitment corporate responsibility programmes countries gsk committed connecting business decisions ethical also introduced orange cards providing discounts social environmental concerns thus corporate responsibility certain gsk prescription medicines eligible patients number integral embedded part way gsk business countries nature discounts varies countries ways healthcare systems operate improving access medicines patient advocacy access healthcare developing world easy solutions challenge providing patient advocacy initiative demonstrated significant sustainable access healthcare developing countries poverty progress since inception initially launched us single biggest barrier many countries people programme critical initiative throughout gsk patient enough food access clean water supply hospitals clinics advocacy teams usa europe share best practices receive treatment healthcare professionals care established processes optimise interaction patient groups typically relationships provide mutual opportunities learn patient needs priorities patient groups committed playing full part addressing develop understanding drug development challenges healthcare challenges developing world taking innovative responsible sustainable approach continued partner patient groups gsk making vital contribution developing country healthcare common issues advocating access medicines treatment action number areas including preferential increasing funding health programs improving health pricing antiretrovirals antimalarials tiered pricing care delivery considered trustworthy partner vaccines investing rd targets diseases particularly patient groups worked patient groups affecting developing world see community trade associations increase transparency investment activities partnerships foster effective interactions healthcare see seeking innovative partnerships work communities solutions cover contribution improving access work partner underserved communities medicines extensively corporate responsibility report developed developing world supporting programmes clear leader first access medicines atm index innovative sustainable bring real benefits produced atm foundation continue communities global community investment build product pricing partnership commitments help million compares million like improve healthcare developing world february like basis increase due expansion us patient announced series commitments un defined list assistance programme increased humanitarian product donations least developed countries including flexible approach scale donation albendazole lymphatic intellectual property research neglected diseases filariasis lf programme giving comprised product commitment invest healthcare infrastructure price caps donations million cash giving million inkind patented medicines significant increase resources donations million plus costs million manage global community still needed support rd provide deliver community programmes almost countries access resultant medicines vaccines product donations include million gsks patient assistance programmes million worth albendazole much achieved sustainable progress occur programme million humanitarian product donations significant barriers stand way better access since product donations valued cost healthcare tackled shared responsibility sectors average cost goods rather wholesale price wac global society governments international agencies charities accurate reflection cost gsk believe academic institutions pharmaceutical industry others first pharmaceutical company adopt practice access medicines developed world comparative purposes total value donations programmes usa using wac products would million compared working provide access medicines people million limited financial resources without prescription operate single charitable foundation drug insurance community investment programmes number uninsured americans qualify medicare countrybased foundations grants included medicaid gsk nine pharmaceutical companies created investment total together rx access programme qualified individuals offering reductions pharmacy cost medicines million together rx access cardholders saved million gsk annual report pp weiver ssenisub responsibility cash giving targeted primarily health education phase initiatives follows phase programme personal hygiene sanitation education initiated us providing education hundreds thousands school children countries improve health hygiene fight infectious diseases health expanded programme uganda extended phase education slum areas mumbai india also brought phase arts culture uk piloted three schools hounslow near environment global headquarters humanitarian product donations donated essential products antibiotics nonprofit partners including americares direct relief global health programmes international map international project hope support humanitarian relief efforts community healthcare following eliminating lymphatic filariasis lf series natural disasters asiapacific region central effort eliminate lf one worlds disabling america total value international humanitarian product diseases continued close partnership governments donations million average cost countries disease endemic world health organization partner organisations founding immediately following devastating earthquake struck partner leader global elimination effort haiti january gsk provided donations medicines committed donating much antiparasitic drug million stocks held warehouses several non albendazole required reach one billion people risk profit partners continuing donate requested medicines countries million albendazole treatments support medium longerterm needs also donated donated countries donated billion british red cross support deployment albendazole treatments since global elimination programme mass sanitation unit water sanitation needs started community initiatives positive action hivaids dedicated strengthening fabric communities positive action pioneering global programme working providing health education initiatives support communities affected aids started supports local civic cultural institutions improve quality communitybased organisations deliver effective hiv aids life uk contributed million education prevention healthcare services july continuing programme charitable activities supporting announced creation new positive action children organisations health medical research science education fund fund make million available ten years arts environment help prevent mothertochild transmission hiv support programmes north america national local level focused orphans vulnerable children new fund complement improving public education increasing access healthcare ongoing work support hiv community children homeless healthcare preventionaccess launch viiv healthcare positive action programmes people dealing breast gynaecologic cancers gsks impact managed new hivfocused company awards recognise organisations significantly improved glaxosmithkline african malaria partnership health local communities expanded beyond coalitions malaria created malaria uk philadelphia reach communities near research advocacy programme mobilising malaria continued triangle park north carolina facility total funding north increase awareness malaria mobilise resources american programmes million target countries uk belgium france ethiopia mozambique gsk continues communitymark company award cameroon year announced launch next excellence community investment awarded phase african malaria partnership projects focused three years community health workers educationbehaviour change community four new malaria grants awarded total commitment million three years include partnerships save children uk kenya family health international ghana african medical research foundation amref tanzania planned parenthood federation nigeria gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsibility health initiatives contribution improve healthcare included following grants nonprofit partner amount purpose grant childrens health fund continue referral management initiative rmi usa ensures continuity specialist medical care highrisk children often homeless general support gsk impact awards recognise excellence nonprofit community health uk usa organisations charities receive unrestricted grants work dealing diverse difficult social issues access healthcare medical research charities support medical research programmes uk education initiatives nonprofit partner amount purpose grant institute competitive workforce improve education create skilled workforce future usa working partnership broad business coalition staffed us chamber commerce science summer teach basic scientific concepts inspire school children philadelphia pittsburgh north carolina enquirybased science education programme project enthuse support continuing professional development cpd science uk teachers ultimately encourage children engage science pursue careers science technology royal society chemistry support programme target science teachers uk uk chemistry specialists provide key skills confidence effective chemistry teaching information gsk grants programmes available wwwgskcom employee involvement employees encouraged contribute local communities employee volunteering schemes support includes employee time cash donations charities employees volunteer matching gift programmes us gsk matching gift program matched employee retiree gifts value million plus million united way campaign gsks give programme provided grants organisations us employees volunteered ukbased nonprofit organisations via gsk making difference programme groupwide volunteer initiative launched give every gsk employee one paid day year volunteer good cause employees supported wide range charities projects including work local schools shelters homeless community gardens nursing homes aiding communities affected natural disasters gsk pulse volunteer partnership new initiative launched april empowers highperforming employees volunteer period three six months lending professional expertise pulse volunteers work fulltime one partner nongovernmental organisations ngo create sustainable change impoverished communities around world intake pulse volunteers working different countries nongovernmental organisations employees continue receive gsk salary placement represented inkind donation gsk annual report pp weiver ssenisub responsibility responsibility environment mass efficiency glaxosmithklines environmental responsibility spans demand increasing efficiency use materials priority raw materials converting products increased target originally introduced aiming impacts use efficiency new products launched first time also set mass efficiency target vision environmental sustainability ultimately transform manufacturing sites achieve additional improvements business following principles industrial ecology take processes rd longterm aspiration using renewable resources converting wastes byproducts achieve efficiency five times typical level become inputs processes pharmaceutical industry reduce input materials first steps towards goal optimise efficiency waste processes minimising use energy resources mass efficiency average amount waste generate also need reduce carbon dioxide emissions energy used contribution tackling climate change environmental activities overseen sustainability council composed senior executives manage environmental issues well occupational health safety using management system aligned recognised international standards central audit group includes environmental issues routine audits sites processes strategy plans strategy three elements beginning embedding environmental fundamentals energy management waste reduction eliminate adverse impacts operations second stage embrace sustainability businesses developing culture product stewardship climate change sustainable resource use strategy also requires transparency biggest direct climate impact comes propellants used informing stakeholders actions performance inhalers diseases asthma reduced impact provide fuller disclosure corporate responsibility report replacing cfc gases continue research ways minimise tenyear strategic plan targets refreshed greenhouse gases released products every five years update plan new since implementing climate change challenging targets key targets programme ambitious targets emissions energy pursuing since progress towards include use operations transport aiming reduction per unit sales energy use emissions reduction per unit sales cut operations transport achieved levels emissions energy consumption reduction energy use emissions per unit sales fell respectively reductions follow two years limited progress means need average material efficiency products transferred outstanding performance meet interim target research development current average energy reduction identified key objective annual reduction water use per unit sales business result energy consumption included achieved reduction since key business metrics remuneration senior managers manufacturing linked achievement energy reduction targets also created central fund finance energy saving projects climate change team identified energy saving projects helped last two years avoid around tonnes greenhouse gas emissions ycneiciffe ssam stage stage stage stage transferred manufacturing key average weighted average gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp responsibility well mitigating climate change impact also aim identify ways respond changing disease patterns caused climate change gsks carbon footprint million tonnes co equivalent key climate impact use inhalers patient climate impact operations energy climate impact travel transport climate impact environmental concerns sustainability requires holistic view everything especially relating optimal use resources water particularly important natural resource recognise businesses play positive role managing sustainably endorsed united nations ceo water mandate water consumption fell per unit sales exceeds target also targets improving quality wastewater reducing waste disposal emissions air exceeded targets areas track completely eliminate ozonedepleting cfcs end environmental audit scores also moving close targets packaging provides opportunities reduce resources use several projects reduce environmental impact packaging instance using lighter toothpaste caps saving tonnes plastic year read environmental performance aspects sustainability corporate responsibility report may viewed line wwwgskcom gsk annual report pp weiver ssenisub regulation regulation pharmaceuticals regulation consumer healthcare region countryspecific laws regulations define consumer healthcare industry subject national regulation information needed show safety efficacy comparable prescription medicines testing pharmaceutical products well governing testing approval manufacturing labelling marketing products approval manufacturing labelling marketing high standards technical appraisal frequently involve lengthy regulatory requirements major factor approval process new product launched determining whether marketable product may january saw historymaking first otc industry successfully developed approved european medicines agency granted centralised highly regulated environment increasing approval weight loss medicine alli resulted cooperation exchange information among major paneuropean launch alli first licenced weight loss regulatory authorities consequently treatment available without prescription across eu transformed structure regulatory affairs department countries additional national licences alli better match global regulatory environment granted approval countries operate existing us eu international groups value money integrated one department global regulatory affairs change enables us effectively formulate global payers around world concerned cost strategies obtain regulatory approvals gsk products based healthcare pricing medicines requirement regional expertise new structure also make us better satisfy healthcare purchasers value money becoming positioned interact regulatory customers additional hurdle product acceptance dynamic globallyconnected external environment regulatory tests safety efficacy quality although evaluation benefit risk continue price controls paramount considerations approval new drug many countries prices pharmaceutical products usa increased focus safety medicines controlled law governments may also influence prices fda amendments act mandates rigorous fda review control national healthcare organisations may bear safety approval postmarketing phase large part cost supplying medicines consumers product fda examining better ways identify recent government healthcare reforms countries france counterfeit medicines communicate new risk information spain germany may restrict pricing reimbursement public remain engaged key areas interest currently usa government price controls europe new regulations aimed strengthening safety private sector purchases federal law requires pharmaceutical monitoring medicines improving citizens access reliable manufacturers pay prescribed rebates certain drugs information medicines strengthening eu laws protect eligible reimbursement several state federal citizens better threats posed fake medicines healthcare programmes us president congress discussion eu legislators meanwhile preparation continues dedicated much years legislative process reforming implementation new rules aimed simplifying americas healthcare system drive cost improve quality harmonising eu regulatory framework changes increase access millions americans without health authorised medicinal products hoped changes insurance reforms potential create positive minimise inefficiencies procedures reduce overall changes us healthcare system expand access gsks administrative burden products also potential increase prescribed regulatory environment emerging markets asiapacific rebates governmentrun programmes change continues evolve number countries continuing balance private public sector purchases pressure develop regulatory review systems gsk actively participates control healthcare costs need health reform number specific regional national regulatory continue beyond issues crossborder trade initiatives provide opportunities meaningful scientific acceleration generics market comparative effectiveness regulatory dialogue industry agencies research pharmaceutical pricing continue part stakeholders gsk continues include broader sets patient ongoing reform debate usa fortunately gsk positioned populations number countries medicine constructive contributor debates since development programmes order increase global patient access increased recognition chronic disease primary new innovative medicines optimise regulatory approvals driver healthcare spending pharmaceutical products deliver important interventions help hold healthcare costs gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp world market economy outlook world market pharmaceuticals world economy world economy deteriorated early part global pharmaceutical sales billion compared international financial crisis deepened economies billion many countries contracted year although emerging markets still showed growth world market value geographic region bn total aggressive cuts official interest rates fiscal stimulus measures usa national initiatives support international banking system europe led improvements towards end year however france economic recovery likely remain fragile uneven emerging markets providing strongest growth germany italy equity prices strengthened ftse index uk increasing dow jones industrial average rest world inflationary pressures remained well control however emerging markets modest increase inflation expected asia pacific potential healthcare reforms usa create japan uncertainty strategy designed put canada group position able deliver longterm sustainable total financial performance despite uncertainties market growth cer basis usa europe outlook rest world gsk returned sales growth companys strategy th september gsk two worlds top delivering confident prospects gsk believes pharmaceutical products seretideadvair valtrex moving position deliver goal longterm sustainable financial performance world market value top six therapeutic classes bn total central nervous system cardiovascular alimentary tract metabolic antineoplasticimmunomodulatory antiinfectives bacterial viral fungal excluding vaccines respiratory note data based months th september data market share market growth rates gsk estimates based recent data independent external sources appropriate valued sterling relevant exchange rates figures quoted product market share reflect sales gsk licenseespp weiver ssenisub financial review pharmaceutical turnover cardiovascular urogenital growth rates included review turnover constant cardiovascular urogenital sales increased billion exchange rates cer unless otherwise stated sterling growth continued strong growth key products arixtra rates may found tables pharmaceutical turnover million avodart million lovaza therapeutic areas geographic region million partly offset generic competition pharmaceutical turnover grew billion pharmaceuticals coreg growth helped sales pandemic related products metabolic including relenza hn vaccine products regional basis metabolic sales decreased billion usa declined reflecting continued erosion several products due generic competition strong performances sales avandia million continued decline delivered europe emerging markets asia across regions bonvivaboniva sales declined usa pacificjapan sales contribution stiefel grew europe rest world acquired nd july totalled million oncology emesis pharmaceutical turnover therapeutic area oncology emesis sales increased billion gsk turnover grew impact us generic tyverbtykerb million grew strongly europe competition range gsks products lower avandia sales rest world following product approvals gained declining hiv business offset strong growth zofran declined result generic competition key products seretideadvair avodart lovaza relenza vaccines franchise including hn pandemic vaccine vaccines vaccine sales increased billion respiratory respiratory sales increased billion pandemic vaccine sales million recorded year delivered fourth quarter gsk seretideadvair grew billion especially strong partnered governments respond hn pandemic growth emerging markets million japan million ventolin sales grew sales gsks new synflorix vaccine totalled million reflecting million driven performance usa sales launches several markets beginning shipments doubled million veramyst sales rose brazilian government part year billion agreement million signed august strong contributors growth year included boostrix million cervarix antivirals million rotarix million antivirals increased billion partially offsetting performances sales infanrixpediarix fell relenza sales million million million primarily result continued impact reflecting successful capacity expansion meet government increased competition dtpa sector usa hepatitis orders across world strong retail performance japan vaccines sales also fell million part due million sales valtrex declined billion competitor product returning us market result generic competition product usa began november sales hiv medicines totalled billion year epzicom sales grew million offset declines across rest portfolio viiv healthcare new specialist hiv company established gsk pfizer officially launched rd november cns cns sales decreased billion majority gsks cns franchise impacted generic competition usa wellbutrin decline primarily reflected sale wellbutrin xl usa biovail second quarter gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major products total cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarixflulaval flu pandemic hepatitis engerix fendrix havrix twinrix infanrix pediarix rotarix synflorix stiefel products cer represents growth constant exchange rates represents growth actual exchange rates turnover quarter given financial record pages gsk annual report pp weiver ssenisub financial review regional analysis consumer healthcare turnover turnover reported table represents sales invoiced growth gsks local entity customers local market plus total cer copromotion income within market overthecounter medicines growth alli cer breathe right usa cold sore franchise europe nicotine replacement therapy emerging markets panadol franchise asia pacificjapan tums trading oral healthcare aquafresh franchise cer represents growth constant exchange rates represents growth biotene actual exchange rates denture care including stiefel sensodyne franchise usa nutritional healthcare sales usa declined billion principally reflecting lucozade continued decline avandia competition horlicks infanrixpediarix return market competitor ribena hepatitis franchise generic competition significant products lamictal imigran valtrex requip coreg addition wellbutrin xl sold biovail cer represents growth constant exchange rates represents growth q declines partly offset significant sales actual exchange rates turnover quarter given financial record pages relenza pandemic vaccines doubling ventolin sales good growth lovaza contributions recently total consumer healthcare sales year rose launched products boostrix rotarix billion growth regions categories europe otc medicines sales europe increased billion continued otc product sales grew billion driven sales growth seretide relenza particularly strong vaccines panadol million alli growth driven pandemic vaccine offsetting impact doubled million result launches throughout europe generic competition number products continued price began april sales nicotine replacement therapy cuts governments across region products declined emerging markets oral healthcare sales emerging markets increased billion sales oral healthcare products rose billion sensodyne strong growth across region therapeutic areas helped performed strongly sales million denture care acquisitions ucb bms businesses different sales grew million sales aquafresh declined countries region reduction us white trays market offset growth us aquafresh toothpaste brands helped launch asia pacificjapan new isoactive product sales asia pacificjapan grew billion reflecting continued seretideadvair growth strong relenza sales particularly nutritional healthcare retail market japan strong vaccines growth nutritional healthcare sales grew billion driven strong performance horlicks million partly offset decline lucozade sales million impacted lower sales impulse market uk market gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review results major restructuring restructuring activities follow relate total results acquisitions nature undertaken operational excellence programme also carried october board approved implementation following detailed formal plan management therefore considers detailed formal plan gsk announced significant new appropriate present costs restructuring activities operational excellence restructuring programme second formal manner acquisition stiefel laboratories inc plan representing significant expansion operational july acquisition year meets excellence programme approved board criteria set acquisition year announced february conducted series costs incurred direct result related restructuring business reviews gsk announced expansion programme included major restructuring column restructuring programme deliver billion incremental restructuring costs expected incurred direct result pretax savings approximately savings acquisition estimated approximately million directed bottom line enhance profitability million charged restructuring remainder reinvested business charges costs incurred direct result acquisition reliant incremental programme expected total billion pharmaceuticals inc acquisition since october phased balance mostly meets criteria set charged total approximately cash expenditures paid asset writedowns cumulative savings new programme phased approximately follows groups results costs operational excellence million million majority programme acquisitionrelated restructuring programmes balance meeting criteria described also presented separate column income statement described restructuring programme comprising detailed formal results major restructuring presentation plans covers areas gsks business including manufacturing gsk intends apply consistently future major restructuring selling rd infrastructure estimated total cost programmes material impact gsks operating results approximately billion expanded programme expected manner gsks business conducted deliver annual pretax savings approximately billion adopted show clearly groups results time substantially complete approximately costs restructuring programmes management costs incurred st december believes presentation assists shareholders gaining approximately expected incurred clearer understanding groups financial performance balance mostly total approximately costs making projections future financial performance results expected cash expenditures expected include costs virtue size nature limited accounting writedowns comparative value presentation also consistent way uncertainties exist exact amount timing cash management assesses groups financial performance outflows result potential future exchange rate restructuring costs incurred solely direct result fluctuations many elements restructuring operational excellence programme restructuring programme subject employee consultation procedures programmes following reliant stiefel acquisitions making difficult predict precision procedures reported major restructuring column income completed however majority remaining cash statement restructuring costs principally arisen payments expected made given impairments property plant equipment termination extent cost operational excellence restructuring employment contracts staff made redundant part programme management believes material impact restructuring activities set note financial gsks operating results manner gsks statements major restructuring programme asset impairments business conducted gsk presents restructuring costs staff redundancies together accounted million incurred solely direct result operational excellence million restructuring costs incurred reported restructuring programme amounted major restructuring column million tax million separate column income statement titled major restructuring remaining costs million arose miscellaneous expenditures incurred solely direct result addition restructuring costs operational excellence restructuring programmes including termination programme major restructuring column income leases accelerated depreciation site closure costs consultancy statement includes restructuring costs incurred solely direct project management fees costs arising gsks result restructuring programmes follow relate ongoing operating activities reported major material acquisitions operations acquired business restructuring column overlap extensively gsks existing operations gsk annual report pp weiver ssenisub financial review restructuring costs arise solely direct result selling general administration operational excellence programme restructuring sga costs percentage turnover increased programmes following relating acquisitions meeting percentage points included full year legal charges criteria described continue reported operating million million charges related expenses within results major restructuring costs major restructuring programme million included restructuring costs related minor acquisitions million excluding legal restructuring million costs million related costs sga costs turnover restructuring activity initiated commencement reflected investment growth markets acquisition operational excellence programme none restructuring stiefel increased pension costs donation hn product activity material impact gsks operating results exchange losses intercompany transactions manner business conducted compared exchange gains last year partially offset benefits current restructuring programme anticipated duration operational excellence programme gsk currently expect incur material research development restructuring costs except related programme rd expenditure total turnover acquisitions meeting criteria described included million intangible asset writeoffs unanticipated material restructuring costs arise million partially offset lower charges relating period gsk would expect include also major major restructuring programme million restructuring column million provision release due reassessment gsks operating profit profit taxation taxation receivable balance increased investment vaccines rd profit year discussed terms total late stage pharmaceutical rd broadly offset savings results include major restructuring costs results restructuring programme major restructuring operating income operating profit total results operating income million including gains asset disposals million million primarily total results include restructuring costs related operational reflecting disposal wellbutrin xl various assets aspen excellence programme acquisitions reliant stiefel pharmacare royalty income million million growth royalty dispute settlement gain million onetime cer accounting gain million creation viiv healthcare turnover partially offset equity investment impairments million cost sales operating profit total results selling general total operating profit year million increase administration cer sterling terms compared research operating profit margin increased percentage points reflecting development higher operating income broadly flat rd expenditure operating partially offset increases cost sales sga income profit taxation total results operating profit net finance costs cost sales finance income cost sales percentage turnover reduced marginally turnover principally reflecting impact interest finance income generic competition higher margin products usa unwinding discounts assets changes product mix offset benefits restructuring fair value adjustments hedges programme lower restructuring costs million million finance costs interest costs unwinding discounts liabilities fair value adjustments hedges gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review profit disposal interest associate operating income profit disposal interest associate million operating income million including gains million shares groups holding quest diagnostics asset disposals million million inc sold first quarter primarily reflecting disposal wellbutrin xl various assets aspen pharmacare royalty income million share tax profits associates joint ventures million royalty dispute settlement gain share tax profits associates million million onetime accounting gain million million arises principally groups holding creation viiv healthcare partially offset equity quest investment impairments million profit taxation total results operating income profit disposal taking account net finance costs profit disposal associates amounted million equivalent overall interest associates share profits associates income around million expected total profit taxation million compared operating profit results major restructuring million cer increase sterling increase operating profit major restructuring year million cer decline sterling terms operating profit results major compared operating profit margin restructuring compared margin decline margin results major restructuring set primarily due generic competition usa impacted cost goods increased investment support growth groups diversification strategy impacted sga partly offset cer higher level operating income turnover impact generic competition reduces sga cost sales investment levels stabilise gsks operating profit margin selling general currently expected broadly similar excluding legal administration costs viiv healthcare accounting gain research information operating profit major restructuring development provided note segment information operating income profit taxation results major restructuring operating profit net finance costs cost sales cost sales increased turnover finance income principally reflecting impact generic competition higher interest income margin products usa changes product mix partly unwinding discounts assets offset benefits restructuring programme cost fair value adjustments hedges sales percentage turnover expected around selling general administration sga costs percentage turnover increased finance costs percentage points including full year legal charges interest costs million increase reflected investment growth markets unwinding discounts liabilities acquisition stiefel increased pension costs donation fair value adjustments hedges hn product exchange losses intercompany transactions compared exchange gains last year partially offset benefits current restructuring programme sga costs excluding legal charges expected profit disposal interest associate around turnover profit disposal interests associates million research development million quest shares sold first quarter rd expenditure total turnover included million intangible asset writeoffs million partially offset provision release due reassessment receivable balance increased investment vaccines rd latestage pharmaceutical rd broadly offset savings restructuring programme rd costs percentage turnover expected remain around gsk annual report pp weiver ssenisub financial review share tax profits associates joint ventures profit year share tax profits associates million million arises principally groups holding growth cer quest diagnostics inc total profit taxation profit taxation results major restructuring year taking account net finance costs profit disposal total profit attributable interests associates share profits associates profit shareholders tax major restructuring million compared basic earnings per share pence p p million cer decline increase basic earnings per ads us sterling terms results major restructuring taxation profit taxation year results major restructuring profit attributable shareholders uk corporation tax adjusted earnings per share pence p p overseas taxation adjusted earnings per ads us weighted average number current taxation shares millions deferred taxation diluted total earnings per share pence p p taxation total profits diluted total earnings per ads us charge taxation total profits amounted million diluted weighted average number represented effective tax rate shares millions charge taxation profit major restructuring charges total results including restructuring costs produced basic eps amounting million represents effective tax rate p compared p growth gsk currently expects similar effective cer terms growth sterling terms excluding major tax rate groups balance sheet st december restructuring costs eps p compared p included tax payable liability million tax growth cer increase sterling recoverable asset million terms percentage point currency benefit arose th november irs conceded asserted tax weakness sterling major currencies year deficiencies penalties arising reclassification dividend intercompany financing arrangement debt equity resulting additional tax cost gsk irs claim previously board declared fourth interim dividend pence per estimated million gsk irs share resulting dividend year pence four pence process finalising tax computations increase pence per share equivalent tax years anticipated resolution issue years interim dividend receivable adr holders cents per reflected closing agreement resolution ads based exchange rate exdividend issue impact groups results date th february record date th february payment date th april gsk continues believe made adequate provision liabilities likely arise open assessments ultimate critical accounting policies liability matters may vary amounts provided consolidated financial statements prepared accordance dependent upon outcome litigation proceedings ifrs adopted use european union also negotiations relevant tax authorities ifrs issued iasb following accounting policies approved board described note financial statements accounting principles policies management required make estimates assumptions affect amounts assets liabilities revenue expenses reported financial statements actual amounts results could differ estimates gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review critical accounting policies adopted relate following areas reconciliation gross turnover net turnover us turnover pharmaceuticals business follows taxation legal disputes property plant equipment gross turnover goodwill chargebacks intangible assets managed care medicare part gpo pensions postemployment benefits rebates information judgements estimates made areas us government given note financial statements key accounting state programmes judgements estimates cash discounts respect turnover accounting policy groups largest customer returns business us pharmaceuticals us market prior year adjustments complex arrangements rebates discounts allowances items following briefly describes nature arrangements total deductions existence groups us pharmaceuticals business net turnover g sk arrangements certain indirect customers whereby customer able buy products wholesalers sterling values increased approximately compared reduced prices chargeback represents difference result average exchange rate movements invoice price wholesaler indirect chargebacks increased result higher direct customers contractual discounted price accruals estimating chargebacks relenza sales managed care medicare part chargebacks calculated based terms gpo rebates increased slightly result higher contracting agreement historical experience product growth rates discounts arising competitive pressures market place c ustomer rebates offered key managed care group purchasing organisations gpo direct total accruals rebates discounts allowances returns indirect customers arrangements require customer us pharmaceuticals business follows achieve certain performance targets relating value st st product purchased formulary status predetermined market december december shares relative competitors accrual customer rebates estimated based specific terms agreement historical experience product growth rates chargebacks managed care medicare part us medicaid programme stateadministered gpo rebates programme providing assistance certain poor vulnerable us government state programmes patients medicaid drug rebate program cash discounts established reduce state federal expenditure customer returns prescription drugs gsk participates providing rebates states accruals medicaid rebates calculated based specific terms individual state agreements using total combination historical experience product population growth anticipated price increases impact sterling values decreased largely result yearend contracting strategies exchange rate movements dollar terms provision cash discounts offered customers encourage prompt largely unchanged payment accrued time invoicing monthly process operated monitor inventory levels adjusted subsequently reflect actual experience wholesalers abnormal movements process uses gross historical experience customer returns sales volumes prescription volumes based third party data gsk records accrual estimated sales returns applying sources information received key wholesalers aim historical experience customer returns amounts maintain inventories consistent level year year invoiced together market related information based pattern consumption stock levels wholesalers anticipated price increases basis us pharmaceutical inventory levels wholesalers competitor activity distribution channels st december estimated amount approximately one month turnover calculation uses third party information accuracy totally verified believed sufficiently reliable purpose gsk annual report pp weiver ssenisub financial position resources financial position property plant equipment gsks business sciencebased technologyintensive highly regulated governmental authorities group allocates assets significant financial resources renewal maintenance noncurrent assets property plant equipment minimise risks interruption property plant equipment production achieve compliance regulatory standards goodwill number processes use chemicals hazardous materials intangible assets total cost groups property plant equipment investments associates joint ventures st december million net book value investments million land buildings represented deferred tax assets million plant equipment million assets derivative financial instruments construction million gsk invested noncurrent assets million new renewal property plant equipment mainly related large number projects renewal total noncurrent assets improvement expansion facilities various worldwide sites current assets property mainly held freehold new investment financed inventories group liquid resources st december gsk capital current tax recoverable contractual commitments future expenditure million trade receivables operating lease commitments million gsk believes derivative financial instruments facilities adequate current needs liquid investments group observes stringent procedures uses specialist cash cash equivalents skills manage environmental risks activities assets held sale environmental issues sometimes dating operations total current assets modified discontinued reported responsibility total assets environment note financial statements legal proceedings liabilities goodwill current liabilities shortterm borrowings goodwill increased year million trade payables st december million increase primarily reflects goodwill arising acquisition stiefel derivative financial instruments laboratories inc million pfizer hiv business current tax payable million certain businesses ucb sa million shortterm provisions intangible assets total current liabilities intangible assets include cost intangibles acquired noncurrent liabilities third parties computer software net book value longterm borrowings intangible assets st december million deferred tax liabilities million increase reflects additions pensions postemployment benefits million partly offset currency movements provisions amortisation impairment existing intangibles largest element derivative financial instruments additions million relating acquisition stiefel noncurrent liabilities laboratories inc reflecting brands acquired together total noncurrent liabilities stiefel trade name addition million relates fair value pfizer hiv intellectual property acquired following creation total liabilities viiv healthcare business year million net assets arises acquisition certain businesses ucb sa equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources investments provisions gsk held investments including associates joint ventures group carried deferred tax provisions shortterm carrying value st december million noncurrent provisions million st december million market value st december million respect estimated future liabilities million million largest million related legal disputes provision investments two associates quest diagnostics inc made legal disputes indemnified disposal book value st december million liabilities costs restructuring programmes extent million aspen pharmacare holdings limited balance sheet date actual constructive obligation acquired year book value st december existed could reasonably estimated million investments include equity stakes pensions postemployment benefits companies group research collaborations group accounts pension postemployment provide access biotechnology developments potential interest arrangements accordance ias deficits net interests companies arise business divestments surpluses allowing deferred taxation million derivative financial instruments assets million pension arrangements gsk noncurrent current derivative financial million million unfunded post instruments held fair value million million employment liabilities pension liabilities increased following decrease primarily reflects lower currency volatility euro weakening long term interest rates including reduction us dollar yen market rates rate used discount uk pension liabilities increase estimated long term inflation rate inventories uk partly offset positive impact exchange movements inventory million increased million higher asset values year increase arises hn vaccine synflorix stock builds following regulatory approval key markets acquisition net debt stiefel laboratories inc strategic stock building support growth emerging markets japan offset weakening overseas currencies improvements following implementation cash cash equivalents working capital reduction programme liquid investments borrowings repayable within one year trade receivables borrowings repayable one year trade receivables million increased reflecting relatively high vaccine sales hn last net debt quarter together stiefel acquisition partly offset impact weakening overseas currencies translation net debt decreased million primarily weakening foreign currency receivables sale long outstanding debt foreign currencies group debt denominated certain european markets taiwan reductions overdue total equity receivables certain european asian markets summary movements equity set derivative financial instruments liabilities gsk held current derivative financial instruments held fair value million million current million total equity beginning year noncurrent relating primarily hedging exchange translation total comprehensive income year currency assets consolidation decrease reflects dividends shareholders lower currency volatility euro us dollar yen ordinary shares issued trade payables ordinary shares purchased cancelled trade payables amounting million changes minority shareholdings increased primarily reflecting working capital put option minority interest improvement initiatives extend supplier terms towards consideration received shares transferred groups day term objective acquisition stiefel esop trusts laboratories inc partly offset weakening yearend ordinary shares acquired esop trusts foreign exchange rates sharebased incentive plans tax sharebased incentive plans distributions minority interests total equity end year st december total equity increased million st december million increase arises principally retained profit year partly offset actuarial losses defined benefit pension plans gsk annual report pp weiver ssenisub financial position resources share purchases contractual obligations commitments employee share ownership plan esop trusts following table sets groups contractual obligations acquired million shares gsk plc million commitments st december fall due payment shares held trusts satisfy future exercises options awards group share option award schemes total yr yrs yrs yrs proportion shares held trusts respect loans awards rules scheme require gsk satisfy interest loans exercises market purchases rather issue new finance lease obligations shares shares held trusts matched options finance lease charges awards granted operating lease st december esop trusts held million commitments million gsk shares future exercise intangible assets share options share awards carrying value property plant equipment million million deducted investments reserves market value shares purchase commitments million million pensions gsk repurchase shares cancellation commitments million shares held treasury shares total nil order ensure gsk sufficient flexibility deliver strategic priorities company expect commitments respect loans future interest payable make significant repurchases existing share buyback loans disclosed taking account effect programme exact amount timing future derivatives group entered number purchases extent repurchased shares held research collaborations develop new compounds treasury shares rather cancelled determined pharmaceutical companies terms arrangements company dependent market conditions include upfront fees equity investments loans commitments factors st december gsk held million shares fund specified levels research addition group treasury shares million shares cost often agree make payments future milestones million million deducted achieved agreements relate compounds retained earnings early stages development milestone payments continue purchases since st december number years compounds move successfully existing programme development process generally closer product marketing approval greater possibility success commitments contingent liabilities payments shown within intangible assets represent financial commitments summarised note financial maximum would paid milestones achieved statements commitments contingent liabilities obligations respect short longterm debt set number new commitments made note financial statements contingent liabilities licensing agreements including arrangements note financial statements net debt chroma therapeutics limited concert pharmaceuticals inc idenix pharmaceuticals inc prosensa bv seattle genetics inc amounts provided pensions postretirement benefits set note financial statements pensions gsk reached agreement trustees uk postemployment benefits amounts provided restructuring pension schemes make additional contributions five year programmes legal environmental disputes set period eliminate pension deficit identified note financial statements provisions st december actuarial funding valuation table shows commitment excludes normal ongoing annual funding requirement approximately million information pension obligations see note financial statements pensions postemployment benefits gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources contingent liabilities net cash outflow investing activities million increase million primarily reflected significant following table sets contingent liabilities comprising increase cost business purchases including discounted bills performance guarantees letters credit stiefel laboratories inc million net cash acquired items arising normal course business million certain businesses ucb sa million net expected expire cash acquired million az tika million total yr yrs yrs yrs comparable acquisitions comprised sirtris pharmaceuticals million net cash acquired million egyptian guarantees business bms million net deferred consideration contingent liabilities million addition sales liquid investments realised cash million total free cash flow normal course business gsk provided various indemnification guarantees respect business disposals legal disputes subsequently arisen provision made outflow resources considered probable reasonable estimate made likely outcome dispute included note financial statements provisions groups policy provide settlement costs asserted claims environmental disputes outflow resources considered probable reasonable estimate may made prior point liability recorded legal environmental costs discussed risk factors pages note financial statements legal proceedings gsk continues believe made adequate provision liabilities likely arise open taxation free cash flow amount cash generated business assessments ultimate liability matters may vary meeting obligations interest tax dividends paid significantly amounts provided dependent upon minority interests capital expenditure noncurrent outcome litigation proceedings negotiations tangible intangible assets free cash flow relevant tax authorities discussed note million increase principally financial statements taxation reflected higher operating profit noncash charges primarily major restructuring programmes lower cash flow expenditure intangible assets partly offset higher summary consolidated cash flow set levels net interest paid result debt issuance year billion emtn programme reduced interest income deposits net cash inflow operating activities free cash flow used gsks management planning net cash outflow investing activities reporting purposes discussions presentations net cash outflow financing activities investment analysts rating agencies gsks free cash flow measure defined ifrs measure may directly increase cash bank overdrafts comparable similarly described measures used exchange adjustments companies reconciliation net cash inflow operating cash bank overdrafts beginning year activities closest equivalent ifrs measure free cash bank overdrafts end year cash flow shown reconciliation free cash flow cash bank overdrafts end year comprise cash cash equivalents overdrafts net cash inflow operating activities purchase property plant equipment purchase noncurrent intangible assets disposal property plant equipment net cash inflow operating activities taxation paid interest paid million increase million reflecting higher interest received profit tax excluding impact significant increase dividends received joint ventures noncash charges made year primarily major restructuring programmes associated undertaking dividends paid minority interests free cash flow gsk annual report pp weiver ssenisub financial position resources movements net debt payment policies group companies responsible monitoring managing working capital terms sales collections supplier payments reflect local commercial practice net debt beginning year increase cash bank overdrafts uk company uk subsidiaries cash inflow liquid investments policies ensure suppliers paid time particular net increase longterm loans uk companies seek net repayment shortterm loans settle terms payment suppliers agreeing debt subsidiary undertakings acquired terms transaction exchange movements ensure suppliers made aware agreed terms movements payment net debt end year abide terms payment investment appraisal policy permits arrangements accelerated payment small suppliers gsk formal process assessing potential investment proposals order ensure decisions aligned payment performance groups overall strategy process includes analysis st december average number days payable impact project earnings return invested outstanding represented trade payables parent company capital assessment return based discounted nil nil respect company uk cash flows discount rate used perform financial analysis subsidiaries aggregate days days decided internally allow determination extent investments cover groups cost capital specific treasury policies investments discount rate may adjusted take gsk reports sterling pays dividends sterling profits account country risk weightings role corporate treasury manage monitor external internal funding requirements financial risks capital expenditure financial investment support strategic objectives treasury activities governed cash payments tangible intangible fixed assets amounted policies procedures approved board directors million million million recently st october disposals realised million million million cash payments acquire equity investments treasury management group tmg chaired chief million million million financial officer meets monthly basis review treasury made year sales equity investments realised activities members receive management information relating million million million treasury activities future cash flow capital management group expects future operating cash flow gsk operates global basis primarily subsidiary sufficient fund operating debt service costs satisfy companies established markets trade normal levels capital expenditure meet obligations significant levels patent trademark protection products existing licensing agreements meet expenditure arising compete largely product efficacy differentiation rather major restructuring programmes precise timing price selling margins sufficient cover normal operating uncertain outlined note financial statements major costs operating subsidiaries generally cash generative restructuring programmes meet routine outflows operating cash flow used fund investment research including tax dividends subject risk factors discussed development new products also used make routine pages gsk may time time additional outflows capital expenditure tax dividends repayment demands finance acquisitions access maturing debt extent determined board sources liquidity short longterm capital markets share repurchases banks financial institutions addition cash flow operations needs policy borrow centrally using variety capital market issues borrowing facilities meet anticipated funding requirements borrowings together cash generated operations onlent contributed equity certain subsidiaries used pay dividends make acquisitions gsk make share repurchases gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial position resources liquidity st december centrally available cash reserves st december cash liquid investments billion committed undrawn bank facilities billion held follows date shortterm debt bank overdrafts loans repayable within one year billion manage net borrowing requirements portfolio longterm borrowings including bonds together short bank balances deposits term finance billion commercial paper programme us treasury treasury repo commercial paper programme backed billion money market funds committed facilities facilities last renewed october corporate debt instruments consider level committed facilities adequate government securities given current cash holdings information facilities see note financial statements net debt also benefit strong positive cash flow operating units billion amount managed centrally available european medium term note programme within three months net debt st december billion st december billion billion table summarises cash gross debt notes issue programme also us shelf effects hedging registration statement st december billion billion notes issue programme tmg monitors cash flow forecast monthly basis cash liquid investments longterm borrowings mature dates gross debt fixed longterm debt ratings remained stable since floating february currently rated stable outlook noninterest bearing standard poors stable outlook moodys net debt shortterm debt ratings p standard poors moodys respectively maturity profile gross debt shown table maturity profile gross debt equivalent gbp bonds eur bonds usd bonds commercial paper borrowings leases gsk annual report pp weiver ssenisub financial position resources treasury operations use interest rate swap redenominate one external objective treasury activity manage posttax net borrowings interest rate coupon required gsk cost income financial operations benefit earnings duration swap matches duration principal corporate treasury operate profit centre use instrument interest rate derivative instruments accounted variety financial instruments finance operations fair value cash flow hedges relevant assets liabilities derivative financial instruments manage market risks counterparty risk management operations derivatives principally comprising forward policy counterparty risk management work foreign currency contracts interest rate currency swaps select group relationship banks global counterparty used swap borrowings liquid assets required limits assigned gsks banking investment currencies manage exposure funding risks changes counterparties based longterm credit ratings moodys foreign exchange interest rates standard poors corporate treasurys usage hold issue derivatives speculative purposes limits monitored daily corporate compliance officer cco treasury policies specifically prohibit activity transactions operates independently corporate treasury breach financial instruments undertaken manage risks arising limits reported cfo immediately cco also underlying business activities speculation monitors credit rating counterparties changes ratings occur notifies corporate treasury foreign exchange management changes made investment levels authority limits foreign currency transaction exposures arising internal appropriate full counterparty analysis presented tmg external trade flows hedged exposure overseas annually approval operating subsidiaries transaction risk minimised matching local currency income local currency costs financial assets liabilities analysis net debt given note financial purpose internal trading transactions matched statements net debt analysis financial assets liabilities centrally manage intercompany payment terms reduce carrying value fair value given note financial foreign currency risk exceptional foreign currency cash flows statements financial instruments related disclosures hedged selectively management corporate treasury continue benefit strong positive cash flow manage shortterm cash surpluses borrowing operating activities net debt decreased year requirements subsidiary companies centrally using forward st december despite gsks acquisition activities contracts hedge future repayments back period totalled approximately billion originating currency information activities see note financial seek denominate borrowings currencies statements acquisitions disposals principal assets cash flows primarily denominated financial assets liabilities st december us dollars euros sterling certain borrowings swapped representative treasury policies strategies applied currencies required since july gsk raised approximately billion borrowings denominated swapped foreign currencies billion capital markets make match investments overseas assets may treated share repurchases hedge relevant assets forward contracts also used major currencies reduce exposure investment overseas group assets see net investment hedges section note details tmg reviews ratio borrowings assets major currencies interest rate risk management policy interest rate risk management limits amount floating interest payments prescribed percentage trading profit gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors risks uncertainties relevant groups business patent infringement litigation financial condition results operations may affect groups patents common patents challenged groups performance ability achieve objectives time efforts generic manufacturers may involve challenges factors among group thinks based validity enforceability patent assertions cets recent annual workshop identify generic product infringe groups patents gsk significant risks facing group could cause actual results successful defending attack patents maintaining differ materially expected historical results exclusive rights market one major products risks uncertainties currently known group particularly usa group highest turnover deemed immaterial margins groups financial results may materially adversely affected see note financial statements legal risks described group implemented proceedings discussion patentrelated proceedings system internal control involves policies procedures group involved description communication training programmes supervision resolutions prior proceedings affect dates monitoring processes escalating issues appropriate generic versions groups products may introduced level senior management system helps facilitate groups ability respond appropriately risks achieve generic drug manufacturers seeking market generic versions group objectives helps ensure compliance applicable many groups important products prior laws regulations internal policies possible however expiration groups patents exhibited readiness group implement controls respond risks products future us launch generic may face assurance steps products competing lamictal imitrex paxil cr requip group taken address certain risks manage risks wellbutrin xl valtrex significant impact groups effectively overall turnover earnings groups management risks discussed potential changes intellectual property laws pages corporate governance regulations major risks might affect gsks business proposals change existing patent data exclusivity laws regulations major markets group sells products risk rd deliver commercially successful continuing feature political process countries new products include proposals could effect making continued development commercially viable new products well prosecution patents new products difficult time development additional uses existing products critical consuming adversely affect exclusivity period groups groups ability replace sales older products decline products including biological products proposals upon expiration exclusive rights increase overall sales enacted may materially adversely affect groups developing new products costly lengthy uncertain process financial results new product candidate fail stage process weakness intellectual property protection one late stage product candidates could fail receive certain countries regulatory approval countries group operates patent protection may significantly weaker usa new product candidates may appear promising development european union developing countries reduced significant investment fail reach market threatened reduce effective patent protection limited commercial success example could pharmaceutical products generally particular therapeutic result efficacy safety concerns inability obtain areas facilitate early competition within markets necessary regulatory approvals difficulty manufacturing generic manufacturers loss patent protection including excessive manufacturing costs erosion patent terms result reducing scope patent rights compulsory licensing could lengthy development period infringement patents materially adversely affect groups financial results intellectual property rights others inability differentiate national markets expected material group product adequately competes overall absence adequate patent protection could limit furthermore health authorities us fda european opportunity look markets future sales growth medicines agency japan pharmaceuticals medicines device agency increased focus safety assessing risk substantial adverse outcome litigation benefitrisk balance drugs made difficult government investigations pharmaceutical products gain regulatory approval see note financial statements legal proceedings also increasing pressure healthcare budgets discussion proceedings governmental investigations average age population developed markets increases involving matters proven could give rise civil absolute population developing markets grows payers criminal liabilities group currently involved therefore increasingly demanded greater incremental benefit unfavourable resolution similar future proceedings drugs agreeing reimburse suppliers prices suppliers investigations may material adverse effect groups consider appropriate failure develop commercially successful financial condition results operations group products develop additional uses existing products made material provisions prior years related legal reasons could materially adversely affect groups proceedings investigations reduced earnings financial results gsk annual report pp weiver ssenisub risk factors group may also make additional significant provisions related sales marketing regulation legal proceedings investigations future would group operates globally complex legal regulatory reduce earnings many cases practice plaintiff bar environments often vary among jurisdictions failure claim damages amounts bear relationship comply applicable laws rules regulations underlying harm accordingly may potentially misleading jurisdictions may result civil criminal legal proceedings group quantify based amount damages claimed rules regulations change governmental potential exposure claims proceedings investigations interpretation rules regulations evolve prior conduct type described note financial statements may called question legal proceedings usa example group responding federal recent insurance loss experience including pharmaceutical product state governmental investigations pricing marketing liability exposures increased cost narrowed reimbursement prescription drug products coverage afforded insurance pharmaceutical companies investigations could result related restitution civil false claims generally including group act litigation behalf federal state governments well related proceedings initiated group behalf order contain insurance costs recent years group consumers private payers proceedings may result continued adjust coverage profile accepting greater degree trebling damages awarded fines respect violation uninsured exposure addition claims made law criminal proceedings may also initiated insurance policies insurers may reserve right deny coverage group consequences could materially adversely various grounds denial coverage ultimately upheld affect groups financial results claims could result additional charges may materially adversely affect groups financial results third party competition product liability litigation group operates highly competitive markets pharmaceuticals business faces competition preclinical clinical trials conducted development proprietary products large international manufacturers potential products determine safety efficacy producers generic pharmaceuticals significant product products use humans following approval regulatory innovations technical advances intensification price bodies notwithstanding efforts drugs vaccines competition competitors may materially adversely affect introduced marketplace unanticipated side effects may groups financial results group predict timing become evident impact competitive products potential impact instances third parties may perform analyses published sales groups products continued consolidation clinical trial results although necessarily accurate pharmaceutical industry may adversely affect groups meaningful may raise questions regarding safety competitive position continued consolidation among pharmaceutical products may publicised media groups customers may increase pricing pressures may result product liability claims group currently group nine pharmaceutical products defendant number product liability lawsuits including million annual global sales among products class actions involve substantial claims damages related augmentin ir es lamictal ir paxil valtrex groups pharmaceutical products litigation particularly generic competition usa usa inherently unpredictable excessive verdicts justified evidence occur class actions sweep groups major products become subject together persons prescribed groups products problem unplanned loss patent protection unexpected inflate potential liability force numbers claims side effects regulatory proceedings publicity affecting doctor pain suffering punitive damages frequently asserted patient confidence pressure competitive products product liability actions allowed represent potentially new effective treatment introduced groups open ended exposure thus could materially adversely financial results may materially adversely affected affect groups financial results particular group faces intense competition antitrust litigation manufacturers generic pharmaceutical products usa become increasingly common patent major markets generic products often enter market upon infringement actions prompt claims antitrust laws expiration patents data exclusivity periods groups violated initial prosecution patent products introduction generic products typically leads litigation involving defence patent claims dramatic loss sales reduces groups revenues direct indirect purchasers payers typically filed margins proprietary products expiration dates class actions relief sought may include treble damages patents groups major products description restitution claims damages adverse antitrust verdicts subject litigation settlements may affect dates generic automatic trebling usa similarly antitrust claims may versions groups products may introduced set brought following settlement patent litigation alleging legal proceedings involving patent challenges set settlements anticompetitive violation antitrust laws note financial statements legal proceedings successful antitrust claim group could materially governmental payer controls adversely affect groups financial results pharmaceutical products subject price controls pressures restrictions many markets including japan germany spain france italy governments intervene directly setting prices gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors addition markets major purchasers pharmaceutical risk interruption product supply products whether governmental agencies private health care manufacture pharmaceutical products constituent providers economic power exert substantial pressure materials requires compliance good manufacturing practice prices terms access formularies regulations groups manufacturing sites subject review approval fda regulatory agencies group accurately predict whether existing controls compliance failure suppliers key services materials pressures restrictions increase whether new controls groups manufacturing facilities could lead product pressures restrictions introduced measures may recalls seizures interruption production delays materially adversely affect groups ability introduce approvals new products pending resolution manufacturing new products profitably financial results issues noncompliance also result fines disgorgement example usa group highest margins profits interruption supply incurrence fines sales country pricing pressures could disgorgement could materially adversely affect groups significantly increase experience continues develop financial results outpatient pharmaceutical programme covering medicare although group undertakes business continuity planning beneficiaries began also changes related single sourcing certain components bulk active materials enabling legislation could afford us government direct role finished products creates risk failure supply negotiating prices medicare programme event regulatory noncompliance physical disruption addition us congress considering comprehensive health manufacturing sites care reform legislation could significantly expand scope risk concentration sales wholesalers government health care programs include specific price control mechanisms could increase groups rebate usa line pharmaceutical companies liability respect programs group sells products small number wholesalers addition hospitals pharmacies physicians additionally number states proposed implemented groups sales three largest wholesalers amounted various schemes control prices lowincome senior approximately groups us pharmaceutical sales citizens programmes including increasing rebate liability st december group trade receivables pharmaceutical companies importation countries due three wholesalers totalling million bulk purchases drugs growth number st december million group exposed patients covered large managed care institutions concentration credit risk respect wholesalers usa increased implementation medicare one affected financial difficulty benefit also increases pricing pressures groups products could materially adversely affect groups financial results trends may materially adversely affect groups financial results global political economic conditions described many worlds largest economies regulatory controls including major markets group operates group must comply broad range regulatory controls financial institutions recently faced extreme financial difficulty testing approval manufacturing marketing many including decline asset prices liquidity problems limited pharmaceutical consumer healthcare products particularly availability credit many economies experienced usa countries european union affect sharp recessions economies shown signs cost product development also time required recovery rate recovery may slow reach market uncertainty successfully health authorities increased focus safety continued economic weakness may material adverse effect assessing benefit riskbalance drugs context groups sales results operations financial condition initial product approval also context approval ability raise capital groups businesses including additional indications review information regarding consumer healthcare may particularly sensitive declines marketed products stricter regulatory controls also heighten consumer spending addition renewed declines risk changes product profile withdrawal regulators asset prices may result lower return groups financial basis postapproval concerns product safety investments may cause value groups investments could reduce revenues result product recalls product pension plans decrease requiring group increase liability lawsuits also greater regulatory scrutiny especially funding pension plans usa advertising promotion particular group conducts substantial portion operations outside directtoconsumer advertising uk groups management foreign exchange rates addition cases group may voluntarily cease discussed business review foreign exchange management marketing product face declining sales based concerns see fluctuations exchange rates sterling efficacy safety example decline sales currencies especially us dollar euro avandia beginning following publicity around questions japanese yen could materially adversely affect groups regarding risks associated product whether financial results scientifically justified even absence regulatory action group control changes inflation interest development postapproval adverse event profile rates foreign currency exchange rates controls product product class may materially adversely affect economic factors affecting businesses possibility groups financial results political unrest legal regulatory changes nationalisation jurisdictions group operates gsk annual report pp weiver ssenisub risk factors taxation treasury failure manage properly environmental risks could result groups effective tax rate driven rates tax additional remedial costs may materially adversely jurisdictions higher lower applied affect groups financial results see note financial uk addition many jurisdictions uk belgium statements legal proceedings discussion environmental usa currently offer regimes encourage innovation related proceedings group involved new scientific endeavours providing tax incentives example accounting standards rd tax credits furthermore given scale international new revised accounting standards rules interpretations nature groups business intragroup transfer pricing circulated time time international standard setting inherent tax risk international businesses changes board could result changes recognition income tax laws application respect matters expense may materially adversely affect groups transfer pricing foreign dividends controlled companies rd financial results tax credits restriction tax relief allowed interest intragroup debt could increase groups effective tax rate international standard changes market valuation certain materially adversely affect financial results financial instruments reflected groups reported results gains losses actually realised could tax charge included financial statements groups significant impact income statement given period best estimate tax liability time audits accounting deferred taxation intercompany inventory tax authorities concluded degree uncertainty may give rise volatility depending upon ownership regarding final tax liability period groups policy inventory submit tax returns within statutory time limits engage tax authorities ensure groups tax affairs current regulators regularly review financial statements listed possible differences interpretation tax companies compliance accounting regulatory legislation regulation resolved quickly possible requirements exceptional cases matters settled agreement group believes complies appropriate regulatory tax authorities gsk may resolve disputes requirements concerning financial statements disclosures formal appeals proceedings group currently however companies experienced investigations appealing court decision respect transfer pricing potential noncompliance accounting disclosure canadian tax authorities discussed note financial requirements resulted restatements previously statements taxation reported results sometimes significant penalties may group deals high value transactions frequent basis materially adversely affect groups financial results may result increased risk financial loss due failure third party providers mismanagement cash entering high risk positions unaffiliated thirdparty suppliers provide number goods hedge transactions could materially adversely services groups operations many services affect groups financial results example services provided clinical research organisations pandemic influenza support development key products important market pandemic influenza vaccines experiencing operations groups businesses materials provided significant volatility given changes risk perception developing thirdparty suppliers necessary commercial production epidemiology relative mild nature virus products including speciality chemicals commodities anticipated governments medical community components necessary manufacture fillfinish governments placed orders pandemic packaging many groups pharmaceutical consumer vaccine announced changes planned healthcare products group believe immunisation programmes renegotiated contracts thirdparty relationships individually significant governments seeking may future seek context overall group failure thirdparty supplier renegotiate contracts deliveries pandemic vaccines fulfil contractual obligations timely manner may result provided significant contributions groups results delays service interruptions may materially adversely hn vaccines hn vaccines group expects affect groups financial results level sales hn possibly stockpile agreements protection electronic information assets roughly assurance group relies critical sensitive data personally sales influenza vaccines meet estimates contribute identifiable information trade secrets intellectual property significantly groups results beyond corporate strategic plans security data exposed environmental liabilities increasing threats group also subject various standards environmental laws various jurisdictions impose actual protection personally identifiable information failure potential obligations group remediate contaminated implement appropriate safeguards adequately protect sites group also identified potentially responsible unauthorised unintentional access acquisition party us comprehensive environmental response use modification loss disclosure critical sensitive compensation liability act number sites remediation data may adversely affect groups operations costs relating groups use ownership sites gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp risk factors alliances acquisitions example strategic priority grow diversified business part groups strategy diversify new product involves expanding groups business emerging markets areas markets group grown expects groups pharmaceutical sales emerging markets grew continue grow part acquisitions business nearly billion represents groups alliances intense competition alliance acquisition turnover guarantee groups sales candidates pharmaceutical industry group emerging markets continue grow markets may unable make deals acceptable terms continue experience relatively high growth rates acquiring forming alliances companies group emerging markets may especially vulnerable aftereffects may assume significant debt become subject unknown recent global financial crisis may limited contingent liabilities fail realise benefits expected resources spend healthcare competition markets transactions example pharmaceutical companies staff skills training suitable employment including group may consider acquiring enterprise groups may intense involved patent disputes product liability litigation government emerging markets group may required rely third investigations legal proceedings whose outcome party agents may put group risk liability subject considerable uncertainty assumption debt emerging markets lack sufficient protection crimes unknown contingent liabilities failure realise counterfeiting failure continue expand business expected benefits may materially adversely affect groups emerging growth markets could materially adversely affect financial results groups financial results process integrating companies group may acquire addition group undertaking operational excellence may result disruption ongoing business effort restructuring programme estimated cost integrating organisations different locations among approximately billion expected deliver annual pretax things differing systems corporate cultures may divert savings approximately billion time substantially attention resources result loss key employees complete assurance group adverse consequences may materially able execute fully transformation business adversely affect groups financial results furthermore changes groups structure operations revenues costs efficiency resulting restructuring attraction retention activities strategic initiatives could result higher group relies heavily recruiting retaining talented expected costs difficulties failure realise expected employees range skills meet objectives group cost savings end restructuring programme faces intense competition qualified individuals supply achieve maintain competitive cost base could materially people specific skills specific geographic regions adversely affect groups financial results may limited particularly given groups plans expand operations emerging markets biologicals consumer healthcare inability attract staff specific technical leadership skills retain key employees ensure effective succession planning critical positions may materially adversely affect groups financial results implementing groups strategic priorities group established three strategic priorities grow diversified business deliver products value simplify operating model assurance group able implement strategic priorities fully strategic priorities deliver expected benefits gsk annual report pp weiver ssenisub financial review accordance us sec disclosure requirements following pharmaceutical turnover discussion compares results year st december growth rates included review turnover constant results year st december exchange rates cer unless otherwise stated sterling growth exchange rates may found tables pharmaceutical turnover therapeutic areas currencies influence groups results remain us dollar euro japanese yen total pharmaceutical turnover declined year billion driven largely us performance pound weakened us dollar billion impacted expected generic competition yearend addition pound weakened several mature brands declines avandia sales euro yen new record sales asia pacific japan fell billion reflecting low set december lower government orders relenza impact world market pharmaceuticals pharmaceutical price cuts japan declines partly offset growth europe billion emerging global pharmaceutical sales billion compared markets billion sterling terms pharmaceutical billion turnover grew reflecting weakness sterling world market value major currencies geographic region bn total pharmaceutical turnover therapeutic area usa gsk turnover declined impact lower europe avandia sales us generic competition range gsks products france lower flu prepandemic sales partly offset strong germany growth key products advair valtrex epzicom avodart italy lovaza vaccines franchise uk rest world respiratory emerging markets respiratory sales increased billion asia pacific sales seretideadvair asthma copd rose japan billion usa advair sales rose billion canada return volume growth second half year total fda granted advair indication copd prevention exacerbations helped grow copd th september gsk three worlds top sector advair business europe sales increased pharmaceutical products lamictal seretideadvair billion advair performance particularly strong valtrex emerging markets million japan sales product doubled million following world market value launch top six therapeutic classes bn total antivirals central nervous system cardiovascular antivirals decreased billion alimentary tract metabolic gsks hiv business continues experience strong competition antineoplasticimmunomodulatory epzicomkivexa grew million antiinfectives bacterial offset declines across rest portfolio sales viral fungal excluding valtrex herpes rose billion us sales vaccines fuelling growth sales flu antiviral relenza fell respiratory million reflecting fewer government orders prepandemic stockpiling note data based months th september gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major products total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antivirals hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip requip xl treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin altabax oncology emesis hycamtin zofran tykerb vaccines hepatitis infanrixpediarix fluarix flulaval flu pandemic cervarix rotarix boostrix cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report pp weiver ssenisub financial review cns regional analysis cns sales decreased billion usa sales usa declined billion principally majority gsks cns franchise impacted generic reflecting full year impact avandia generic competition usa generic competition lamictal imigran competition significant products lamictal remaining presentation wellbutrin started imigran wellbutrin xl requip course however positive news coreg ir declines partly offset treximet approved migraine fda april advair valtrex lovaza cardiovascular urogenital proforma basis cardiovascular urogenital sales increased billion europe strong growth across portfolio products partly sales europe increased billion continued growth offset generic competition coreg ir lovaza high seretide particularly strong vaccines growth offsetting triglycerides acquired reliant pharmaceuticals impact generic competition number products grew proforma basis million grew continued price cuts governments across region us market share avodart benign prostatic hyperplasia emerging markets enlarged prostate grew million taking percentage point market share arixtra deep vein thrombosis sales emerging markets increased billion pulmonary embolism grew million coreg strong growth russia china latin cr grew million america growth fuelled primarily vaccines billion respiratory franchise metabolic billion metabolic sales decreased billion asia pacificjapan strong growth bonvivaboniva postmenopausal increased sales seretideadvair million osteoporosis million enough offset offset lower orders relenza japan price cuts full year impact avandia whose sales started fall may avandia product sales declined year consumer healthcare turnover million us sales falling million growth european sales million emerging markets total cer avandia product sales returned growth second half overthecounter year q sales medicines oncology emesis panadol franchise oncology emesis sales decreased billion smoking cessation products tums tykerb breast cancer continued grow following approval cold sore franchise usa last year approvals countries achieved breathe right throughout european approval achieved alli june oral healthcare vaccines aquafresh franchise vaccine sales increased billion sensodyne franchise within vaccines portfolio strong performances dental care hepatitis vaccines million combination nutritional healthcare paediatric vaccines infanrixpediarix million lucozade rotarix rotavirus gastroenteritis rose million horlicks largely driven government tender orders latin america ribena launch product usa august new cervical cancer vaccine cervarix recorded sales million year following several tender wins including national government cer represents growth constant exchange rates represents growth orders uk netherlands actual exchange rates total consumer healthcare sales year rose billion compares growth benefited launch stocking new antiobesity treatment alli sales alli million excluding alli consumer healthcare sales rose gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review otc medicines costs arising gsks ongoing operating activities otc product sales declined billion sales reported major restructuring column smoking cessation products million panadol sales restructuring costs arise solely direct result grew million twice global average operational excellence programme restructuring oral healthcare programmes following relating acquisitions meeting criteria described reported operating expenses sales oral healthcare products rose billion whereas within results major restructuring costs included market grew strong performances restructuring costs related minor acquisitions million sensodyne million aquafresh costs million related restructuring million sensodynes growth represented world activity initiated commencement operational toothpaste growth markets gsk competes excellence programme none restructuring activity nutritional healthcare material impact gsks operating results manner within nutritionals horlicks sales rose million business conducted lucozade sales rose million ribena sales flat gsks operating profit profit taxation taxation profit million although sales lucozade ribena year discussed terms total results second half year declined slightly largely result poor include major restructuring costs results weather uk major restructuring results major restructuring total operating profit total results results total results include restructuring costs related new october gsk announced significant new operational operational excellence programme commenced excellence restructuring programme second plan representing october reliant restructuring programme significant expansion operational excellence programme approved board announced february growth restructuring programme covers areas gsks business cer including manufacturing selling rd infrastructure turnover estimated total cost approximately billion expanded cost sales programme expected deliver annual pretax savings selling general approximately billion time expected administration substantially complete approximately research costs incurred st december given extent cost operational excellence programme gsk presents development restructuring costs incurred solely direct result operating operational excellence programme amounted income million tax million separate operating profit column income statement titled major restructuring cost sales addition restructuring costs column income statement includes restructuring costs incurred solely direct cost sales increased turnover result restructuring programmes follow relate constant exchange rates cost sales percentage turnover material acquisitions operations acquired business increased percentage points reflecting charges overlap extensively gsks existing operations related major restructuring programmes million million unfavourable product regional billion million acquisition reliant pharmaceuticals mix compared partly offset savings inc december acquisition since october restructuring programmes meets criteria total restructuring costs incurred direct result acquisition million selling general administration charged paid sga costs including legal charges turnover increase percentage points constant set note financial statements major exchange rates increase percentage points legal restructuring programme asset impairments staff costs million million included million redundancies together accounted million charge announced january related us investigation million restructuring costs incurred reported gsks marketing promotional practices originated major restructuring column million colorado sga costs included charges million remaining costs million arose million related major restructuring programmes miscellaneous expenditures incurred solely direct result excluding legal costs sga decreased restructuring programmes including consultancy project management fees termination leases site closure costs respect recognition foreign exchange losses following liquidation subsidiary puerto rico gsk annual report pp weiver ssenisub financial review research development profit taxation total results rd expenditure increased included charges related taking account net finance costs share profits major restructuring programmes million associates total profit taxation million million excluding charges rd expenditure compared million cer decline increased cer terms investment late stage pipeline sterling decline partly offset restructuring savings operating profit results major operating income restructuring operating income million million results major restructuring set included strong growth royalty income million million product intellectual property equity growth investment disposals realised million compared cer million roche litigation settlement included turnover cost sales operating profit total results selling general total operating profit million decreased administration sterling terms cer terms compared research pharmaceuticals operating profit million development consumer healthcare operating profit fell operating million income year gains asset disposals settlements operating profit million million costs legal matters million million fair value movements cost sales financial instruments resulted charge million cost sales increased percentage points income million charges relating previous turnover constant exchange rates increase restructuring programmes million million percentage points turnover principally reflecting impact charges related major restructuring programmes generic competition higher margin products usa lower million million impact items avandia sales higher proportion sales generated lower total operating profit million charge margin vaccines brands sold emerging markets consumer compared million charge healthcare products partly offset savings restructuring programmes profit taxation total results net finance costs selling general administration sga costs including legal charges turnover finance income constant exchange rates sga costs increased interest finance income percentage points turnover legal costs fair value adjustments hedges million million included million charge announced january related us investigation gsks marketing promotional practices originated colorado excluding legal costs sga percentage turnover finance costs fell percentage points interest costs growth sterling terms reduction constant unwinding discount liabilities exchange rates reflecting benefits restructuring fair value adjustments hedges programmes selling distribution fell advertising promotion general administration expenditure excluding legal charges share tax profits associates joint ventures research development share tax profits associates million rd expenditure increased turnover million arises principally groups holding investment late stage pipeline partly quest diagnostics inc offset restructuring savings gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial review operating income taxation operating income million million included strong growth royalty income million million product intellectual property equity uk corporation tax investment disposals realised million compared overseas taxation million roche litigation settlement included current taxation deferred taxation operating profit results major restructuring taxation total profits operating profit major restructuring million year increased sterling terms decreased charge taxation profit major restructuring cer terms compared pharmaceuticals charges amounting million million operating profit million consumer represents effective tax rate healthcare operating profit flat cer terms million charge taxation total profits amounted excluding legal costs operating profit decreased million million represented greater turnover decline primarily due effective tax rate groups balance higher cost sales percentage turnover sheet st december included tax payable liability year gains asset disposals settlements million tax recoverable asset million million million costs legal matters groups main open tax issues usa canada million million fair value movements japan financial instruments resulted charge million income million charges relating latest position taxation see taxation previous restructuring programmes million financial review million impact items operating profit year profit major restructuring million charge million growth cer profit taxation results major total profit taxation restructuring year net finance costs total profit attributable shareholders finance income basic earnings per share pence p p interest income basic earnings per ads us fair value adjustments hedges results major restructuring profit taxation year results major restructuring finance costs profit attributable shareholders interest costs adjusted earnings per share pence p p unwinding discount liabilities adjusted earnings per ads us fair value adjustments hedges weighted average number shares millions diluted total earnings per share pence p p taking account net finance costs share profits diluted total earnings per ads us associates profit tax major restructuring diluted weighted average number million compared million shares millions cer decline flat sterling terms total results including restructuring costs produced basic eps p compared p decline cer decline sterling terms dividend board declared fourth interim dividend pence per share resulting dividend year pence four pence increase dividend pence per share gsk annual report pp noitarenumer dna ecnanrevog board sir christopher gent professor sir roy anderson larry culp aged julian heslop aged aged aged appointed st july appointed st april appointed st june appointed st october nonexecutive director chief financial officer chairman nonexecutive director mr culp president chief mr heslop joined glaxo sir christopher nonexecutive professor anderson executive officer danaher wellcome financial controller director ferrari spa professor infectious disease corporation prior joining april january chief executive officer epidemiology faculty danaher held positions appointed senior vice vodafone group plc medicine imperial college accenture previously andersen president operations controller retirement july london member consulting prior joining group nonexecutive director international advisory board held senior finance roles lehman brothers holdings inc hakluyt co ltd grand metropolitan member kpmgs chairmans fellow royal society advisory group senior adviser foreign associate member bain co member institute medicine advisory board reform us national academy sciences french academy sciences former positions include rector imperial college chief scientific adviser ministry defence uk andrew witty aged dr stephanie burns sir crispin davis aged sir deryck maughan appointed st january aged appointed st july aged chief executive officer appointed th february nonexecutive director appointed st june mr witty named chief nonexecutive director march sir crispin nonexecutive director executive officer designate dr burns chairman president chief executive officer sir deryck partner gsk october chief executive officer reed elsevier plc prior kohlberg kravis roberts co appointed chief executive dow corning corporation appointment chief nonexecutive director officer ceo st may also member executive aegis group plc thomson reuters blackrock joined group american chemical society joined guinness inc formerly chairman held senior sits executive committee plc member chief executive officer positions asia africa society chemical main board group citigroup international usa immediately prior industry america section serves managing director united salomon brothers inc appointed ceo andrew board directors distillers spent early president pharmaceuticals american chemistry council career procter gamble europe position held board directors including president january member society womens companys us food division business council health research dr burns holds britain board member phd organic chemistry phrma president efpia iowa state university member singapore economic development boards international advisory council adviser governor guangzhou china gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp board james murdoch aged dr moncef slaoui aged sir robert wilson appointed th may appointed th may aged nonexecutive director chairman research appointed st november mr murdoch chairman development nonexecutive director chief executive europe dr slaoui joined gsk biologicals senior independent director asia news corporation engineered sir robert nonexecutive also nonexecutive development chairman bg group plc chairman bskyb robust vaccines pipeline previously executive member board news subsequently led worldwide chairman rio tinto plc corporation served chief business development retirement october executive officer bskyb pharmaceuticals chairman economist also appointment lead rd group previously chairman chief member board executive officer star tv agency science also serves leadership technology research astar council climate group phd molecular biology immunology universit libre de bruxelles dr daniel podolsky tom de swaan aged directors aged appointed st january sir ian prosser dr ronaldo appointed st july nonexecutive director schmitz retired nonexecutive director mr de swaan chairman board th may dr podolsky president supervisory board university texas southwestern vanlanschot bankiers medical center dallas holds member board directors phillip obryan montgomery zurich financial services jr md distinguished presidential also vice chairman chair academic administration supervisory board chairman doris bryan audit committee royal wildenthal distinguished chair ahold member medical science member supervisory board royal dsm institute medicine january us national academy sciences member managing board also chairman board chief financial officer scientific cofounder abn amro gi company gsk annual report pp noitarenumer dna ecnanrevog corporate executive team cet john clarke abbas hussain president consumer healthcare president emerging markets john responsible abbas joined gsk june consumer healthcare business eli lilly company produces oral healthcare spent years overthecounter nutritional overseeing markets throughout healthcare products joined europe africamiddle east beecham australasia andrew witty president future group eddie gray chief executive officer current appointment president andrew appointed chief january pharmaceuticals europe executive officer may eddie became responsible joined glaxo uk groups operations career europe january company held roles joined beecham managing director south africa prior current vice president general appointment senior vice manager marketing president general manager usa senior vice president pharmaceuticals uk duncan learmouth asia pacific appointed senior vice president president pharmaceuticals deirdre connelly global communications europe glaxosmithkline president north america duncan responsible january pharmaceuticals groups investor relations deirdre joined gsk february internal external working eli lilly communications corporate company years responsibility partnerships held variety positions communities joined including sales professional glaxo vice general manager puerto rico president global investor executive director human julian heslop relations appointment resources recently chief financial officer current position july president us operations julian became chief financial officer april head simon bicknell finance function senior vice president responsible activities company secretary corporate financial reporting control compliance officer tax treasury finance systems simon ensures compliance insurance joined glaxo risk management wellcome financial controller effectively embedded within april business oversees corporate marc dunoyer bill louv governance group president pharmaceuticals chief information officer also responsible asia pacificjapan bill appointed chief internal audit assurance marc appointed president information officer january simon joined corporate pharmaceuticals asia pacific responsible secretariat japan may addition information technology across appointed deputy company current role gsk bill joined glaxo secretary glaxo wellcome appointed chairman gsk japan vice president medical data company secretary january february sciences prior current role glaxosmithkline plc lead rare diseases bill senior vice president business gsk rd rd information technology commercialisation joined group president pharmaceuticals japan january current appointment gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate executive team cet david redfern dan troy chief strategy officer senior vice president david responsible proactive general counsel exploration new business dan joined gsk senior vice opportunities strategic president general counsel planning began career september previously gsk corporate partner washington development law firm sidley austin llp dan phelan jean stphenne appointed finance director chief counsel fda chief staff president general europe pharmaceuticals chaired dan responsible corporate manager biologicals appointed area director america bar associations section strategy development jean led gsks global central europe administrative law hr real estate facilities vaccines business since northern europe previously adjunct scholar environmental health safety previously vice president american enterprise institute global security joined human vaccines research washington dc smith kline french development previously held role production joined senior vice president human company head resources appointment bacterial viral vaccines chief staff may production jean named baron king albert ii belgians recognition leading contribution moncef slaoui rd industry belgium chairman research development moncef leads groups drug discovery development activities joined group key player david pulman building gsks vaccines pipeline president global appointed manufacturing supply senior vice president worldwide david responsible business development global manufacturing claire thomas current appointment supply organisation senior vice president june global procurement joined human resources glaxo broad claire leads global human experience manufacturing resources hr function operations previously led previously oversaw hr primary supply european pharmaceuticals international manufacturing north american pharmaceuticals europe manufacturing global logistics claire joined company manufacturing appointed strategy organisations director human resources uk pharmaceuticals claire honoured outstanding european woman achievement gsk annual report pp noitarenumer dna ecnanrevog corporate governance governance policy chairman ceo section discusses gsks management structures sir christopher gent chaired company since st january governance procedures section together chairman throughout remuneration report pages includes details mr witty chief executive officer ceo mr wittys company applies complies principles biographical details found pages provisions combined code corporate governance chairman leads board represents board financial reporting council combined code us laws ceo cet members necessary board regulation meetings ceo manages group implements board corporate executive team strategy policies adopted board chairman directors listed board pages chairmen board committees communicate regularly ceo cet members division responsibilities board responsible groups system corporate role chairman ceo set governance ultimately accountable groups activities writing agreed board appears full strategy risk management financial performance companys website independence ceo responsible executive management group board considers nonexecutive directors assisted cet cet meets least times per year independent character judgement otherwise necessary members responsibilities listed corporate executive team pages dr schmitz served board ten years retirement director th may appointed senior independent director board glaxo wellcome plc st january sir robert wilson appointed senior independent director sid consideration annual review board effectiveness th may following sir ian prossers retirement meeting january board concluded board date sir ian held role since january dr schmitz remained independent notwithstanding length service opinion board dr schmitz continued board process demonstrate characteristics independence board authority accountable shareholders objectively challenging management taking part rigorous ensuring group appropriately managed debate time possessing outstanding achieves strategic objectives sets board discharges knowledge companys business affairs together responsibilities annual programme meetings experience gained chairman audit committee includes approval overall budgetary planning business long cycle investment business gsk considered strategy board reviews groups internal controls risk particularly important experienced members management policies approves governance structure board sir ian prosser also considered independent code ethics accordance recommendations combined code board appraises approves major financing investment prior retirement board licensing decisions excess defined thresholds addition sir christopher gent appointed board deputy board evaluates monitors performance group chairman determined board independent whole includes upon taking chairmanship board st january engaging board meetings ceo executive accordance combined code excluded directors members cet appropriate determination whether least half board financial operating performance gsk external independent nonexecutive directors sir christopher gent issues material groups prospects member remuneration committee permitted evaluating progress towards achievement groups combined code light independence upon appointment financial business objectives annual plans chairman monitoring reports received directly various board considers professor sir roy anderson dr burns committees significant risks facing group mr culp sir crispin davis sir deryck maughan mr murdoch dr podolsky mr de swaan sir robert wilson independent accordance recommendations combined code date publication throughout majority board members excluding chairman independent nonexecutive directors gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance board overall responsibility succession planning independent advice ceo executive directors board given board recognises may occasions one ceo broad authority operate business group directors feel necessary take independent legal ceo accountable reports board andor financial advice companys expense performance business cet members make regular agreed procedure enable explained presentations board areas responsibility governance section companys website board meets cet members annual basis indemnification directors discuss collectively groups strategy qualifying third party indemnity provisions defined section primary element induction process new nonexecutive companies act force benefit directors undertaken members cet non directors former directors held office executive directors encouraged separate informal discussions discretion cet members directors conflicts interest directors duty avoid situation board met six times member attending direct indirect conflict interest possible conflict follows interest company duty applies particular number meetings exploitation property information opportunity whether held whilst board number gsk could take advantage companys articles member meetings attended association include general power board authorise sir christopher gent conflicts breach duty relevant matter mr witty authorised advance mr j heslop board established procedures handling situational dr slaoui conflicts interest line best practice professor sir roy anderson guidance issued general counsel group dr burns accordance companys articles authorised mr l culp nominations committee grant review periodically event annually potential actual conflict authorisations sir crispin davis directors counted quorum authorisation sir deryck maughan actual potential conflicts company secretary mr j murdoch minutes consideration conflict authorisations granted dr podolsky recorded company secretary register conflict mr de swaan authorisations noted board next meeting sir robert wilson ongoing basis directors responsible informing company secretary new actual potential conflicts sir ian prosser may arise changes circumstances dr r schmitz may affect authorisation previously given even provided authorisation director absolved duty mr james murdoch appointed board th may sir ian prosser dr ronaldo schmitz retired board th promote success company actual conflict arises may post authorisation board choose exclude director relevant information debate suspend director addition six scheduled meetings board also met board last resort require director resign quorate basis six occasions company secretary business environment development company secretary responsible board ensure board kept uptodate important matters available individual directors respect board procedures including legal governance regulatory developments company secretary mr simon bicknell appointed presentations made regular basis external may barrister joined group internal advisers secretary board committees except remuneration addition nonexecutive directors gain greater insight committee deputy company secretary mrs victoria whyte understanding business visits group operational appointed secretary remuneration committee facilities attendance various internal management meetings effect th january solicitor fellow including cet research development executive product institute chartered secretaries administrators marketing board meetings ad hoc basis board committees customised induction process conducted new board established number committees nonexecutive directors focusing particular experience provides sufficient resources enable undertake taking account different backgrounds process includes duties executive directors members audit meeting members cet senior executives risk remuneration nominations corporate responsibility visiting particular operational facilities group committees although may invited attend meetings director member corporate administration transactions finance committees gsk annual report pp noitarenumer dna ecnanrevog corporate governance corporate governance framework board chairman executive directors independent nonexecutive directors audit risk committee remuneration committee corporate responsibility chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive directors directors chairman directors chairman nominations committee finance committee corporate administration independent nonexecutive executive nonexecutive transactions committee cet directors chairman directors directors cet members key board committees management committee current membership committees shown table corporate audit risk remuneration nominations responsibility sir christopher gent c c professor sir roy anderson dr burns mr l culp sir crispin davis c sir deryck maughan mr j murdoch dr podolsky mr de swaan c sir robert wilson key c chairman member gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance committee written terms reference approved board following summary role terms reference committee current full terms reference committee may obtained company secretary governance section companys website meetings committee report committee role terms reference membership comprises per year audit risk reviews financial internal reporting independent non process system internal controls executive directors identification management risks external internal audit process committee also proposes shareholders appointment external auditors directly responsible remuneration oversight work remuneration determines terms service remuneration independent non executive directors members executive directors cet assistance external chairman independent advisers evaluates makes recommendations board overall executive remuneration policy chairman ceo responsible evaluating making recommendations board remuneration nonexecutive directors nominations reviews structure size composition independent non board appointment members executive directors board cet makes recommendations chairman board appropriate committee also monitors planning succession board senior management corporate provides boardlevel forum regular independent non responsibility review external issues potential executive directors serious impact upon groups business chairman reputation committee also responsible oversight gsks worldwide donations community support finance reviews approves behalf board executive non necessary annual report form f convening executive directors agm together preliminary quarterly statements trading results also approves certain major licensing capital transactions changes groups investment instrument counterparty limits corporate reviews approves matters connection executive non necessary administration administration groups business executive directors transactions certain corporate transactions cet members company secretary gsk annual report pp noitarenumer dna ecnanrevog corporate governance evaluation board board committees directors dialogue shareholders board commissioned dr long boardroom review financial results announced quarterly act independent facilitator boards evaluation process company reports formally shareholders twice year actions process formed basis boards halfyear fullyear results announced fullyear internal review process namely results included companys annual report identify utilise time spent board committee published shareholders meetings effectively facilitate contribution nonexecutive directors broader range issues company produces annual summary sent eek enhance nonexecutive directors shareholders advise availability annual continuing education process beyond initial induction report notice meeting wwwgskcom ceo cfo give presentations fullyear results institutional p rovide greater visibility board gsks executive talent investors analysts media management succession planning process normally webcast teleconferences release senior independent director sir robert wilson conducted first second third quarter results institutional investors evaluation performance chairman analysts media annual report summary board committees directors collaboration quarterly results available companys website committee chairmen agm takes place london formal notification sent board evaluation process included onetoone interview shareholders least one month advance meeting director topics discussed included variety business presentation made shareholders directors able aspects associated board effectiveness including board attend available formally agm informally committee roles responsibilities culture dynamics afterwards questions committee chairmen ordinarily attend processes support individual effectiveness feedback agm respond shareholders questions entire board evaluation provided form written report attendance companys agm may save board discussed findings sir deryck maughan prevented attending due chairman board committees undertook urgent business commitments arose shortly separate evaluations outcome reported meeting resolutions agm decided poll respective committee board required companys articles association results poll announced london stock exchange posted board review concluded high level companys website details agm set satisfaction way mr witty grown section annual general meeting see notice ceo role openess dialogue executive agm published companys website directors nonexecutive directors board members also met separately without chairman present discuss ensure nonexecutive directors aware chairmans performance contribution also high understand views major shareholders company level confidence sir christophers chairmanship board board place process focusing sectorspecific issues unanimous unequivocal support well general shareholder preferences directors executive nonexecutive ceo cfo chairman maintain dialogue institutional board committees believed operating shareholders performance plans objectives effectively high level programme regular meetings since appointment ceo may mr witty undertaken extensive ongoing series board agreed following actions discussion meetings gsks institutional shareholders evaluation report groups investor relations department offices london identify increase amount board time philadelphia acts focal point contact investors devoted strategic discussion indicators success throughout year delivery rd pipeline chairman meets regularly institutional investors devote time focused consideration companys hear views discuss issues mutual importance key risks ongoing basis communicates views investors board whole provide board regular updates insights sid also available shareholders newly enhanced management succession chairman remuneration committee chairman planning process svp human resources meet annually major shareholders board taken policy decision undertake externally discuss executive remuneration policy facilitated evaluation process every three years intervening nonexecutive directors including new appointees available period review facilitated sid chairman meet major shareholders requested companys website provides access current financial business information group gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance share capital control bank new york mellon depositary companys details companys authorised issued share capital ads listed new york stock exchange ordinary number shares held treasury st december shares representing companys adr program found note financial statements share capital managed depositary registered name bny share premium account gsks shares listed london nominees limited details number ordinary shares held stock exchange also quoted new york stock depositary found exchange nyse form american depositary shares ads company acquired disposed interests ads represents two ordinary shares shares period review details shares holders ordinary shares entitled receive dividends purchased prior years cancelled held declared companys report accounts attend treasury shares disclosed note financial statements speak general meetings company appoint proxies share capital share premium account exercise voting rights directors officers restrictions transfer limitations holding interests directors officers connected ordinary shares requirements obtain prior approval persons issued share capital company given transfers ordinary shares carry special rights remuneration report pages regard control company restrictions rules appointment replacement directors voting rights major shareholders voting rights per contained companys articles association companys share shareholders known arrangements articles must approved shareholders accordance financial rights held person legislation force time time holder shares known agreements restrictions share transfers voting rights articles provide directors may appointed ordinary resolution members resolution directors shares acquired gsk share schemes plans rank provided latter instance director appointed equally shares issue special rights way retires first agm following appointment trustees companys employee share ownership plan esop trusts waived rights dividends shares held articles also provide directors subject esop trusts reelection agm intervals three years annually held office continuous period nine years change control essential contracts companys members may remove director passing company contracts arrangements ordinary resolution special notice given individually essential businesses party passing special resolution director may automatically significant agreements would take effect alter cease director terminate upon change control following takeover bid becomes bankrupt compounds company agreements director creditors generally officer would provide compensation loss office ceases director virtue companies acts employment resulting takeover except provisions articles companys share plans may cause options awards granted plans vest takeover details termination suffering mental ill health provisions companys framework contracts executive missed directors meetings continuous period directors given six months without permission board resolves shall cease director interests voting rights prohibited director law stated far company aware persons significant direct indirect holdings resigns company information provided company pursuant offers resign board accept offer financial services authoritys fsa disclosure transparency directors least three number require rules dtrs published regulatory information service resign companys website th february company received notifications accordance fsas dtrs following notifiable interests voting rights companys issued share capital percentage issued shares capital blackrock inc legal general group plc percentage ordinary shares issue excluding treasury shares th february gsk annual report pp noitarenumer dna ecnanrevog corporate governance articles association notwithstanding new policy company continues support powers directors determined uk legislation gsk political action committee pac employees usa companys articles association available gsks gives political donations pac employee organisation website articles may amended special resolution allows employees contribute fund political members directors may exercise companys powers donations employees decide upon recipients pac provided articles applicable legislation stipulate donations total powers must exercised members donated political organisations gsk pac directors authorised issue allot ordinary agm may shareholders first authorised shares current article power current article company make donations eu political organisations authority company make purchases incur eu political expenditure provisions political shares subject shareholder authorities sought parties elections referendums act annual basis agm shares purchased year authority since renewed annually law company may cancelled held treasury shares requires companies continue obtain shareholder approval share buyback programme make donations eu political organisations incur eu political expenditure however company billion programme share repurchases commenced make intend make donations political parties july shares costing billion repurchased independent election candidates make donations programme repurchases made eu political organisations incur eu political expenditure company expect make significant repurchases programme covered purchases definitions political donations political expenditure company shares cancellation held treasury political organisations used legislation wide shares accordance authority renewed shareholders particular definition eu political organisations may agm may company authorised extend bodies concerned policy review law purchase maximum million shares details reform representation business community special shares purchased prior years cancelled held interest groups concerned environment treasury shares disclosed note financial statements company subsidiaries might wish support share capital share premium account result definitions may cover legitimate business activities ordinary sense considered political donations exact amount timing future purchases political expenditure activities designed support extent repurchased shares held treasury shares political party independent election candidate authority rather cancelled determined company board sought annually precautionary measure dependent market conditions factors ensure company subsidiaries inadvertently donations political organisations political breach legislation expenditure effect st january ensure consistent approach political contributions across group gsk introduced global policy stop voluntarily political contributions political donations eu political organisations noneu political organisations comprising usa canada prior introduction groups new approach political contributions usa largest recipient political donations line us law corporate donations made federal level candidates political parties state local levels gsk supported candidates sought environment appropriately rewarded highrisk highinvestment industries situation similar canada rest world donations rare low value gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance annual general meeting internal control framework board recognises responsibility present balanced agm held pm thursday th may understandable assessment groups position prospects queen elizabeth ii conference centre broad sanctuary westminster london swp ee business transacted board accountability reviewing approving meeting include adequacy effectiveness internal controls operated group including financial operational compliance controls receiving adopting glaxosmithklines risk management board delegated responsibility annual report review audit risk committee receives approving remuneration report regular reporting aligned gsks assurance programme remuneration report pages sets responsibility management cet implement remuneration policies operated glaxosmithkline board policies risk control cet responsible disclosures directors remuneration including identifying approving monitoring enforcing key policies required companies act large go heart group conducts business mediumsized companies groups accounts reports internal control framework includes central direction resource regulations resolution proposed approve allocation risk management key activities research remuneration report development manufacturing marketing sales legal human resources information systems financial practice part retirement reelection directors framework comprehensive planning system dr stephanie burns mr julian heslop sir deryck maughan annual budget approved board results operating dr daniel podolsky sir robert wilson retire units reported monthly compared budget offer reelection board current forecasts prepared regularly year article companys articles association group also place established procedures identify reappointment remuneration auditors consolidate reporting entities groups control activities include resolutions proposed authorise audit risk policies practices covering appropriate authorisation committee reappoint pricewaterhousecoopers llp approval transactions application financial reporting standards auditors determine remuneration reviews significant judgements financial performance pecial business extensive financial regulatory operational controls procedures company seek authority risk activities reviewed groups internal auditors make donations eu political organisations incur responsibility however clearly delegated local business units eu political expenditure capped supported regional management structure principles allot ordinary shares company designed provide environment central leadership give directors authority disapply preemption rights coupled local operating autonomy framework allotting new shares connection rights issues exercise accountability control within group otherwise maximum current group also attaches importance clear principles issued share capital purchase ordinary shares procedures designed achieve appropriate accountability maximum current issued control group policy risk management legal compliance share capital mandates business units establish processes managing exempt auditors state name monitoring risks significant businesses group senior statutory auditor company gsks internal control framework also relies following annual report overseeing reporting risk compliance issues reduce notice required call general meeting less clear days risk oversight compliance council rocc rocc council senior executives authorised board amend companys articles association line assist audit risk committee oversee risk management companies act shareholder rights directive internal control activities group membership comprises include limit annual fees paid directors several cet members heads departments shareholders entitled appoint one proxies attend internal control risk management assurance audit agm speak vote behalf provided compliance responsibilities event single shareholder appoints multiple proxies rocc meets regular basis review assess significant proxy appointed exercise rights attached risks mitigation plans provide oversight internal different share shares held member controls ensure compliance applicable laws regulations details appoint appointed corporate internal gsk policies rocc responding group policy representative proxy found notice referred provided business units framework agm published companys website risk management upward reporting significant risks mitigation planning identification manager overall responsibility management given risk requirement gsk annual report pp noitarenumer dna ecnanrevog corporate governance risk oversight audit risk compliance committee council internal assurance business unit assertion audit assessment assessment independent external audit emerging business internal review business regulatory incidents risk control audit business unit monitoring agency outcome events management infrastructure activity internal audit activity gsk risk universe management internal assurance audit risk management compliance boards rmcbs new alignment global audit functions rmcbs established major business units strengthens gsks governance model affording internal membership often comprises members senior executive audit group greater independence reduces fragmentation among team respective business unit augmented specialists global audit functions provides direct reporting line appropriate rmcbs oversee management internal audit group gsks company secretary corporate risks considered important respective business compliance officer chairman audit risk units including risks designated significant committee ensure significant issues escalated timely glaxosmithkline whole thus increasing number risks manner helped eliminate overlaps gaps potential actively managed across group overunder auditing existed previous structure business unit corporate function must periodically review also provides clear platform developing common significant risks facing businesses review approach conduct internal audits helps ensure include identifying operational risks legal compliance risks risks consistency audit activities performed achievement strategic goals objectives review efficient effective way must occur least annually embedded within assurance reporting aligned annual planning process ensure significant assurance reporting audit risk committee follow risks identified changes management direction structured programme integrating reporting business units external environment assurance internal audit assurance business units corporate functions required present assurance programme implemented reports annually rocc audit risk committee enhance governance provide independent assessment detail risk management compliance approach providing governance risk management control processes balanced assessment status internal controls key risks organisation within gsk comprises four main elements highlighting significant compliance issues management internal audit must oversee risks considered important respective business units including risks designated significant gsks internal audit group responsibility independently group information regarding controls place manage assessing adequacy effectiveness management risks provided assure audit risk committee significant risk areas reporting audit risk risks adequately managed within internal control committee line agreed annual assurance plan framework gsks internal audit functions undergone significant transformation four global audit functions group internal internal audit reports audit risk committee audit manufacturing internal audit rd internal audit time business unit provides independent assessment environment health safety sustainability internal audit whether adequate controls place manage significant risks consolidated single organisation leadership head audit assurance head audit assurance reports gsks company secretary corporate compliance officer separate reporting responsibility chairman audit risk committee gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance issues control deficiencies identified internal audit areas groups business necessary recommends processes improvement gsk managers develop take risks achieve satisfactory return shareholders corrective action plans eliminate causes noncompliance investment rd acquiring new products businesses address gaps internal controls internal audit tracks cases groups objective apply expertise plans completion reports results senior management prudent management rather elimination risk audit risk committee directors review relates company subsidiaries extend material associated undertakings joint significant compliance issues internal audit results escalated ventures investments audit risk committee earliest opportunity board audit risk committee reviewed risk management assessment risks internal control framework groups risk management programme extends beyond operates glaxosmithkline considered effectiveness legal regulatory issues considers groups overall system internal control operation group strategy changes external environment furthermore year covered report date approval risk management principles embedded within management board process followed board reviewing practices part business strategy objectives system internal controls accords guidance internal setting process control issued turnbull committee details risks affecting group see risk factors pages committee reports note financial statements legal proceedings board committees report regularly board performance strategic risk evaluations sres activities assigned sres new approach delivering enterprisewide assurance audit risk committee report significant issues facing gsk conducted assurance teams partnership business approach designed evaluate areas incomplete understanding risk enable development implementation appropriate mitigation plans sre sponsored cet member risk owner oversight sre provided rocc corporate ethics compliance cec rocc also supported cec department responsible supporting development implementation practices facilitate employees compliance laws group policy department provides assistance help employees meet high ethical standards comply applicable laws regulations corporate responsibility tom de swaan thrust groups compliance effort due diligence audit risk committee chairman preventing detecting misconduct noncompliance law regulation promoting ethical behaviour compliance attendance full meetings laws regulations corporate responsibility levels members committee member since effective compliance systems mr de swaan st january cec department managed company secretary chairman corporate compliance officer reports directly ceo st september company secretary corporate compliance officer chairs professor sir roy th may rocc provides summary reports roccs activities anderson groups significant risks cet audit risk committee regular basis corporate compliance officers sir deryck maughan st january direct reporting line audit risk committee provides dr podolsky st january mechanism bypassing executive management sir robert wilson th december need ever arise sir ian prosser th december effectiveness controls dr r schmitz th december internal control framework operation whole year review continues operate sir ian prosser dr schmitz retired board th may date approval report system internal controls addition six scheduled meetings committee also met designed manage rather eliminate risk achieving quorate basis five occasions business objectives provide reasonable absolute assurance material misstatement loss audit risk committee receives reports areas significant risk group related internal controls following consideration reports received via assurance framework audit risk committee reports annually board effectiveness controls gsk annual report pp noitarenumer dna ecnanrevog corporate governance attendees committee meetings financial accounting experience ceo mr tom de swaan chief financial officer abn amro cfo st december chairman determined board audit general counsel committee financial expert defined sarbanes oxley act sarbanesoxley head audit assurance company secretary corporate compliance officer sir deryck maughan partner kohlberg kravis roberts co head global internal audit appropriate kkr chairman kkr japan external auditors former chairman ceo citigroup committees main responsibilities include international vice chairman citigroup inc r eviewing corporate accounting financial reporting former chairman cochief executive process officer salomon smith barney monitoring integrity financial statements former chairman chief executive e valuating system internal control identifying officer salomon brothers inc managing risks including relation financial reporting process preparation consolidated accounts sir robert wilson economist former nonexecutive verseeing activities groups compliance chairman economist group audit functions overseeing compliance laws chairman bg group plc regulations ethical codes practice retired rio tinto held senior management positions culminating committees oversight role requires address regularly appointment executive chairman relationships management internal external auditors understand monitor reporting relationships tiers accountability scientific expertise committee receives regular reports members professor sir roy world renowned medical scientist cet senior managers covering key risk management anderson advanced knowledge infectious disease compliance activities group including covering rd epidemiology manufacturing sales marketing corporate functions professor infectious disease epidemiology details reporting framework committee faculty medicine imperial college set pages internal control framework london fellow royal society december committees terms reference amended reflect role overseeing identification foreign associate member institute management risk new assurancebased audit medicine us national academy framework referred pages time sciences name audit committee changed audit foreign associate member french risk committee academy sciences former rector imperial college london qualifications audit risk committee members former chief scientific adviser ministry committee members exception professor sir roy defence uk anderson dr podolsky bring considerable financial accounting experience committees work members dr daniel podolsky world renowned researcher past employment experience either finance accounting roles advanced knowledge underlying comparable experience corporate activities professor sir mechanisms disease new therapies roy dr podolskys backgrounds world renowned medical gastrointestinal disorders scientists researchers enable bring scientific expertise president university texas committees deliberations southwestern medical centre professor internal medicine member institute medicalnational academy sciences former mallinckrodt professor medicine harvard medical school former chief academic officer partners healthcare gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance committee worked structured programme committee primary responsibility making activities standing items committee required recommendation shareholders appointment consider meeting together matters focused reappointment removal external auditors annually coincide key events annual financial reporting cycle assessing qualifications expertise resources independence external auditors effectiveness audit process external auditors reported critical accounting evaluating effectiveness audit process prior making policies significant judgements recommendation reappointment external auditors practices used group alternative committee reviews effectiveness performance accounting treatments criteria agrees conjunction management discussed management beginning years audit part process resultant conclusion material written committee considers feedback prior years external audit communications management gathered survey facilitated auditors client service restrictions access information review team independent engagement team undertook audit work survey seeks feedback cfo reported financial performance number sources including certain members board company technical financial involved audit process financial management accounting matters team corporate business unit level general counsel reported material litigation agreeing audit fee proposed external auditors company secretary reported corporate governance committee considers cost comparisons ensure fair corporate activities undertaken rocc appropriate gsk contractual obligations compliance officer restrict committees capacity recommend particular firm external auditors group pricewaterhousecoopers llp heads audit majority heads groups remained place auditors since groups inception assurance reported audit scope annual december groups compliance coverage audit resources audit groups results audits conducted throughout making assessment committee considers papers year detail relevant uk legislative regulatory professional requirements relating external auditors evaluates company secretary reported matters affected reports external auditors compliance chairman quality timely disclosure financial requirements safeguards established disclosure material information internal quality control procedures consideration committee board public markets also given committee need include risk shareholders enabled withdrawal external auditors market risk committee review clarity evaluation planning completeness disclosures published annual financial statements external auditors provide nonaudit services interim reports quarterly preliminary committee ensures auditor objectivity independence results announcements formal safeguarded policy requiring preapproval announcements relating financial committee services services may include audit performance prior approval services auditrelated services tax services services board preapproval detailed particular service categories services subject specific budget audit risk committee management internal auditors external auditors management report regularly full board work together ensure quality companys committee regarding extent services provided accordance corporate accounting financial reporting committee preapproval fees services performed serves primary link board external committee may also preapprove additional services internal auditors facilitates necessary independence casebycase basis expenditure audit nonaudit services management encourages external internal auditors set note financial statements operating profit communicate freely regularly committee committee met collectively separately guidelines set companys policy engaging external auditors head audit assurance external auditors provide nonaudit services include ascertaining corporate compliance officer without members management skills experience external auditors make present suitable supplier nonaudit services adequate safeguards place objectivity independence audit threatened compromised fee levels relative annual audit fee within limits set committee company also wellestablished policies including code ethics available website helpline facility reporting investigation unlawful conduct waivers code made gsk annual report pp noitarenumer dna ecnanrevog corporate governance nominations committee report process continues committee placing emphasis candidates current ceos financial expertise professional search agencies engaged specialising recruitment high calibre nonexecutive directors dossiers potential nonexecutive appointees provided committee candidates shortlisted interview merit objective criteria considering relevant qualifications appointing new executive directors cet members committee considers skills knowledge experience required particular executive position committee consider potential external internal candidates recommending board approve new appointment new directors offer election companys next agm appointments announced publicly ms deirdre connelly appointed president north america sir christopher gent pharmaceuticals th february also became member nominations committee chairman cet attendance full meetings committees recommendation board approved members committee member since following changes took effect retirement sir ian prosser dr schmitz board conclusion sir christopher gent th december agm may sir robert wilson replaced sir ian chairman sid sir crispin davis replaced sir robert chairman st january remuneration committee professor sir roy anderson became mr l culp th march member audit risk committee mr de swaan stepped sir crispin davis th july corporate responsibility committee became sir deryck maughan th july member remuneration committee mr murdoch became member corporate responsibility committee addition sir robert wilson th march committees recommendation board approved sir ian prosser th december appointment sir crispin sir deryck maughan members committee chairman nominations committee effect th july februarydecember committee also recommended board approved appointment mr murdoch member remuneration dr r schmitz th may committee effect st october sir ian prosser dr schmitz retired board th may remuneration report attendees committee meetings remuneration report found pages ceo chief staff head hr company secretary relevant appropriate external advisers committees main responsibilities include proposing appointment board committee members committees main focus recruitment new nonexecutive directors refresh board appointment new head north american pharmaceuticals recruiting nonexecutive directors committee considers particular skills knowledge experience would benefit board significantly appointment broad selection criteria used focus achieving balance representation european uk us markets individuals ceo experience skills developed various sectors specialities particular focus placed upon recruiting replacements sir ian prosser dr ronaldo schmitz retired agm committee recommended appointment mr james murdoch nonexecutive director gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp corporate governance corporate responsibility committee report year committee reviewed areas including pandemic flu including access vaccine antiviral medicine developing countries access pricing medicines developing countries rd diseases developing world patent pool community partnerships investment humanitarian donations sales marketing practices including harmonisation gsk codes practice disclosure payments healthcare professionals communication clinical trial results use animals research employment practices including diversity inclusion sir christopher gent corporate responsibility committee chairman employee wellbeing employee relations including consultation arrangements attendance employment litigation usa full meetings members committee member since supply chain management sir christopher gent th december climate change energy use reduction chairman manufacturing efficiency st january data privacy dr burns th december corruption prevention mr j murdoch th may gsk publishes comprehensive corporate responsibility report dr podolsky st july available companys website sir ian prosser th may combined code mr de swaan st july throughout company complied provisions applied main principles section combined code sir ian prosser retired board th may mr de swaan also ceased member committee date except regards aspect following provision attendees committee meetings may include chairman arrange chairmen audit remuneration nomination committees ceo available answer questions agm directors general counsel attend h ead corporate communications community entire board attendance companys agm partnerships may save sir deryck maughan prevented head corporate responsibility attending due urgent business commitments company secretary arose shortly meeting therefore needed convey apologies absence augment gsks engagement stakeholder opinion march ms sophia tickell appointed independent external us law regulation adviser committee ms tickell director pharma number provisions us law regulation apply gsk futures series aims align better societal shareholder companys shares quoted nyse value chairs international advisory group form ads medicines transparency alliance ms tickell attends meetings committee advises company capacity nyse rules general nyse rules permit company follow uk main responsibilities corporate responsibility corporate governance practices instead applied usa committee set committee rolling provided company explains significant variations agenda receives reports members cet explanation contained companys form f filing senior managers ensure progress meeting gsks accessed securities exchange commissions corporate responsibility principles reviewed five principles sec edgar database via companys website nyse rules access medicines standards ethical conduct research came effect require company file annual innovation employment practices global community interim written affirmations concerning audit risk committee partnerships reviewed annually principles discussed companys statement significant differences least every two years committee also reviews corporate governance approves corporate responsibility report gsk annual report pp noitarenumer dna ecnanrevog corporate governance sarbanesoxley act disclosed based recent evaluation following number corporate accounting scandals internal control financial reporting external usa congress passed sarbanesoxley act sarbanes auditors audit risk committee significant oxley wide ranging piece legislation concerned largely deficiencies material weaknesses design financial reporting corporate governance operation internal controls financial reporting reasonably likely affect adversely companys ability recommended sec gsk established disclosure record process summarise report financial information committee committee reports ceo cfo fraud regardless materiality involving persons audit risk committee chaired company secretary significant role companys internal control members consist senior managers finance legal financial reporting compliance corporate communications investor relations group carried evaluation supervision external legal counsel external auditors invited attend participation groups management including meetings periodically responsibility considering ceo cfo effectiveness design materiality information timely basis determining operation groups disclosure controls procedures disclosure information responsibility timely filing st december reports sec formal review annual report form f committee met times inherent limitations effectiveness system disclosure controls procedures including possibility sarbanesoxley requires annual report contains statement human error circumvention overriding controls whether member companys audit risk committee procedures accordingly even effective disclosure controls audit committee financial expert defined sarbanesoxley procedures provide reasonable assurance achieving summary regarding boards judgement matter refer control objectives additional disclosure requirements arise section section sarbanesoxley respect disclosure ceo cfo expect complete certifications controls procedures internal control financial reporting report conclusions effectiveness disclosure controls procedures st march following section corporate responsibility financial reports certificates filed sec part groups sarbanesoxley also introduced requirement ceo form f cfo complete formal certifications confirming section managements annual report internal reviewed annual report form f control financial reporting b ased knowledge contains material accordance requirements section sarbanes misstatements omissions oxley following report provided management respect b ased knowledge financial statements companys internal control financial reporting financial information fairly present material respects defined rules af df us securities financial condition results operations cash flows exchange act dates periods presented annual report management responsible establishing maintaining form f adequate internal control financial reporting hey responsible establishing maintaining disclosure group internal control financial reporting designed controls procedures ensure material information provide reasonable assurance regarding reliability made known evaluated effectiveness financial reporting preparation financial statements controls procedures yearend results external purposes accordance ifrs evaluation contained annual report management conducted evaluation effectiveness form f internal control financial reporting based hey responsible establishing maintaining internal framework internal control integrated framework control financial reporting provides reasonable issued committee sponsoring organisations assurance regarding reliability financial reporting treadway commission preparation financial statements external purposes changes groups internal control accordance generally accepted accounting principles financial reporting materially hey disclosed annual report form f affected reasonably likely affect materially changes internal controls financial reporting groups internal control financial reporting period covered annual report form f management assessed effectiveness internal control materially affected reasonably likely affect materially financial reporting st december companys internal control financial reporting conclusion filed part groups form f pricewaterhousecoopers llp audited consolidated financial statements group year ended st december also assessed effectiveness groups internal control financial reporting auditing standard public company accounting oversight board united states audit report filed groups form f gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report sir crispin davis remuneration committee chairman dear shareholder new chairman gsks remuneration committee pleased present committees remuneration report seeking approval shareholders agm may know made important changes gsks remuneration policy uk executive directors last year deliver appropriately structured pay alignment market gsks key strategic priorities high level shareholder engagement relation changes pleased receive strong vote favour last years remuneration report agm senior management alignment competitiveness since made progress simplifying aligning remuneration structures across corporate executive team cet result primary pay benchmarks based nature individual role rather industry benchmark previously used share options normally longer granted instead cet members receive performance share plan awards also eligible participate gsks deferred annual bonus plan also standardised pay mix across cet roles executive directors committee would want reward failure considers severance terms limited therefore determined contracts new cet appointees would normally include severance terms one years base salary bonus entitlement addition pleased report ceo agreed remove contractual entitlement bonus event termination employment also note increase holding gsk shares strategic alignment introduction second performance measure performance share plan provided clear focus cash generation business continuing develop measures align remuneration ongoing work transform gsk given importance long term organic growth rd productivity future gsk assessing meaningful ways measuring success areas may considered performance measures future awards good governance number corporate governance developments past year response economic turmoil likely come reviewed arrangements last year wanted ensure motivate excessive risk taking introduced new deferred annual bonus plan one first companies introduce clawback mechanism annual bonuses problems arise years bonus award made continue monitor best practice governance developments commit regular reviews remuneration arrangements ensure continue encourage right behaviours leadership team following report provides detail gsks current remuneration arrangements including changes made implemented committee believes changes support future business best interests shareholders sir crispin davis remuneration committee chairman th february gsk annual report pp noitarenumer dna ecnanrevog remuneration report remuneration committee two quorate meetings held year approve role committee formal grant longterm incentive lti awards accordance gsks remuneration policy role committee set companys remuneration policy executive directors cet members together exception mrs whyte deputy company secretary executives ensuring consistent companys secretary committee employees company scale scope operations supports business strategy involved conduct committee meetings mr witty ceo growth plans helps drive creation shareholder value mr heslop cfo mr bicknell senior vice president company setting remuneration policy levels senior secretary corporate compliance officer mr phelan chief executives committee gives consideration remuneration staff ms thomas senior vice president human resources policy levels wider employee population mr powley senior vice president corporate compensation invited attend part meetings committee terms reference required attend individual remuneration committees full terms reference conform discussed director involved deciding requirements combined code available companys remuneration website obtained company secretary committee access external advice required deloitte governance llp appointed committee provide board considers members committee independent advice executive remuneration year independent nonexecutive directors accordance deloitte llp provided independent commentary matters combined code exception chairman consideration committee provided updates best company sir christopher gent independent practice legislative requirements market practice appointment company deloitte llp also provided tax consulting services committee met times member gsk year provide advice executive attending follows remuneration matters committee towers number number watson provided additional market data committee meetings meetings held attended commitment shareholders committee member whilst whilst members since member member committee engages regular dialogue shareholders sir crispin davis st july holds annual meeting gsks largest investors chairman discuss take feedback remuneration policy th may key developments year particular committee discusses significant changes policy measures sir robert wilson st january used assess performance chairman th may th may summary policy result remuneration review changes mr l culp st january made remuneration packages ceo cfo sir christopher gent st january mr j murdoch st october remuneration structure cet members including mr de swaan th may chairman research development harmonised dr ronaldo schmitz th may ceo cfo result effect share options normally longer granted mr de swaan also chairman audit risk committee cet members instead cet members receive additional dr schmitz retired board th may performance share awards also eligible participate member committee prior date gsks deferred annual bonus plan gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report key elements remuneration policy onwards salary salary levels reviewed annually influenced executives role experience benchmarked relevant comparator groups annual bonus majority bonus based achievement financial targets based group profit interest tax business unit operating profit individual performance predetermined personal objectives also taken account determining individual bonus payments rd specific key performance indicators rd employees achievement additional operational efficiency goals also taken account determining annual bonuses respect individual including ceo maximum bonus opportunity salary committee reviews ongoing financial impact prior year activities executives role may make appropriate adjustments individual bonus awards reflect circumstances deferred individuals may elect defer bonus earned annual respect ceo cfo eligible participate bonus plan executives may participate deferred bonuses may matched oneforone subject relative total shareholder return tsr performance three years tsr vesting psp performance vesting based relative tsr using comparator group currently comprising pharmaceutical share companies plan psp half tsr component measured three years half four years vesting median vesting upper quartile performance twelvemonth averaging period tsr vesting based adjusted free cash flow measured three years vesting threshold rising stretching performance exceeding set threshold specified margin operating maximum face value annual performance share awards follows salary ceo chairman research development cfo share option options longer normally granted executives plan pension uk executives defined contribution plan legacy final salary plans closed new entrants since executives participating defined contribution plan benefit company contribution base salary plus matched contribution base salary us executives gsk operates us cash balance plan executives benefit contributions salary gsk annual report pp noitarenumer dna ecnanrevog remuneration report total remuneration benchmarking ceo committee reviews gsks total remuneration comparable companies regular basis ensure salary remuneration arrangements structured appropriately deliver cash bonus value money shareholders longer term deferred bonus including match competitive relevant comparator groups determined performance shares individual executive benchmarking purposes total remuneration incorporates base salary bonus ltis setting pay committee also considers pension arrangements cfo uk crossindustry comparator group global pharmaceutical comparator group salary angloamerican france sanofiaventis cash bonus astrazeneca switzerland novartis deferred bonus including match barclays roche holdings performance shares bg group uk astrazeneca bhp billiton usa abbott laboratories bp amgen british american tobacco bristolmyers squibb chairman rd diageo eli lilly hsbc johnson johnson salary reckitt benckiser merck cash bonus royal dutch shell pfizer rio tinto deferred bonus including match performance shares standard chartered tesco unilever vodafone committee considered current economic revised reflect delisting scheringplough wyeth see conditions new gsk harmonised pay philosophy amgen included benchmarking current accordingly agreed ceo cfo pay would tsr comparator group held levels part alignment pay structures across cet dr slaouis base salary adjusted reflect individual elements remuneration new balance also market rate pay responsibilities balance fixed base salary variable annual table immediately following sets current base salaries bonus lti elements remuneration varies depending proposed performance charts right show anticipated mix salary increases typically take effect st april year fixed variable pay expected value basis new remuneration policy actual mix may higher base effective date base effective date lower depending performance gsk individual salary salary salary salary change typically significant portion approximately mr witty st april st april executive directors package variable mr heslop st april st april base salary dr slaoui st april st april base salaries set reference relevant comparator group level considered appropriate secure talent needed deliver gsks strategic priorities gsks remuneration policy based principle achieving competitiveness global pharmaceutical industry primary pay comparator committee decides individual executive basis whether primary pay comparator global pharmaceutical sector ukbased large crossindustry multinationals andor comparator groups primary comparator group uk crossindustry global pharmaceutical mr witty ceo mr heslop cfo dr slaoui chairman rd salary levels reviewed annually influenced executives role experience pay environment gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report annual bonus bonus targets ceo set board setting objectives ceo board focuses strategies annual bonus designed drive achievement developed company set pages gsks annual financial strategic business targets well personal objectives annual report reasons commercial sensitivity specific objectives kept confidential following end ontarget bonus executive directors given financial year board reviews ceos performance table generally set objectives committee determines bonus payable ontarget bonus base salary ceo executives ceo makes recommendations cfo committee regarding performance objectives chairman rd recommendations considered committee determining level bonuses payable maximum bonuses set reference individual ontarget year committee reviews ongoing financial impact bonus levels cap bonus payments prior year activities role individual executives salary cap remains unchanged annual bonus activities committee may make appropriate adjustments pensionable individual bonus awards reflect circumstances last year committee revised annual bonus plan chairman audit risk committee member strengthen alignment new business strategy details committee provides input audit risk committees set pages budgeting process review groups performance adjustments made respect bonuses bonus measures rd employees including dr slaoui linked group profit interest pipeline robust governance structure established tax ensure bonus payable fairly reflects rd productivity performance well performance profit targets stretching process requires review progress targets rd financial bonus compensation review committee includes ceo annual targets business unit companys two nonexecutive directors designated bonus operating profit scientific experts professor sir roy anderson dr podolsky targets committee reviewed plan operation year decided continue annual bonus rd committee continue keep operation review may future consider extending executives including ceo individual objectives bonus awards objectives set company focused particular continued development launch late stage pipeline assets delivery commercial targets execution restructuring majority annual bonus opportunity based formal programmes simplify operating model review performance stretching financial targets based group profit interest tax business unit operating committee took account gsks success achieving profit targets remainder based achievements objectives well individuals performance specific individual objectives annual bonuses calibrated determining bonus awards actual bonus payments reflect stretching targets established executive directors shown ranged drive significant changes gsks business model bonus base salaries st december threshold target maximum payable bonuses set committee reflect gsks increased sales achievement target bonus threshold profit cash flow performance year challenging reflects stretching nature bonus targets market conditions significant loss sales generics usa also includes achievement key strategic individual objectives including delivering continued growth vaccine portfolio geographic diversification particularly within emerging markets consumer healthcare achieving key milestones transformation rd productivity particularly relation late stage rd pipeline products simplification gsks business model achievement operational efficiencies gsk annual report pp noitarenumer dna ecnanrevog remuneration report deferred annual bonus plan performance shares new deferred annual bonus plan introduced performance share plan ensures focus gsks encourage longterm shareholding discourage longterm shareholder returns relative excessive risk taking help drive longterm shareholder pharmaceutical companies delivery gsks returns relative global pharmaceutical companies strategic priorities eligibility bonus year restricted ceo plan measurement performance broadened cfo cet members invited participate senior team incentivised operational bonus year onwards part simplification cet measures aligned gsks business strategy well tsr remuneration structure tsr remains appropriate comparative measure since focuses return shareholders wellunderstood tested annual bonus earned may deferred three mechanism measure performance allows comparison years company match shares oneforone depending companies operating different countries therefore companys relative tsr period performance typically proportion award made executives measure vesting schedule consistent threeyear continue subject relative tsr balance based tsr component performance share plan described strategic operational measures support business strategy ceo elected participate gsks deferred annual bonus emphasis working plan respect bonus result capital cash management ceos bonus deferred shares company retesting performance matching award number shares made may vest february subject companys awards relative tsr performance continued employment performance share awards executives made february dividend equivalents accrue delivered respect deferred shares matching shares vest tsr measure awards made award based longterm incentive plans relative tsr using comparator group currently comprising new lti plans approved shareholders agm global pharmaceutical companies tsr element provide better alignment uk market practice percentage vesting median full vesting upper ceo cfo receive share option grants instead quartile tsr performance graph shows tsr vesting ltis form performance shares also schedule awards granted opportunity defer part bonus earned shares proportion vesting outlined eligible receive matching shares subject achievement additional performance conditions chairman research development continued receive share options eligible participate new deferred annual bonus arrangement however onwards remuneration arrangements cet members including chairman research development aligned ceo cfo result share options normally longer granted instead cet members receive performance share awards new lti plans committee may reduce grant vesting levels determines participant engaged conduct contrary legitimate expectations company employee participants position typically awards delivered us resident executives form ads awards delivered form ordinary shares executives resident uk countries awards tsr rank position made plans incorporate dilution limits consistent guidelines provided association british insurers provide focus sustained longerterm performance current estimated dilution existing awards gsk performance period extended awards made employee share schemes made since merger approximately half tsr element award measured companys share capital st december three years half four years lti plans summarised relevant sections measure performance stable basis reflect better together basis awards made longterm nature pharmaceutical industry tsr averaging executives period twelve months awards made onwards gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report ensures focus award based return relative tsr available shareholders end year global pharmaceutical phasing drives psp companies sustained longer award term performance paid shares amount varies based performance award based adjusted free cash flow adjusted free cash flow measure vesting awards recognise importance effective working capital committee reviewed performance performance share cash management remaining vest subject awards granted executive directors february achievement adjusted free cash flow targets target may threeyear performance period starting st january adjusted material factors could distort free cash flow ending st december company ranked performance measure typically include exchange median revised comparator group therefore rate movements may also include legal major taxation awards vested awards made senior executives settlements special pension contributions could dependent part tsr performance part materially distort calculation impact acquisition eps performance eps portion awards vest divestment quantified adjusted vesting tables recent performance share awards together event major adjustments calculation disclosed share option awards shown shareholders awards targets b share options adjusted free cash flow targets vesting part remuneration review undertaken threshold vesting billion decided share options would longer granted billion ceo cfo align packages better uk billion market outlined since decided simplify maximum vesting billion remuneration structure cet members share options normally longer granted cet members points vesting calculated straight onwards line basis element based adjusted free cash flow measured three years details subsisting options performance conditions attached grant provided audited section award values report individual award limit maximum initial value performance shares may granted individual vesting awards one year exceptional circumstances maximum performance conditions share option awards granted face value performance shares may granted met result awards lapsed individual one year six times salary value c historical vesting gsks ltis performance share awards granted executive directors shown table gsks lti performance conditions continue challenging demonstrated table tsr important base salary award part lti measures many years measure retained current policy ceo shares cfo shares chairman rd ads adjusted reflect removal share options provide closer link shareholder returns payments executives notional dividends reinvested paid proportion vesting award value reinvested dividends incorporated benchmarking award levels gsk annual report year year year year available end year recognises importance available effective working end year capital management cashpp noitarenumer dna ecnanrevog remuneration report following table shows vesting levels gsks performance b us pension arrangements share share option awards executives since usa gsk operates us cash balance plan provides remuneration review tsr vesting percentage annual contribution interest sum accumulated indicates gsks tsr performance median cash balance plan contractual promise provide comparator group performance period specific levels retirement income plan incorporates performance share share option executive pension credit senior us executives contribution plan plan rates plan range base salary vesting vesting depending grade current senior us executives eligible tsr eps performance period measure measure executive pension credit capped employees usa benefits cap provided unfunded nonqualified plan share ownership requirements align interests executives average annual vesting shareholders executives required build maintain significant holdings shares gsk time award made due change award cycle current share ownership requirements sor set table pensions share ownership requirement pensions provide important tool creating longterm ceo x base salary culture loyalty executive directors x base salary executives participate gsk senior executive pension plans cet members x base salary pension arrangements structured accordance year mr witty building shareholding plans operated executives country actively purchasing shares market spent total likely retire details individual arrangements executive tax earnings since publication last directors set annual report help build towards sor addition new executives gsk eligible either defined acquisition shares dividend reinvestment also contribution scheme cash balance plan existing obligations elected participate gsks deferred annual bonus plan defined benefit schemes uk continue respect pretax bonus resultant honoured award deferred shares included mr wittys sor table uk pension arrangements company currently operates defined contribution plan shareholdings purpose sor th february legacy final salary plans closed new entrants newly hired executives uk participate defined holding holding contribution plan sor purposes sor purposes increase shareholding uk government announced series changes mr witty pensions impact pensions approximately ordinary shares ordinary shares executives gsk proposed pension legislation mr heslop implemented full could significant negative consequences ordinary shares ordinary shares uk executives effectiveness pensions dr slaoui significantly reduced pensions continue ordinary shares ordinary shares important tool creating longterm culture promoting employee retention therefore gsk keeping situation executives required continue satisfy shareholding active review requirements minimum twelve months following executives participating defined contribution plan receive retirement company support longterm nature company contribution base salary depending business grade also opportunity receive remuneration elements matched contributions line policy executives participate various allemployee share plans members pension plan either uk usa legacy final salary plans provide twothirds final sharesave plan sharereward plan uk hm salary age employees subject cap benefits revenue customs approved plans open uk employees excess cap currently provided unfunded terms arrangements legacy final salary plans actuarial reduction factors apply participant leaves employment mr witty mr heslop members sharesave plan hisher accord age mr witty mr heslop contribute month plan provides option buy shares end employment terminated company cause threeyear savings period line opportunity available way members legacy final uk employees salary plans reduction factors apply gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report mr witty mr heslop also contribute per month buy case outstanding awards glaxosmithkline shares sharereward plan company matches annual investment plan closed new deferrals number shares bought month effect first quarter provided agreement terminated cause deferred executives also receive benefits including healthcare amount income gains automatically medical dental personal financial advice life assurance distributed soon administratively practicable cash value benefits received executive directors termination shown line policy applicable us senior executives executive director terms conditions dr slaoui may become eligible future date receive executive director contracts continuing medical dental insurance retirement policy set provides framework contracts following merger participants legacy share option executive directors schemes elected exchange legacy options options glaxosmithkline shares receive additional cash notice period calendar months benefit equal grant price original option termination additional benefit triggered option exercised employing company lapses qualify additional cash benefit participants executive retain options least second anniversary termination payment x annual salary effective date merger x annual ontarget bonus outside appointments executive directors mitigation required outside appointments must approved chairman vesting ltis rules relevant incentive plan behalf board companys policy remuneration approved shareholders earned appointments may kept individual executive director pension based existing arrangements terms relevant pension plan nonexecutive director terms conditions nonexecutive directors glaxosmithkline service noncompete clause months termination contracts instead letters appointment notice date agreed serve company nonexecutive director ceo agreed amendment contract remove contractual conclusion agm following third anniversary entitlement bonus part termination package contracts appointment case extended new executives normally include bonus element termination term three years mutual agreement directors serve payment however extent company imposes noncompete term longer three years without offering provisions restricts individual working elsewhere compensatory reelection shareholders payment may made nonexecutive directors entitled compensation ability impose month noncompete period nonsolicitation restriction executive considered important company order appointment terminated ability protect groups intellectual property staff light following table shows date initial letter committee believes would appropriate provide appointment nonexecutive director mitigation contracts following table sets details executive directors nonexecutive director date letter appointment service contracts professor sir roy anderson current directors date contract effective date expiry date dr burns mr l culp mr witty sir crispin davis mr j heslop sir deryck maughan dr slaoui mr j murdoch mr wittys contract renewed june following appointment dr podolsky ceo supplemented th february reflect changes mr de swaan severance terms outlined sir robert wilson termination payments made respect part sir ian prosser notice period extending beyond contract expiry date dr r schmitz entitlements sir ian prosser dr ronaldo schmitz retired board conclusion addition contractual provisions outlined agm th may event executive directors service agreements terminated employing company following apply gsk annual report pp noitarenumer dna ecnanrevog remuneration report nonexecutive directors fees shares ads notionally awarded company aims provide nonexecutive directors fees nonexecutive directors allocated interest accounts competitive paid companies included within directors interests tables equivalent size complexity fees applying st december accumulated balance shares ads together follows notional dividends subsequently reinvested paid nonexecutive directors retirement board per annum upon retirement nonexecutive directors receive either standard annual cash retainer fee shares ads cash amount equal value shares supplemental fees ads date retirement chairman chairman audit risk committee sir christopher gents letter appointment board senior independent director dated th may agreed would scientificmedical experts serve company deputy chairman st december st january chairman conclusion chairman remuneration corporate agm following third anniversary appointment responsibility committee extended term three years mutual agreement nonexecutive director undertaking effect reelection director agm held intercontinental travel meetings per meeting st may chairmans fees currently per annum plus chairman current chairman corporate allocation shares value per annum responsibility committee receive additional fee listed tsr performance graph reflect increased focus within company following graph sets performance company compliance risk gsk significantly enlarged remit relative ftse index company responsibilities audit risk committee constituent pharmaceutical performance comparator commitment required chairman company agreed group st january st december graph time requirement role committee chairman prepared accordance regulations moving approximately days approximately days indication likely vesting awards granted per annum reflected increase fees companys incentive plans payable details changes committees terms tsr performance reference new audit assurance model given pages following independent review supplemental fee chairman audit risk committee increased per annum per annum effect st october exchange rate fees paid us dollars converted following exchange rates exchange rate date approval period rate applied us us us us us glaxosmithkline total return index given recent fluctuations us dollar exchange rate agreed glaxosmithkline pharma peers return index effect st october exchange rate would set ftse total return index annually based average daily rate last quarter year prior payment rate would reviewed exchange rates moved significantly directors senior management remuneration year following tables set directors glaxosmithkline nonexecutive directors share allocation plan plc remuneration earned interests shares enhance link directors shareholders gsk glaxosmithkline plc interests share options incentive requires nonexecutive directors receive significant part plans pension benefits members cet also fees form shares least nonexecutive participate remuneration plans executive directors total fees excluding chairman paid form directors aggregate remuneration interests shares ads allocated share account non directors senior management also provided executive directors may also take opportunity invest part balance fees share account gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report annual remuneration total total fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors mr witty abc mr j heslop b dr slaoui bd nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch e mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky former directors dr barzach mr j coombe sir ian prosser h dr r schmitz h dr jp garnier b dr l shapiro f mr c viehbacher bg dr yamada b total remuneration analysed executive directors nonexecutive directors former directors total remuneration remuneration directors us payroll reported dollars dollar amounts included totals based conversion sterling average exchange rates year mr witty joined board st january remuneration disclosed date b following merger order encourage employees convert nonsavings related options held legacy shares ads options glaxosmithkline shares ads employees granted additional cash benefit equal grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses underwater qualify additional cash benefit participants retain options least second anniversary effective date merger year mr witty received mr heslop received dr slaoui received result options granted lapsing dr garnier received mr viehbacher received nil dr yamada received nil result options granted lapsing c mr witty elected participate gsks deferred annual bonus plan respect bonus described dr slaoui nonexecutive director agency science technology research astar respect received included e mr murdoch appointed board effect th may f dr shapiro retired board th may stepped member gsks scientific advisory board st july received fees form ads included within fees salary g mr viehbacher appointed board st january remuneration disclosed date resigned board th september left company st december h sir ian prosser dr r schmitz retired nonexecutive directors company th may leaving board sir ian prosser dr r schmitz received accumulated balance shares previously awarded nonexecutive directors share arrangements based current share price differs value dates allocation set table included within fees salaries dr barzach received fees glaxosmithkline france healthcare consultancy provided included within fees salary none directors received reimbursement expenses year requiring separate disclosure required regulations gsk annual report pp noitarenumer dna ecnanrevog remuneration report nonexecutive directors remuneration total cash sharesads total cash sharesads fees current nonexecutive directors professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky former nonexecutive directors sir ian prosser dr r schmitz total remuneration table sets remuneration received nonexecutive directors company nonexecutive directors required take least part total fees form shares allocated share account paid retirement board see details total value shares ads date award together cash payment forms total fees included within annual remuneration table fees salary table sets value fees received form cash shares ads table sets accumulated number shares ads held nonexecutive directors relation fees received board members st december together movements accounts year number shares ads allocated dividends nonexecutive directors share arrangements footnote elected reinvested paid current nonexecutive directors shares professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch b mr de swaan sir robert wilson ads dr burns mr l culp sir deryck maughan dr podolsky former nonexecutive directors sir ian prosser dr r schmitz chairman receives allocation shares value per annum b mr murdoch appointed board effect th may gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report table sets settlement former nonexecutive directors share arrangements leaving board value value date awards awards payments footnote leaving allocation leaving sir ian prosser ab dr r schmitz ac change value awards allocation leaving attributable dividends reinvested change share price dates award dates leaving b awards sir ian prosser nonexecutive directors share arrangements partially settled shares balance shares settled c awards dr r schmitz nonexecutive directors share arrangements settled cash directors interests following interests directors company connected persons shown accordance fsa listing rules shares ads st january th february st december date th february st december st january footnote appointment executive directors mr witty mr j heslop dr slaoui b nonexecutive directors professor sir roy anderson c dr burns c mr l culp c sir crispin davis c sir christopher gent c sir deryck maughan c mr j murdoch cd dr podolsky c mr de swaan c sir robert wilson c one glaxosmithkline ads represents two glaxosmithkline shares interests abovementioned directors th february reflect change yearend date includes shares purchased glaxosmithkline sharereward plan mr witty totalling st december st december shares th february mr heslop totalling st december st december shares th february b includes ads purchased glaxosmithkline stock fund within us retirement savings plan us executive supplemental savings plan c includes shares ads received part fees described nonexecutive directors share allocation plan dividends received shares ads converted shares ads st december mr murdoch appointed board effect th may holdings shown date gsk annual report pp noitarenumer dna ecnanrevog remuneration report incentive plans share options options shares granted footnote date grant exercise period grant price number lapsed mr witty mr j heslop dr slaoui b options ads granted date grant exercise period grant price number lapsed dr slaoui b grant share options mr heslop respect participation sharesave plan b details include interests dr slaouis connected person also employee gsk options outstanding st december earliest latest vesting lapse dates options market price glaxosmithkline share yearend given table weighted average vesting date lapse date mr witty grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested unvested total share options st december weighted average vesting date lapse date mr j heslop grant price number earliest latest earliest latest options market price yearend vested unvested options market price yearend vested unvested total share options st december weighted average vesting date lapse date dr slaoui grant price number earliest latest earliest latest options market price yearend vested options market price yearend vested total share options st december options market price yearend unvested options market price yearend unvested total ads options st december includes share options held dr slaouis connected person also employee gsk gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report gsk granted share options executive directors annual basis directors hold options various share option plans referred note financial statements employee share schemes none nonexecutive directors interest option companys shares table sets share options granted respect performance periods performance targets whether options vested st december performance target vesting status annualised growth percentage grant footnote performance period eps award vesting february unvested rpi february unvested rpi rpi rpi rpi performance targets share options met result lapsed third anniversary date grant table sets share options granted respect performance period targets performance target vesting status annualised growth percentage grant performance period eps award vesting february award unvested rpi february award unvested rpi rpi rpi rpi highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline ads year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december prices th february per glaxosmithkline share per glaxosmithkline ads performance share plan psp awards performance share awards made executive directors annual basis directors hold options various psp plans referred note financial statements market additional mr witty shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested market additional mr j heslop shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested gsk annual report pp noitarenumer dna ecnanrevog remuneration report market additional dr slaoui shares number price vested shares unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested market additional dr slaoui ads number price vested ads unvested granted date market dividends unvested performance period grant number price gain lapsed reinvested includes performance shares held dr slaouis connected person also employee gsk terms psp number shares actually vesting determined following end relevant measurement period dependent gsks performance period described pages committee adjusted comparator group removing scheringplough wyeth following delisting revised vesting schedule accordingly outstanding future awards tsr performance measured revised comparator group including gsk set dividends reinvested performance shares awarded executives throughout performance period date final award dividend reinvestment calculated dividend payment date terms psp us participants may defer receipt part vested awards total gain vesting psp awards made executive directors connected persons following vesting schedules apply psp awards made tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median following vesting schedules apply psp awards made tsr vesting schedule award award performance period tsr rank companies percentage award vesting median median adjusted free cash flow vesting schedule cash flow targets award award performance period bn percentage award vesting gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp remuneration report share value plan awards market dr slaoui shares ads number price vested deferred unvested granted date market unvested plan year grant number price gain shares ads ads ads ads executive director dr slaoui eligible receive awards share value plan awards shown reflect holdings dr slaouis connected person employee gsk awards subject threeyear vesting periods vesting contingent continued employment gsk pension benefits accrued annual pension benefits transfer values executive directors office st december retirement set companies act requires disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change pensions executive directors disclosed currency pension payable change change personal accrued transfer value accrued accrued accrued contributions transfer transfer change benefit change benefit benefit benefit made value value transfer year net accrued year year value inflation benefit executive directors mr witty mr j heslop dr slaoui dr slaoui shown net contributions made individual mr witty mr heslop participate glaxo wellcome defined benefit plan accrual rate th final pensionable salary per annum benefits accrued glaxo wellcome uk pension arrangements augmented trustees plans reflect distribution surplus augmentation apply element mr witty mr heslops pension earnings st march mr wittys mr heslops transfer values calculated basis actuarial advice accordance pensions regulation transfer value represents present value future payments made pension plan mr wittys annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year mr heslops annual accrued benefit increased excluding effects inflation transfer value less personal contributions increased year gsk annual report pp noitarenumer dna ecnanrevog remuneration report dr slaoui member us executive cash balance pension th february group comprising persons owned plan plan provides executive pension credit shares ads constituting less gsk makes annual contributions calculated percentage issued share capital company group also held executives base salary gsk makes contributions date options purchase shares base pay fund increases interest rate set annually ads shares ads awarded advance based year us treasury bond rate provide performance share plan including shares ads cash sum retirement plan entitlement spouses vested deferred vested deferred ads pension pension increases legacy smithkline beecham midterm incentive plan shares ads awarded share value plan transfer value cash sum increased notional shares awarded deferred investment award dr slaoui year result accumulation plan holdings issued various executive share interest contributions paid company option plans described note financial statements dr slaoui active participant belgium fortis plan employee share schemes st may plan defined benefit plan directors interests contracts lump sum payable normal retirement age except described note financial statements related plan transfer value cash sum dr slaouis plan party transactions end financial year increased year result director connected person material interest accumulation interest contract significance relation groups business dr slaoui member us retirement savings plan k group company savings scheme open us employees executive basis preparation supplemental savings plan savings scheme open executives accrue benefits us government limits imposed directors remuneration report prepared retirement savings plan contributions plans invested accordance companies act large range funds value accumulated funds paid mediumsized companies groups accounts reports retirement regulations regulations meets relevant requirements fsa listing rules accordance contributions paid regulations following sections remuneration report two schemes gsk respect dr slaoui subject audit annual remuneration nonexecutive directors directors senior management remuneration incentive plans share options performance share plan awards vesting criteria share value plan awards information also provided compensation interests pension benefits opinion thereon expressed directors senior management group group remaining sections subject audit purpose group defined executive pages referred within audited sections nonexecutive directors members cet financial remuneration report approved board year total compensation paid members group directors signed behalf periods served capacity aggregate increase accrued pension benefits net inflation aggregate payment defined contribution schemes sir christopher gent members group granted chairman share options ads options share option th february plan awarded shares ads performance share plan awarded shares ads share value plan notional shares ads granted deferred investment award plan members group awarded reinvestment dividends shares ads performance share plan notional shares deferred investment award plan gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp financial statements financial statements provide summary directors statement responsibilities independent auditors report groups financial performance financial statements throughout position consolidated income statement st december consolidated statement comprehensive income consolidated financial consolidated balance sheet statements prepared consolidated statement changes equity accordance ifrs consolidated cash flow statement adopted european union notes financial statements also ifrs issued presentation financial statements international accounting accounting principles policies key accounting judgements estimates standards board new accounting requirements exchange rates segment information major restructuring programmes operating income operating profit employee costs finance income financial statements finance costs consolidated financial statements present associates joint ventures profit cash flow year balance taxation sheet position end year earnings per share dividends property plant equipment notes financial statements goodwill notes financial statements provide intangible assets supporting analyses primary statements investments associates joint ventures investments noncurrent assets financial statements glaxosmithkline plc inventories financial statements glaxosmithkline plc trade receivables provide information company cash cash equivalents prepared uk gaap assets held sale trade payables pensions postemployment benefits provisions noncurrent liabilities contingent liabilities net debt share capital share premium account movements equity related party transactions adjustments reconciling profit tax operating cash flows reconciliation net cash flow movement net debt acquisitions disposals commitments post balance sheet events financial instruments related disclosures employee share schemes principal group companies legal proceedings financial statements glaxosmithkline plc prepared uk gaap gsk annual report pp stnemetats laicnanif directors statement responsibilities directors statement responsibilities relation business review section contained annual report group financial statements includes fair review development performance business position group together directors responsible preparing annual report description principal risks uncertainties faces remuneration report group financial statements accordance applicable law regulations disclosure information auditors company law requires directors prepare financial statements directors office date report financial year law directors elected confirmed prepare group financial statements accordance far aware relevant audit international financial reporting standards ifrs adopted information companys auditors unaware european union preparing group financial statements directors also elected comply ifrs issued taken steps ought international accounting standards board iasb company taken director make aware law directors must approve group financial statements relevant audit information establish companys unless satisfied give true fair view auditors aware information state affairs group profit loss group period confirmation given interpreted accordance provisions section companies act preparing financial statements directors required going concern basis select suitable accounting policies apply consistently business review pages contains information performance group financial position cash flows make judgements accounting estimates net debt position borrowing facilities information reasonable prudent including treasury risk management policies exposures market state group financial statements comply ifrs credit risk hedging activities given note adopted european union ifrs issued financial statements financial instruments related disclosures iasb subject material departures disclosed explained financial statements making enquiries directors reasonable expectation group adequate resources continue directors responsible keeping adequate accounting operational existence foreseeable future reason records sufficient show explain companys continue adopt going concern basis preparing transactions disclose reasonable accuracy time financial statements financial position group enable ensure group financial statements directors remuneration internal control report comply companies act article board audit risk committee reviewed ias regulation also responsible safeguarding assessment risks internal control framework operates assets group hence taking reasonable steps gsk considered effectiveness system internal prevention detection fraud irregularities control operation group year covered report date approval board directors group financial statements year ended st december comprising principal statements supporting notes combined code set financial statements pages board considers glaxosmithkline plc applies main report principles combined code corporate governance responsibilities auditors relation group financial financial reporting council described corporate statements set independent auditors report governance pages complied provisions except described group financial statements year ended st december required listing rules financial services authority included annual report published auditors considered directors statement hardcopy printed form made available companys compliance relation points combined code website directors responsible maintenance specified review integrity annual report website accordance annual report uk legislation governing preparation dissemination annual report year ended st december financial statements access website available comprising report directors remuneration report outside uk comparable legislation may different financial statements additional information investors current directors whose names functions listed approved board directors signed corporate governance section annual report behalf confirms best knowledge sir christopher gent group financial statements prepared chairman accordance ifrs adopted eu ifrs issued th february iasb give true fair view assets liabilities financial position profit group gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp independent auditors report members glaxosmithkline plc audited group financial statements opinion matter prescribed glaxosmithkline plc year ended st december companies act comprise consolidated income statement consolidated opinion information given directors report statement comprehensive income consolidated balance financial year group financial statements sheet consolidated statement changes equity prepared consistent group financial statements consolidated cash flow statement related notes financial reporting framework applied matters required report preparation applicable law international financial reporting exception standards ifrss adopted european union nothing report respect following respective responsibilities directors companies act required report auditors opinion explained fully directors statement certain disclosures directors remuneration specified law responsibilities set directors responsible made preparation group financial statements received information explanations satisfied give true fair view responsibility require audit audit group financial statements accordance applicable law international standards auditing uk ireland listing rules required review standards require us comply auditing practices directors statement set relation boards ethical standards auditors going concern report including opinions prepared part corporate governance statement relating companys members body accordance companys compliance nine provisions june chapter part companies act combined code specified review purpose giving opinions accept assume matters responsibility purpose person report shown whose hands may come save reported separately parent company financial expressly agreed prior consent writing statements glaxosmithkline plc year ended st december information directors scope audit financial statements remuneration report described audited audit involves obtaining evidence amounts company passed resolution accordance section disclosures financial statements sufficient give reasonable companies act senior statutory auditors assurance financial statements free material name stated misstatement whether caused fraud error includes assessment whether accounting policies appropriate groups circumstances consistently applied adequately disclosed reasonableness significant accounting pricewaterhousecoopers llp estimates made directors overall presentation chartered accountants statutory auditors financial statements london opinion financial statements th february opinion group financial statements g ive true fair view state groups affairs st december profit cash flows year ended properly prepared accordance ifrss adopted european union prepared accordance requirements companies act article las regulation separate opinion relation ifrss issued iasb explained note group financial statements group addition complying legal obligation apply ifrss adopted european union also applied ifrss issued international accounting standards board iasb opinion group financial statements comply ifrss issued iasb gsk annual report pp stnemetats laicnanif consolidated income statement year ended st december results major major restructuring restructuring total notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p diluted earnings per share pence p calculation results major restructuring described note presentation financial statements consolidated statement comprehensive income year ended st december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation overseas subsidiary tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments actuarial lossesgains defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income expense fair value movement subsidiary acquisition comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders minority interests total comprehensive income year gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp results results results major major major major major major restructuring restructuring total restructuring restructuring total restructuring restructuring total notes turnover cost sales gross profit selling general administration research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p calculation results major restructuring described note presentation financial statements consolidated statement comprehensive income year ended st december profit year exchange movements overseas net assets net investment hedges reclassification exchange liquidation overseas subsidiary tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments actuarial lossesgains defined benefit plans deferred tax actuarial movements defined benefit plans fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income expense fair value movement subsidiary acquisition comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders minority interests total comprehensive income year gsk annual report pp stnemetats laicnanif consolidated balance sheet st december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity minority interests total equity approved board th february sir christopher gent chairman gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp consolidated statement changes equity year ended st december shareholders equity share share retained minority total capital premium earnings reserves total interests equity st january profit year comprehensive income year distributions minority interests dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december profit year comprehensive income year distributions minority interests dividends shareholders ordinary shares issued ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december profit year comprehensive expense year distributions minority interests changes minority shareholdings put option minority interest dividends shareholders ordinary shares issued ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans st december gsk annual report pp stnemetats laicnanif consolidated cash flow statement year ended st december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired investments associates joint ventures decreaseincrease liquid investments interest received dividends associates joint ventures proceeds disposal associates net cash outflow investing activities cash flow financing activities proceeds shares employee share options shares acquired esop trusts issue share capital purchase shares cancellation purchase treasury shares increase longterm loans repayment longterm loans increase shortterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders dividends paid minority interests financing cash flows net cash outflow financing activities increase cash bank overdrafts exchange adjustments cash bank overdrafts beginning year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements presentation financial statements estimated total cost approximately billion description business expanded programme expected deliver annual pretax savings approximately billion time substantially glaxosmithkline major global healthcare group complete given extent cost operational engaged creation discovery development manufacture excellence programme management believes material marketing pharmaceutical products including vaccines impact gsks operating results manner overthecounter otc medicines healthrelated consumer gsks business conducted gsk presents restructuring costs products gsks principal pharmaceutical products include incurred solely direct result operational excellence medicines following therapeutic areas respiratory antivirals programme separate column income statement titled central nervous system cardiovascular urogenital metabolic major restructuring antibacterials oncology emesis dermatalogicals vaccines addition restructuring costs operational excellence compliance applicable law ifrs programme major restructuring column income financial statements prepared accordance statement includes restructuring costs incurred solely direct companies act article ias regulation result restructuring programmes follow relate international accounting standards ias international financial material acquisitions operations acquired business reporting standards ifrs related interpretations adopted overlap extensively gsks existing operations european union restructuring activities follow relate financial statements also compliance ifrs issued acquisitions nature undertaken international accounting standards board operational excellence programme also carried following detailed formal plan management therefore considers composition financial statements appropriate present costs restructuring activities consolidated financial statements drawn sterling manner billion million acquisition functional currency glaxosmithkline plc accordance reliant pharmaceuticals december billion ifrs accounting presentation financial statements comprise billion acquisition stiefel laboratories july consolidated income statement acquisitions since october meet criteria set acquisitions costs incurred consolidated statement comprehensive income direct result related restructuring programme consolidated balance sheet included within major restructuring column consolidated statement changes equity groups results costs operational excellence consolidated cash flow statement programme acquisitionrelated restructuring programmes notes financial statements meeting criteria described also presented separate column income statement described accounting convention results major restructuring presentation financial statements prepared using historical gsk intends apply consistently future major restructuring cost convention modified revaluation certain items programmes material impact gsks operating results stated accounting policies manner gsks business conducted financial period adopted show clearly groups results financial statements cover financial year st january costs restructuring programmes management st december comparative figures financial believes presentation assists investors gaining clearer years st january st december understanding groups financial performance appropriate st january st december making projections future financial performance results include costs virtue size nature limited composition group comparative value presentation also consistent way list subsidiary associated undertakings management assesses groups financial performance opinion directors principally affected amount profit restructuring costs arise solely direct result net assets group given note principal group operational excellence programme restructuring companies programmes following relating acquisitions meeting presentation restructuring costs criteria described continue reported operating october board approved implementation expenses within results major restructuring detailed formal plan gsk announced significant new operational excellence restructuring programme second formal plan representing significant expansion operational excellence programme approved board announced february expansion approved board announced february restructuring programme comprising detailed formal plans covers areas gsks business including manufacturing selling rd infrastructure gsk annual report pp stnemetats laicnanif notes financial statements presentation financial statements accounting principles policies continued consolidation consolidated financial statements include accounting principles policies preparation financial statements conformity assets liabilities results cash flows generally accepted accounting principles requires management company subsidiaries including esop trusts make estimates assumptions affect reported amounts groups share results net assets associates assets liabilities disclosure contingent assets joint ventures liabilities date financial statements reported amounts revenues expenses reporting period financial statements entities consolidated made actual results could differ estimates st december year financial statements prepared accordance entities group power govern groups accounting policies approved board financial operating policies accounted subsidiaries described note accounting principles policies group ability exercise joint control information application accounting policies entities accounted joint ventures group including areas estimation judgement given note ability exercise significant influence accounted key accounting judgements estimates appropriate associates results assets liabilities associates comparative figures reclassified ensure consistent joint ventures incorporated consolidated financial presentation current year information statements using equity method accounting implementation new accounting standards interests acquired entities consolidated date effect st january gsk implemented ifrs group acquires control interests sold deconsolidated operating segments ias revised presentation financial date control ceases statements ias revised borrowing costs minor transactions balances subsidiaries eliminated amendments number accounting standards profit tax taken sales subsidiaries implementation ifrs resulted changes products sold customers outside group segmental information reported gsk comparative information relevant proportion profits transactions joint presented consistent basis information ventures associates also deferred products sold given note segment information third parties deferred tax relief unrealised intragroup profit parent company financial statements accounted extent considered recoverable financial statements parent company glaxosmithkline goodwill arising acquisition interests subsidiaries joint plc prepared accordance uk gaap uk ventures associates representing excess acquisition accounting presentation company balance sheet presented cost groups share fair values identifiable accounting policies given assets liabilities contingent liabilities acquired capitalised separate item case subsidiaries part cost investment case joint ventures associates goodwill denominated currency operation acquired cost acquisition fair value net assets acquired difference recognised directly income statement gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements accounting principles policies continued expenditure expenditure recognised respect goods services received foreign currency translation supplied accordance contractual terms provision foreign currency transactions booked functional currency made obligation exists future liability respect group company exchange rate ruling date past event amount obligation reliably transaction foreign currency monetary assets liabilities estimated manufacturing startup costs validation retranslated functional currency rates exchange ruling achievement normal production expensed incurred balance sheet date exchange differences included advertising promotion expenditure charged income income statement statement incurred shipment costs intercompany transfers consolidation assets liabilities including related goodwill charged cost sales distribution costs sales customers overseas subsidiaries associates joint ventures included selling general administrative expenditure translated sterling rates exchange ruling balance restructuring costs recognised provided sheet date results cash flows overseas subsidiaries appropriate respect direct expenditure business associates joint ventures translated sterling using reorganisation plans sufficiently detailed well average rates exchange advanced appropriate communication exchange adjustments arising opening net assets affected undertaken profits year retained overseas subsidiaries associates research development joint ventures translated sterling less exchange differences research development expenditure charged income arising related foreign currency borrowings hedge statement period incurred development groups net investment operations taken separate expenditure capitalised criteria recognising asset component equity met usually regulatory filing made major translating sterling assets liabilities results market approval considered highly probable property plant cash flows overseas subsidiaries associates joint ventures equipment used research development depreciated reported currencies hyperinflationary economies accordance groups policy adjustments made material reflect current price levels environmental expenditure loss net monetary assets charged consolidated environmental expenditure related existing conditions resulting income statement past current operations current revenue future benefit discernible charged income statement revenue recognised income statement goods group recognises liability sitebysite basis services supplied made available external customers reliably estimated liability includes groups portion orders received title risk loss passed total costs also portion potentially responsible customer reliable estimates made relevant parties costs probable able deductions turnover represents net invoice value satisfy respective shares cleanup obligation recoveries deduction discounts allowances given accruals reimbursements recorded assets virtually certain estimated future rebates returns methodology legal disputes assumptions used estimate rebates returns monitored provision made anticipated settlement costs legal adjusted regularly light contractual legal disputes group outflow resources obligations historical trends past experience projected market considered probable reasonable estimate made conditions market conditions evaluated using wholesaler likely outcome addition provision made legal thirdparty analyses market research data internally expenses arising claims received disputes generated information value added tax sales taxes respect product liability claims related products excluded revenue sufficient history claims made settlements incurred group copromotes product third party reported ibnr actuarial technique used determine records sale group records share revenue reasonable estimate groups exposure unasserted claims copromotion income within turnover nature copromotion products provision made basis activities group records costs sales provision made unasserted claims respect pharmaceutical turnover includes copromotion revenue number legal proceedings group involved million million million possible make reasonable estimate expected royalty income recognised operating income financial effect result ultimate resolution accruals basis accordance terms relevant proceedings cases group may disclose licensing agreements information respect nature facts case provision typically made costs associated claims made group third parties charged income statement incurred gsk annual report pp stnemetats laicnanif notes financial statements accounting principles policies continued leases leasing agreements transfer group substantially pensions postemployment benefits benefits risks ownership asset treated costs providing pensions defined benefit schemes finance leases asset purchased outright calculated using projected unit credit method spread assets included ppe computer software period benefit expected derived capital elements leasing commitments shown employees services consistent advice qualified obligations finance leases assets held finance leases actuaries pension obligations measured present value depreciated basis consistent similar owned assets estimated future cash flows discounted rates reflecting yields lease term shorter interest element lease rental high quality corporate bonds included income statement leases operating pension scheme assets measured fair value balance leases rental costs charged income statement sheet date actuarial gains losses differences straightline basis lease term expected actual returns assets effect changes goodwill actuarial assumptions recognised statement goodwill stated cost less impairments goodwill deemed comprehensive income year arise groups indefinite useful life tested impairment annually contributions defined contribution plans charged income statement incurred costs postemployment fair value interest acquired entitys assets liabilities calculated similar way defined benefit pension liabilities contingent liabilities exceeds consideration paid schemes spread period benefit excess recognised immediately gain income expected derived employees services accordance statement advice qualified actuaries intangible assets employee share plans intangible assets stated cost less provisions amortisation incentives form shares provided employees impairments share option share award schemes licences patents knowhow marketing rights separately fair values options awards calculated acquired acquired part business combination grant dates using blackscholes option pricing model amortised estimated useful lives generally charged income statement relevant vesting periods exceeding years using straightline basis time available use estimated useful lives group provides finance esop trusts purchase company determining amortisation charge take account patent shares open market meet obligation provide shares lives applicable well value obtained periods employees exercise options awards costs running nonexclusivity asset lives reviewed appropriate esop trusts charged income statement shares held adjusted annually contingent milestone payments recognised esop trusts deducted reserves transfer point contingent event becomes certain made reserves retained earnings development costs incurred group associated vesting periods related share options awards reflect acquired licences patents knowhow marketing rights ultimate proceeds receivable employees exercise written income statement incurred unless property plant equipment criteria recognition internally generated intangible property plant equipment ppe stated cost asset met usually regulatory filing made purchase construction less provisions depreciation major market approval considered highly probable impairment financing costs capitalised within cost acquired brands valued independently part fair value qualifying assets construction businesses acquired third parties brand depreciation calculated write cost less residual value value substantial longterm brands ppe excluding freehold land using straightline basis either contractual legal nature sold separately expected useful life residual values lives reviewed rest businesses acquired brands amortised appropriate adjusted annually normal expected useful estimated useful lives years except lives major categories ppe considered useful economic life indefinite costs acquiring developing computer software freehold buildings years internal use internet sites external use capitalised leasehold land intangible fixed assets software site supports buildings lease term years significant business system expenditure leads plant machinery years creation durable asset erp systems software amortised fixtures equipment years seven years computer software three five years disposal ppe cost related accumulated depreciation impairments removed financial statements net amount less proceeds taken income statement gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements accounting principles policies continued trade receivables trade receivables carried original invoice amount less impairment noncurrent assets provisions doubtful debts provisions made carrying values noncurrent assets reviewed evidence risk nonpayment taking account ageing impairment indication assets might previous experience general economic conditions trade impaired additionally goodwill intangible assets indefinite receivable determined uncollectable written firstly useful lives intangible assets yet available use provision available income statement tested impairment annually provision impairment charged income statement year concerned subsequent recoveries amounts previously provided credited income statement longterm receivables impairments goodwill reversed impairment losses discounted effect material noncurrent assets reversed change estimates used determine recoverable amounts trade payables extent revised recoverable amounts trade payables held amortised cost equates exceed carrying values would existed net nominal value longterm payables discounted depreciation amortisation impairments recognised effect material investments associates joint ventures cash cash equivalents investments associates joint ventures carried cash cash equivalents comprise cash hand current balances consolidated balance sheet groups share net assets banks similar institutions highly liquid investments date acquisition postacquisition retained profits original maturities three months less readily losses together goodwill arising acquisition convertible known amounts cash insignificant risk changes value availableforsale investments liquid investments investments classified available borrowings forsale investments initially recorded fair value plus borrowings initially recorded amount proceeds transaction costs remeasured subsequent reporting received net transaction costs borrowings subsequently dates fair value unrealised gains losses availableforsale carried amortised cost difference investments recognised directly comprehensive income proceeds net transaction costs amount due impairments arising significant prolonged decline fair redemption recognised charge income statement value equity investment reduce carrying amount period relevant borrowing asset directly charged income statement taxation disposal impairment investments gains current tax provided amounts expected paid losses deferred comprehensive income applying tax rates enacted substantively enacted reclassified income statement dividends equity balance sheet date investments recognised income statement deferred tax provided full using liability method groups right receive payment established equity investments temporary differences arising tax bases assets recorded noncurrent assets unless expected liabilities carrying amounts financial statements sold within one year deferred tax assets recognised extent probable purchases sales equity investments accounted future taxable profits available trade date purchases sales availableforsale temporary differences utilised deferred tax provided investments accounted settlement date temporary differences arising investments subsidiaries associates joint ventures except timing inventories reversal temporary difference controlled inventories included financial statements lower probable temporary difference reverse cost including raw materials direct labour direct costs foreseeable future deferred tax provided using rates tax related production overheads net realisable value enacted substantively enacted balance sheet cost generally determined first first basis prelaunch date deferred tax liabilities assets discounted inventory held asset high probability regulatory approval product point provision made carrying value recoverable amount provision reversed point high probability regulatory approval determined gsk annual report pp stnemetats laicnanif notes financial statements accounting principles policies continued key accounting judgements estimates preparing financial statements management required derivative financial instruments hedging make estimates assumptions affect amounts derivative financial instruments used manage exposure assets liabilities revenue expenses reported financial market risks treasury operations principal derivative statements actual amounts results could differ instruments used glaxosmithkline foreign currency swaps estimates following considered key accounting interest rate swaps forward foreign exchange contracts judgements estimates made group hold issue derivative financial instruments trading speculative purposes turnover revenue recognised title risk loss passed derivative financial instruments classified heldfortrading customer reliable estimates made relevant carried balance sheet fair value derivatives deductions gross turnover reduced rebates discounts designated hedging instruments classified inception allowances product returns given expected given cash flow hedges net investment hedges fair value hedges vary product arrangements buying groups changes fair value derivatives designated cash flow arrangements purchasing organisations dependent hedges recognised comprehensive income upon submission claims time initial extent hedges effective ineffective portions recognition sale accruals made time sale recognised profit loss immediately amounts deferred estimated rebates discounts allowances payable returns comprehensive income reclassified income statement made based available market information hedged item affects profit loss historical experience net investment hedges accounted similar way cash amounts estimated may fully reflect flow hedges final outcome amounts subject change dependent upon amongst things types buying group changes fair value derivatives designated fair value product sales mix hedges recorded income statement together changes fair value hedged asset liability level accrual reviewed adjusted regularly light contractual legal obligations historical trends past changes fair value derivative instruments experience projected market conditions market conditions qualify hedge accounting recognised immediately evaluated using wholesaler thirdparty analyses market income statement research data internally generated information future events discounting could cause assumptions accruals based time effect money material balances discounted change could affect future results group current values using appropriate rates interest unwinding taxation discounts recorded finance income finance costs current tax provided amounts expected paid deferred tax provided temporary differences tax bases assets liabilities carrying amounts rates enacted substantively enacted balance sheet date group open tax issues number revenue authorities gsk continues believe made adequate provision liabilities likely arise open assessments open issues exist ultimate liability matters may vary amounts provided dependent upon outcome negotiations relevant tax authorities necessary litigation proceedings gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements key accounting judgements estimates intangible assets continued intangible assets acquired gsk third parties costs acquisition capitalised licences compounds legal disputes development amortised point gsk provides anticipated settlement costs outflow available use estimated useful lives may resources considered probable reasonable estimate may include periods nonexclusivity estimated useful lives made likely outcome dispute legal reviewed annually impairment tests undertaken events expenses arising claims group occur call question carrying values assets companys directors taken legal advice brands acquired businesses capitalised independently established provisions taking account relevant separable expected life facts circumstances matter accordance one year brands amortised straightline basis accounting requirements provisions product liability claims estimated useful lives exceeding years except certain products made incurred reported end useful economic life foreseen brands basis sufficient history claims made settlements amortised subject annual impairment tests available provisions made unasserted initial valuations valuations subsequent impairment claims respect number legal proceedings tests based established market multiples riskadjusted group involved possible make reasonable estimate future cash flows discounted using appropriate interest rates expected financial effect result ultimate future cash flows based business forecasts resolution proceedings cases group may therefore inherently judgemental future events could cause disclose information respect nature facts assumptions used impairment reviews change cases provision typically made st december consequent adverse effect future results group provisions legal disputes amounted million million pensions postemployment benefits costs providing pensions postemployment ultimate liability legal claims may vary amounts benefits charged income statement accordance provided dependent upon outcome litigation ias period benefit derived proceedings investigations possible settlement negotiations employees services costs assessed basis position could change time therefore assumptions selected management assumptions assurance losses result outcome include future earnings pension increases discount rates legal proceedings exceed amount provisions expected long term rates return assets mortality reported groups financial statements rates disclosed note pensions post property plant equipment employment benefits carrying values property plant equipment tested expected long term rates return bonds determined impairment indication values based portfolio mix indexlinked government assets might impaired impairment determined reference corporate bonds equity risk premium added higher fair value less costs sell value use equities measured assessing riskadjusted future cash flows discounted using appropriate interest rates future cash flows based discount rates derived aa rated corporate bond yields business forecasts therefore inherently judgemental except countries deep market corporate future events could cause assumptions used bonds government bond yields used sensitivity analysis impairment tests set note property plant provided note pensions postemployment equipment change consequent adverse effect benefits reduction discount rate would lead future results group increase net pension deficit approximately million increase annual pension cost goodwill approximately million selection different assumptions goodwill arising business combinations capitalised could affect future results group allocated appropriate cash generating unit deemed indefinite life amortised annual impairment tests relevant cash generating units performed impairment tests based established market multiples riskadjusted future cash flows discounted using appropriate interest rates future cash flows based business forecasts therefore inherently judgemental future events could cause assumptions used impairment tests set note goodwill change consequent adverse effect future results group gsk annual report pp stnemetats laicnanif notes financial statements new accounting requirements following new standards interpretations yet following new amended accounting standards ifric endorsed eu interpretations issued iasb likely iasbs annual improvements project published april affect future annual reports although none expected changes effective st january material impact results financial position group project makes minor amendments number standards ifrs revised business combinations issued january areas including operating segments sharebased payments leases apply business combinations arising intangible assets financial instruments st january amongst changes new standard amendment ifrs sharebased payment group cash require recognition subsequent changes fair value settled sharebased payment transactions issued june contingent consideration income statement rather implemented gsk st january goodwill transaction costs recognised amendment clarifies scope ifrs accounting immediately income statement fair value gains group cashsettled sharebased payment transactions losses existing investments acquired company financial statements individual group entities recognised income statement date acquisition ias revised related party disclosures issued november ias revised consolidated separate financial statements implemented gsk st january issued january implemented revised standard clarifies definition related party time ifrs revised respect transactions provides exemptions government related entities noncontrolling interests group entities result change control revised standard requires ifrs financial instruments issued november difference consideration paid received implemented gsk st january recorded noncontrolling interest recognised equity standard first step project replace ias case divestment subsidiary retained interest covers classification measurement financial assets remeasured fair value difference fair value iasb intends expand ifrs add new requirements previous carrying value recognised immediately classification measurement financial liabilities derecognition income statement financial instruments impairment hedge accounting become complete replacement ias end ifrs revised ias revised applied prospectively transactions occurring st january ifric extinguishing financial liabilities equity instruments issued november implemented amendment ias financial instruments recognition gsk st january interpretation addresses measurement eligible hedged items issued july accounting entity issues equity instruments order implemented gsk st january settle financial liability part full amendment clarifies two aspects hedge accounting relating hedging options identification inflation amendment ifric prepayments minimum hedged risk funding requirement issued november implemented gsk st january amendment amendment ias financial instruments presentation permits voluntary prepayment minimum funding requirement classification rights issues issued october recognised asset implemented gsk st january amendment requires issue existing shareholders rights acquire exchange rates additional shares recognised equity regardless group uses average exchange rates prevailing currency shares period translate results cash flows overseas subsidiaries joint ventures associated undertakings ifric distributions noncash assets owners published sterling period end rates translate net assets november implemented gsk undertakings currencies influence st january interpretation specifies entity translations relevant exchange rates account distributions noncash assets owners average rates us euro yen period end rates us euro yen gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements segment information gsk implemented ifrs operating segments effect st january resulted change segmental information reported gsk comparative information presented consistent basis gsks operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet individual members cet responsible geographic regions pharmaceuticals business consumer healthcare business whole respectively major restructuring rd investment essential sustainability pharmaceutical businesses however segment reporting usa europe emerging markets asia pacificjapan regional pharmaceutical operating profits exclude allocations globally funded rd well central costs principally corporate functions unallocated manufacturing costs gsks management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis trading pharmaceuticals segment includes canada puerto rico stiefel central vaccine tender sales contract manufacturing sales stiefel business integrated gsk effect st january results reported within relevant geographical pharmaceuticals segments line way business managed gsk acquired hiv business pfizer effect th october return minority stake combined hiv businesses called viiv healthcare limited line way viiv healthcare business managed reported separate segment st january gsk hiv business reported within relevant pharmaceuticals segments incremental income costs since creation viiv healthcare reported within trading pharmaceuticals pharmaceuticals rd segment responsibility chairman research development therefore reported separate segment unallocated pharmaceuticals costs include costs vaccines rd central manufacturing costs attributed segments corporate unallocated costs disposal profits include corporate functions costs legal matters fair value movements financial instruments investments unallocated profits asset disposals restated restated turnover segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals turnover consumer healthcare turnover pharmaceutical turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines consumer healthcare turnover category otc medicines oral healthcare nutritional healthcare gsk annual report pp stnemetats laicnanif notes financial statements segment information continued us pharmaceuticals business made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals rd unallocated pharmaceuticals costs pharmaceuticals operating profit consumer healthcare operating profit segment profit corporate unallocated costs disposal profits operating profit major restructuring major restructuring total operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restated restated us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals rd unallocated pharmaceuticals pharmaceuticals depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructuring major restructuring total depreciation amortisation gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements segment information continued ppe intangible asset impairment segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals rd unallocated pharmaceuticals pharmaceuticals impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructuring major restructuring total impairment ppe intangible asset impairment reversals segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals rd unallocated pharmaceuticals pharmaceuticals impairment reversals consumer healthcare impairment reversals segment impairment reversals corporate unallocated impairment reversals impairment reversals major restructuring major restructuring total impairment reversals geographical information uk regarded groups country domicile turnover location customer restated restated uk usa rest world external turnover noncurrent assets location uk usa rest world noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts recoverable insurance contracts certain noncurrent receivables gsk annual report pp stnemetats laicnanif notes financial statements segment information continued restated total assets segment us pharmaceuticals europe pharmaceuticals emerging markets pharmaceuticals asia pacificjapan pharmaceuticals trading pharmaceuticals pharmaceuticals rd unallocated pharmaceuticals pharmaceuticals operating assets consumer healthcare operating assets segment operating assets corporate unallocated assets total operating assets investments associates joint ventures liquid investments derivative financial instruments cash cash equivalents current deferred taxation assets held sale total assets unallocated pharmaceuticals segment includes assets centrally managed pharmaceutical vaccine manufacturing operations depreciation totalling million million million recovered standard cost product charged businesses major restructuring programme october gsk announced significant new operational excellence programme improve effectiveness productivity operations significant expansion operational excellence programme approved board announced february expansion approved board announced february total costs implementation expanded programme expected increase billion approximately billion incurred period approximately costs incurred st december approximately expected incurred balance mostly total approximately costs expected cash expenditures expected asset writedowns uncertainties exist exact amount timing cash outflows result potential future exchange rate fluctuations many elements restructuring programme subject employee consultation procedures making difficult predict precision procedures completed however majority remaining cash payments expected made programme estimated deliver total annual pretax savings billion savings realised across business total restructuring costs million incurred million incurred operational excellence programme following areas closure number manufacturing sites including dartford crawley uk cidra puerto rico giving rise asset writedowns staff reductions adoption customised sales approaches leading staff reductions number sales forces principally france c ost saving projects rd focused primarily simplification streamlining support infrastructure including site rationalisations p rojects simplify eliminate processes leading staff reductions administrative support functions addition costs million incurred year restructuring programme related integration stiefel laboratories inc business usa following acquisition july gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements major restructuring programme continued analysis costs incurred programmes follows asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect operating profit net finance expense effect profit taxation effect taxation effect earnings asset staff impairment reductions costs total cost sales selling general administration research development effect profit taxation effect taxation effect earnings asset impairments million million million net costs totalling million million nil noncash items charges settled cash restructuring costs reported major restructuring column income statement costs related minor restructuring activity initiated prior october amounting million million reported within results major restructuring costs major restructuring programmes arisen follows increase provision major restructuring programmes see note amount provision reversed unused see note impairments property plant equipment see note foreign exchange gainloss recognised liquidation subsidiary noncash charges cash costs net finance expense effect profit taxation noncash charges principally accelerated depreciation arising asset lives shortened result major restructuring programmes cash costs include termination leases site closure costs consultancy project management fees gsk annual report pp stnemetats laicnanif notes financial statements operating income royalty income milestone income impairment equity investments disposal equity investments disposal assets legal settlements gain recognised creation viiv healthcare fair value adjustments derivative financial instruments income royalty milestone income principally core recurring income outlicensing intellectual property fair value adjustments derivative financial instruments include movements expired quest collar theravance put call options operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets net reversals net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration fees payable companys auditor associates audit parent company consolidated financial statements audit accounts groups uk overseas subsidiaries pursuant legislation assurance services pursuant legislation including attestation sarbanesoxley act audit assurance services tax services services including regulatory compliance treasury related services st december amount due pricewaterhousecoopers llp associates fees yet invoiced million comprising statutory audit million taxation services million services million fees payable pricewaterhousecoopers llp associates audit assurance services remained flat cer terms addition fees paid respect gsk pension schemes audit services gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities wages salaries increased cer terms group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables realised gains liquid investments fair value adjustments derivatives fair value profit loss net investment hedge ineffectiveness unwinding discounts assets derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest income arising derivatives fair value profit loss relates swap interest income gsk annual report pp stnemetats laicnanif notes financial statements finance costs interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value adjustments derivatives designated hedging instruments fair value adjustments hedged items fair value adjustments derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions derivatives fair value profit loss except designated effective hedging instruments classified heldfortrading financial instruments ias associates joint ventures associates share tax profits quest diagnostics inc share tax profits aspen pharmacare holdings limited share tax losses associates share tax lossesprofits joint ventures share turnover joint ventures sales joint ventures associates summarised income statement information respect groups associates set total turnover quest diagnostics inc aspen pharmacare holdings limited others total profit quest diagnostics inc aspen pharmacare holdings limited others results aspen pharmacare holdings limited included summarised income statement information represent estimated earnings aspen group period since becoming associated undertaking based analysts forecasts gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements taxation taxation charge based profits year uk corporation tax uk statutory rate less double taxation relief overseas taxation current taxation deferred taxation additional uk corporation tax double taxation relief arose dividends received overseas subsidiaries reconciliation taxation rate group profits uk statutory rate taxation differences overseas taxation rates benefit special tax status rd credits intercompany stock profit impact share based payments tax profit associates differences prior year items restructuring tax rate tax items charged equity statement comprehensive income current taxation share based payments foreign exchange movements deferred taxation share based payments defined benefit plans fair value movement cash flow hedges fair value movements availableforsale investments items charged statement comprehensive income except tax share based payments group operates countries tax rate differs uk tax rate impact overseas taxes overall rate tax shown profits arising certain operations singapore accorded special status taxed reduced rates compared normal rates tax territory effect reduction taxation charge increased earnings per share p p p group required ifrs create deferred tax asset respect unrealised intercompany profit arising inventory held group yearend applying tax rate country inventory held rather tax rate country profit originally made tax paid practice uk us gaap result difference accounting treatment group tax rate current period intercompany profit ifrs increased increase decrease arising changes location workinprogress finished goods integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax resolution issues continuing fact life gsk gsk annual report pp stnemetats laicnanif notes financial statements taxation continued following audit period irs issued statutory notices deficiency gsk asserting income withholding tax deficiencies associated penalties arising irss reclassification intercompany financing arrangement years debt equity consequent recharacterisation amounts paid dividends subject withholding tax us uk treaty amounts due financing arrangement paid timely basis final payment made april gsk disagreed irss position august initiated actions united states tax court contest statutory notices deficiency th november gsk irs filed stipulation tax court irs conceded asserted tax deficiencies penalties arising reclassification intercompany financing arrangement debt equity resulting additional tax cost gsk irs claim previously estimated gsk irs process finalising tax computations tax years anticipated resolution issue years reflected closing agreement resolution issue impact groups results canada gsk continuing contest court decision respect transfer pricing early date appeal hearing set march gsk continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome litigation appropriate agreement relevant tax authorities provision made taxation would arise distribution profits retained overseas subsidiaries grounds group able control timing reversal temporary differences probable reverse foreseeable future aggregate amount unremitted profits balance sheet date approximately billion billion introduction uk dividend exemption st july enables reasonable quantification incremental liability repatriation profits uk deferred tax unremitted earnings st december estimated approximately million relates taxes payable repatriation dividend withholding taxes levied overseas tax jurisdictions payable recoverable net movement current tax account st january exchange adjustments charge year cash paid movements st december movement deferred tax assets liabilities pensions manu share accelerated intra post legal facturing stock option net offset deferred taxation capital group retirement tax restruct valuation award temporary within allowances intangibles profit benefits losses disputes uring adjustments schemes differences countries total assetsliabilities deferred tax assets st january deferred tax liabilities st january st january exchange adjustments creditcharge income statement creditcharge equity creditcharge statement comprehensive income acquisitions st december deferred tax assets st december deferred tax liabilities st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements taxation continued deferred tax charge income relating changes tax rates million deferred tax movements arise origination reversal temporary differences net temporary differences include accrued expenses provisions st december group recognised deferred tax asset million million respect income tax losses approximately million million losses million million due expire million million due expire million million available indefinitely st december group recognised deferred tax asset respect income tax losses approximately million million million million due expire million million due expire million million available indefinitely group capital losses st december approximately billion respect deferred tax asset recognised deferred tax assets recognised probable future taxable profit available utilise losses factors affecting tax charge future years global organisation many factors could affect future effective tax rate group mix profits across different territories transfer pricing disputes tax authorities location research development activity significant impact groups effective tax rate changes tax legislation territories gsk business operations could also impact groups effective tax rate uk tax authorities proposed significant changes uk taxation system december uk government announced intends introduce patent box regime applying reduced rate corporation tax income patents changes expected effect april following period consultation uk government also continues consult business proposed changes controlled foreign company regime changes expected enacted earnings per share pence pence pence basic earnings per share adjustment major restructuring basic earnings per share major restructuring diluted earnings per share adjustment major restructuring diluted earnings per share major restructuring basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares adjusted earnings per share calculated using results major restructuring earnings calculation results major restructuring described note presentation financial statements diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options diluted shares held esop trusts excluded trustees waived rights dividends shares held esop trusts gsk annual report pp stnemetats laicnanif notes financial statements dividends first interim second interim third interim fourth interim total total dividend dividend per share pence paidpayable th july th october th january th april total dividend dividend per share pence paid th july th october th january th april total dividend dividend per share pence paid th july th october th january th april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders property plant equipment plant land equipment assets buildings vehicles construction total cost st january exchange adjustments additions additions business combinations disposals writeoffs reclassifications transfer assets held sale cost st december exchange adjustments additions additions business combinations capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements property plant equipment continued plant land equipment assets buildings vehicles construction total depreciation st january exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december exchange adjustments provision year disposals writeoffs transfer assets held sale depreciation st december impairment st january exchange adjustments disposals writeoffs impairment losses reclassifications reversal impairments impairment st december exchange adjustments disposals writeoffs impairment losses reversal impairments impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings st december leased assets cost million million accumulated depreciation million million impairment nil million net book value million million included plant equipment vehicles st december leased assets cost million million accumulated depreciation million million net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs sell value use value use calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate country specific risks impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately impairment losses charged cost sales million rd million sga million include million million arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales gsk annual report pp stnemetats laicnanif notes financial statements goodwill cost st january exchange adjustments additions business combinations cost st december net book value st january net book value st december additions year translated acquisition exchange rates arise acquisition following businesses stiefel laboratories inc pfizer hiv business ucb sa novamin technology inc az tika laboratoire pharmaceutique algrien others see note acquisitions disposals details carrying value goodwill translated yearend exchange rates made balances arising acquisition following businesses cash generating unit stiefel laboratories inc stiefel laboratories inc reliant pharmaceuticals inc us pharmaceuticals id biomedical corporation five pharmaceutical segments sirtris pharmaceuticals inc five pharmaceutical segments pfizer hiv business viiv healthcare group glaxosmithkline kk japan pharmaceuticals domantis limited five pharmaceutical segments cns inc consumer healthcare polfa poznan sa poland pharmaceuticals certain businesses ucb sa emerging markets asia pacificjapan pharmaceuticals novamin technology inc consumer healthcare others gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements goodwill continued goodwill allocated cash generating units tested impairment least annually following implementation ifrs operating segments cash generating units goodwill balances allocated changed goodwill arising acquisitions id biomedical sirtris pharmaceuticals domantis split five pharmaceutical segments usa europe emerging markets asia pacificjapan impairment testing purposes either benefit acquired businesses split among five pharmaceutical segments generate independent cash flows valuation us pharmaceuticals cash generating unit reliant pharmaceuticals prepared fair value less costs sell basis using turnover earnings multiples derived observed market data value goodwill inherent us pharmaceuticals cash generating unit considerably excess book value acquired goodwill recoverable amounts cash generating units assessed using either value use fair value less costs sell model value use calculated net present value projected riskadjusted posttax cash flows plus terminal value cash generating unit goodwill allocated initially posttax discount rate applied calculate net present value posttax cash flows posttax discount rate used based group wacc cash generating units integrated operations across large parts group group wacc equivalent pretax discount rate approximately discount rate increased specific country risks sufficiently significant material impact outcome impairment test impairment test indicates recoverable value unit close carrying value test reperformed using pretax discount rate pretax cash flows order determine impairment exists establish magnitude fair value calculated using similar discounted cash flow approach based groups acquisition valuation model posttax discount rate applied projected riskadjusted posttax cash flows terminal value details relating discounted cash flow models used impairment tests significant goodwill balances follows stiefel laboratories cgu viiv healthcare cgu five pharmaceutical segments cgus valuation basis fair value less costs sell fair value less costs sell value use key assumptions sales growth rates sales growth rates sales growth rates profit margins profit margins profit margins achievement synergy targets discount rate discount rate discount rate determination growth rates internal growth rates internal growth rates internal forecasts assumptions forecasts based internal forecasts based internal based internal external market information external market information external market information margins reflect past experience margins reflect past experience margins reflect past experience adjusted expected changes adjusted expected changes adjusted expected changes postacquisition synergy targets discount rate based discount rate based reflect management expectations group wacc group wacc cost savings achieved discount rate based group wacc period specific projected cash flows years years years discount rate terminal growth rate pa pa pa gsk annual report pp stnemetats laicnanif notes financial statements goodwill continued japan pharmaceuticals cgu consumer healthcare cgu poland pharmaceuticals cgu glaxosmithkline kk cns polfa poznan valuation basis fair value less costs sell fair value less costs sell value use key assumptions sales growth rates sales growth rates sales growth rates profit margins advertising promotion profit margins discount rate investment discount rate terminal growth rate discount rate determination growth rates internal growth rates internal growth rates internal assumptions forecasts based internal forecasts based internal forecasts based internal external market information external market information external market information margins reflect past experience advertising promotion margins reflect past experience adjusted expected changes investment based historical adjusted expected changes discount rate based levels adjusted managements discount rate based group group wacc view support needed wacc adjusted country innovation expansion specific risks terminal growth rate based managements estimate future longterm average growth rates discount rate based group wacc period specific projected cash flows years years years discount rate terminal growth rate pa pa pa decline terminal growth rates exceed longterm projected growth rates relevant markets terminal growth rate used value use calculation poland pharmaceuticals cash generating unit reflects impact future generic competition takes account new product launches consumer healthcare cash generating unit comprises collection smaller cash generating units including brands indefinite lives carrying value million million stiefel laboratories cash generating unit also comprises collection smaller cash generating units including assets indefinite lives carrying value million details indefinite life brands given note intangible assets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements intangible assets computer licences amortised indefinite life software patents etc brands brands total cost st january exchange adjustments capitalised internal development costs additions business combinations additions disposals asset writeoffs transfer assets held sale cost st december exchange adjustments capitalised internal development costs additions business combinations additions disposals asset writeoffs reclassifications cost st december amortisation st january exchange adjustments provision year disposals asset writeoffs amortisation st december exchange adjustments provision year disposals asset writeoffs amortisation st december impairment st january exchange adjustments impairment losses reversal impairments impairment st december exchange adjustments impairment losses disposals asset writeoffs impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report pp stnemetats laicnanif notes financial statements intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development net book value computer software includes million million internally generated costs licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development net book value includes million million internally generated costs impairment losses million million principally arise assets development longer actively pursued note acquisitions disposals gives details additions business combinations year book values largest individual items follows fluviral lovaza selzentry arzerra duac fraxiparine others amortised brands include otc rights relating alli book value st december million million indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows panadol sensodyne stiefel trade name breathe right physiogel polident corega biotene poligrip solpadeine others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment applying fair value less costs sell methodology generally using four year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate countryspecific risks main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment brands gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements investments associates joint ventures joint associated joint associated ventures undertakings total ventures undertakings total st january exchange adjustments additions disposals transfer investments fair value adjustment retained lossprofit year st december group held two significant associated undertakings st december quest diagnostics inc us clinical laboratory business listed new york stock exchange investment book value st december million million market value million million st december group owned quest year group sold million shares quest realising profit million although group holds less ownership interest voting control quest group ability exercise significant influence significant shareholding nominated directors active participation quest board directors board subcommittees november gsk increased shareholding aspen pharmacare holdings limited acquiring million shares consideration transfer certain assets gsks shareholding aspen st december million shares aspen listed johannesburg stock exchange africas largest pharmaceutical manufacturer major supplier branded generic pharmaceutical healthcare nutritional products southern african selected international markets elimination unrealised gains investment book value st december million including estimated goodwill million market value shares held gsk st december million although group holds less ownership interest voting control aspen group ability exercise significant influence shareholding nominated directors active participation aspen board directors transfer investments relates groups holding aspen previously classified within investments august gsk invested million establish interest shenzhen glaxosmithkline neptunus biologicals co ltd new joint venture primarily operating fields research development manufacture flu vaccines gsk made additional capital contributions totalling million shionogiglaxosmithkline holdings lp summarised balance sheet information respect groups associates set total assets quest diagnostics inc aspen pharmacare holdings limited others total liabilities quest diagnostics inc aspen pharmacare holdings limited others net assets summarised balance sheet information respect aspen pharmacare holdings limited based analysts forecasts available st december investments joint ventures comprise million share gross assets million million share gross liabilities million principally arise interests two joint ventures shionogiglaxosmithkline holdings lp developing specified chemical compounds glaxosmithkline shire canada primarily comarkets combivir trizivir epivir certain territories part viiv healthcare business investments joint ventures also include interest pharmaceutical insurance limited mutual insurance company covering pharmaceutical business risk interest glaxosmithkline neptunusbio flu vaccine research development manufacturing venture gsk annual report pp stnemetats laicnanif notes financial statements investments st january exchange adjustments additions net fair value movements impairment losses transfer investments associates joint ventures disposals st december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated reference current market value similar instruments reference discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million disposal investments fair value movements reclassified reserves income statement based average cost shares acquired different times impairment losses recorded tables recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement st december impaired assets fair value million million included investments transfer associates relates groups holding aspen pharmacare holdings limited increased year noncurrent assets amounts recoverable insurance contracts pension schemes surplus receivables inventories raw materials consumables work progress finished goods gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements trade receivables trade receivables prepaid pension contributions prepayments accrued income interest receivable employee loans advances receivables trade receivables include million million due associates joint ventures bad doubtful debt provision st january exchange adjustments charge year subsequent recoveries amounts provided utilised st december cash cash equivalents cash bank hand shortterm deposits assets held sale land buildings plant equipment vehicles gsk annual report pp stnemetats laicnanif notes financial statements trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers principally usa provisions made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome amounts subject change dependent upon amongst things types buying group product sales mix level provision reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions provisions based change could affect future results group pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes postemployment costs costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments expected rate return bonds reflects portfolio mix indexlinked government corporate bonds equity risk premium added longer term government bond yields give expected rate return equities projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting pca standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line medium cohort ie improvements recently observed higher levels assumed continue minimum improvements thereafter per year males females usa mortality rates calculated using rp fully generational table projected using scale aa white collar adjustment average life expectancy assumed individual age projected apply individual age follows uk usa male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment following asset liability study group decided adopt strategy reduce gradually allocation investment equities agreed pace reallocation would increased primarily investment deficit reduction contributions bonds target allocation equities property us scheme reduced total uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme usa former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one usa group applied following financial assumptions assessing defined benefit liabilities uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended st december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost expected return pension scheme assets interest scheme liabilities settlements curtailments actuarial lossesgains recorded statement comprehensive income total actuarial losses recorded statement comprehensive income since st january amount million amounts included within settlements curtailments include million million million augmentation costs arising major restructuring programmes see note provisions gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations unrecognised past service cost restriction surplus recognised balance sheet included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued uk usa rest world group average expected rate fair expected rate fair expected rate fair fair st december return value return value return value value equities property bonds assets fair value assets present value scheme obligations included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued postretirement pensions benefits movements defined benefit obligations uk usa rest world group group obligations st january exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers provisions recognised balance sheet st december unrecognised past service cost obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial gains scheme participants contributions benefits paid transfers provisions obligations st december exchange adjustments service cost interest cost settlements curtailments actuarial lossesgains scheme participants contributions benefits paid acquisitions obligations st december unrecognised past service cost recognised balance sheet st december uk defined benefit schemes include defined contribution sections obligations totalling million st december million million liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation reducing per year thereafter us postretirement healthcare scheme amended main change increase cap group costs us pension postretirement healthcare plan amended changes resulted oneoff gain million income statement st december us plan obligation million million million however accordance ias unvested part benefit improvement recognised immediately balance sheet recognised gradually income statement st december unrecognised amount million million million primarily relates effect change us postretirement scheme st december past service cost recognised scheme amounted million gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded postretirement benefits unfunded postretirement pensions benefits movements fair values assets uk usa rest world group group assets st january exchange adjustments expected return assets settlements curtailments actuarial gainslosses employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial losses employer contributions scheme participants contributions benefits paid assets st december exchange adjustments expected return assets settlements curtailments actuarial gains employer contributions scheme participants contributions benefits paid acquisitions assets st december uk defined benefit schemes include defined contribution sections account balances totalling million st december million million group made special funding contributions uk pension schemes totalling million million us scheme million uk pension schemes gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified st december actuarial funding valuation additional contributions expected million per year contributions based discount rate inflation assumption next review contribution levels expected st december actuarial valuation although group agreed review mortality assumptions could result earlier revision contributions employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements pensions postemployment benefits continued postretirement pensions benefits history experience gains losses uk usa rest world group group experience gains scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience losses scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes experience gainslosses scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficitssurpluses schemes experience gains scheme assets percentage scheme assets st december experience losses scheme liabilities percentage scheme obligations st december fair value assets present value scheme obligations deficits schemes gsk annual report pp stnemetats laicnanif notes financial statements pensions postemployment benefits continued sensitivity analysis effect changes assumptions used annual defined benefit pension postretirement costs benefit obligations decrease discount rate would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation decrease expected rates returns assets would following approximate effect increase annual pension cost increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation provisions integration legal major employee restructuring related manufacturing disputes programmes provisions reorganisation provisions total st january exchange adjustments charge year reversed unused unwinding discount utilised acquisition subsidiary transfer pensions obligations reclassifications movements st december settled within one year settled one year st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements provisions continued employee related provisions employee related provisions includes exchange offer incentive legal disputes programme operated time merger gsk involved number legal disputes encourage staff convert glaxo wellcome smithkline beecham including notification possible claims set note share options glaxosmithkline share options incentive legal proceedings provisions legal disputes paid either employees exercise relevant options include amounts relating us antitrust product liability options lapse impact discounting contract terminations selfinsurance environmental cleanup provision nil calculated using property rental riskfree rates return group also provides certain medical discount provisions increased million benefits disabled employees spouses usa million decrease calculated using st december provision benefits riskadjusted projected cash flows riskfree rates return amounted million employee benefits reflect movement includes increase million variety provisions severance costs jubilee awards arising change discount rate year certain longservice benefits products history claims made settlements integration manufacturing reorganisation makes possible use ibnr incurred reported provisions integration manufacturing reorganisations actuarial technique determine reasonable estimate reflect costs related ongoing restructuring programmes groups exposure unasserted claims relation included within costs disclosed note major products apart ibnr provision provisions restructuring programmes made unasserted claims ultimate liability matters may vary amounts provided dependent upon provisions outcome litigation proceedings investigations possible group recognised contingent consideration respect settlement negotiations acquisitions bristol myers squibb pakistan private limited stiefel laboratories inc described note acquisitions nature groups business number disposals contingent consideration payable upon matters including provided using ibnr actuarial certain criteria met certain specified dates future techniquemay subject negotiation litigation initial recognition provisions included within several years largest individual amounts provided expected reclassifications movements aggregate provision settled within three years items amounts million st december st december expected million million provision made legal disputes reimbursed third party insurers amount included within receivables note noncurrent assets note trade receivables discussion legal issues see note legal proceedings major restructuring programmes october gsk announced significant new operational excellence programme improve effectiveness productivity operations see note major restructuring programme significant expansion operational excellence programme approved board announced february expansion approved board announced february provisions staff severance payments made management made formal decision eliminate certain positions communicated groups employees affected provision made staff severance payments made immediately pension augmentations arising staff redundancies million charged year transferred pension obligations provision shown note pensions postemployment benefits asset writedowns recognised impairments property plant equipment note property plant equipment gsk annual report pp stnemetats laicnanif notes financial statements noncurrent liabilities accruals deferred income payables contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million st december million million financial assets pledged collateral contingent liabilities discussions tax legal issues refer note taxation note legal proceedings net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings european medium term note london stock exchange us floating rate note new york stock exchange commercial paper bank loans overdrafts loan stock loans obligations finance leases longterm borrowings us floating rate note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange loan stock bank loans loans private financing obligations finance leases net debt gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements net debt continued current assets liquid investments classified availableforsale investments st december included us treasury notes government bonds effective interest rate liquid investments st december approximately approximately liquid investment balances st december earning interest floating fixed rates amount million million respectively million million effective interest rate cash cash equivalents st december approximately approximately cash cash equivalents balances st december earning interest floating fixed rates amount million million respectively million million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings commercial paper comprises us billion programme billion million issue st december nil nil backed committed facilities days duration billion billion billion billion renewable annually liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts st december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years longterm borrowings repayable five years carry interest effective rates repayment dates range average effective interest rate notes st december approximately approximately secured liabilities gsk loans secured charges noncurrent current assets year nil group pledged investments us treasury notes par value million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations finance lease obligations st december bearing interest floating fixed rates amount million million respectively million million gsk annual report pp stnemetats laicnanif notes financial statements share capital share premium account share ordinary shares p premium number share capital authorised st december st december st december share capital issued fully paid st january issued share option schemes share capital purchased cancelled st december issued share option schemes share capital purchased cancelled st december issued share option schemes st december st december st december number shares issuable outstanding options note number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes company make purchases shares purchases since st december gsk expect make significant share repurchases gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements movements equity retained earnings reserves amounted million st december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity shown following table net translation exchange included total fair value retained minority translation reserve earnings interest exchange st january exchange movements overseas net assets st december exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary st december exchange movements overseas net assets reclassification exchange liquidation overseas subsidiary st december analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total st january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts st december transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares acquired esop trusts ordinary shares transferred esop trusts writedown shares held esop trusts put option minority interest st december reserves include various nondistributable merger premerger reserves amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million gsk annual report pp stnemetats laicnanif notes financial statements related party transactions gsk held interest quest diagnostics inc st december group quest diagnostics parties longterm contractual relationship quest diagnostics primary provider clinical laboratory testing support groups clinical trials testing requirements worldwide quest diagnostics provided services million million group st december balance payable gsk quest diagnostics million nil march shares groups associate quest diagnostics inc sold cash consideration million majority shares sold direct quest diagnostics inc remainder sold market th november gsk completed extension strategic relationship aspen pharmacare holdings limited acquisition minority shareholding south african based pharmaceutical company transaction resulted gsk acquiring million shares aspen consideration transfer certain assets aspen becoming associate gain million transaction included within operating income st december gsk held million shares interest aspen december gsk distributed million products aspens extensive distribution network st december balance due gsk aspen million nil balance payable gsk aspen million nil group shionogi co ltd entered transactions us joint venture company support research development activities conducted joint venture company gsk provided services joint venture million million st december balance due gsk joint venture million million aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance costs depreciation amortisation intangible assets impairment assets written profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increase inventories increasedecrease trade receivables increasedecrease receivables increasedecrease trade payables increasedecrease payables decreaseincrease pension provisions sharebased incentive plans cash generated operations gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements reconciliation net cash flow movement net debt net debt beginning year increase cash bank overdrafts cash inflowoutflow liquid investments net increase longterm loans net repayment ofincrease shortterm loans net repayment obligations finance leases debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year analysis changes net debt exchange reclassifications acquisitions cash flow liquid investments cash cash equivalents overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing net debt information significant changes net debt see note net debt acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures businesses given acquisitions genelabs technologies inc th january group acquired share capital genelabs technologies inc california biotechnology company strong focused portfolio hepatitis c vaccines purchase price million included million cash cash equivalents remainder represented preliminary net asset valuations million transaction accounted purchase method accounting genelabs technologies inc turnover nil loss tax million year turnover nil million loss tax related period since acquisition included group accounts gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued acquisitions continued genelabs technologies inc continued book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax asset liabilities goodwill total consideration bristol myers squibb pakistan private limited th january group acquired share capital bristol myers squibb pakistan private limited certain associated trademarks consideration million result group acquired portfolio wellestablished pharmaceutical brands many occupy leading market positions key therapeutic disease areas pakistan purchase price million represented provisional valuations intangible assets million goodwill million net assets million goodwill arising acquisition reflects potential product growth throughout region expected synergies group transaction accounted purchase method accounting bristol myers squibb pakistan private limited turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration certain businesses ucb sa st march group acquired ucb sa marketed product portfolio across certain territories africa middle east asia pacific latin america includes several leading pharmaceutical brands number disease areas subsequent date group completed country acquisitions formed part original transaction purchase price million included million net cash million intangible assets million goodwill million net liabilities provisional valuations may change future goodwill arising acquisition business reflects potential product growth throughout regions expected synergies group transaction accounted purchase method accounting transaction included acquisition number legal entities product rights previously marketed outside entities product portfolio acquired integrated gsk business period since acquisition therefore practicable identify result tax arising result transaction period acquisition prior acquisition estimated product portfolio recorded turnover million since acquisition gsk recorded turnover million products acquired gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements acquisitions disposals continued certain businesses ucb sa continued book fair value fair value adjustment value net assets acquired intangible assets property plant equipment cash cash equivalents deferred tax provision liabilities goodwill total consideration az tika st april group acquired share capital az tika wholly owned subsidiary astra zeneca plc cash consideration million result group acquired number leading overthecounter products predominantly sold sweden including alvedon countrys leading analgesic treatment purchase price million represented intangible assets million goodwill million net liabilities million goodwill arising acquisition reflects potential product growth expected synergies group transaction accounted purchase method accounting prior acquisition products acquired marketed outside entity acquired products acquired integrated gsk business period since acquisition therefore practicable identify result tax arising result transaction period acquisition prior acquisition estimated product portfolio recorded turnover million since acquisition gsk recorded turnover million products acquired book fair value fair value adjustment value net assets acquired intangible assets assets including cash cash equivalents deferred tax provision goodwill total consideration stiefel laboratories inc nd july group acquired share capital stiefel laboratories inc worlds largest private dermatological company cash consideration million net cash acquired including million debt repaid acquisition purchase price million including contingent cash consideration million payable upon certain criteria met specified dates future included million cash cash equivalents million intangible assets million goodwill representing potential additional growth combination stiefel business gsks existing dermatology portfolio million net liabilities purchase price includes potential obligations make additional payments million million depending future performance certain products provisional valuations may change future stiefel laboratories inc turnover million loss tax including restructuring costs million year ended st december million turnover million loss tax including restructuring costs related period since acquisition included group accounts since acquisition stiefel made operating profit million restructuring costs intangible assets amortisation new business provide significant opportunities sales cost synergies stiefels products benefit gsks global distribution commercial organisations particularly markets brazil russia india china japan gsks products benefit stiefels speciality sales force relationships experienced management dermatology cost synergies new business expected primarily combining manufacturing administrative functions previously reported gsk expects deliver annual pretax cost savings million restructuring costs approximately million million charged remainder incurred next two years excluding restructuring costs stiefel acquisition resulted dilution gsks earnings per share less expected result improvement gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued stiefel laboratories inc continued book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration viiv healthcare limited th october gsk acquired pfizer incs hiv business combined hiv business form viiv healthcare limited subgroup owned gsk pfizer consideration given gsk representing net value gsks hiv business contingent consideration transaction costs valued million represented million intangible assets million deferred tax liability million net assets million increase minority interests million goodwill representing economies scale gained combination two businesses potential growth partners hiv products within viiv healthcare provisional valuations may change future minority interest represents pfizers interest viiv healthcare including right preferential dividends based sales performance certain products gsk recognised accounting gain million transaction arising disposal interest gsks hiv business pfizer recorded book value return pfizers hiv business recorded fair value acquired pfizer hiv business turnover million loss tax million year taking account transition status various territories million turnover million loss tax recognised group accounts including restructuring costs book fair value fair value adjustment value net assets acquired intangible assets assets including cash cash equivalents deferred tax provision minority interests goodwill total consideration consideration fair value assets contributed gsk fair value contingent equity contributed gsk direct costs total consideration gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements acquisitions disposals continued acquisitions continued laboratoire pharmaceutique algrien th november gsk acquired share capital algerian pharmaceutical manufacturing distribution group laboratoire pharmaceutique algrien cash consideration million net cash acquired purchase price million included million cash cash equivalents million goodwill million net liabilities million reduction value existing investment provisional valuations may change future goodwill reflects potential business synergies sales growth increase gsks market presence following acquisition established market participant transaction accounted purchase method accounting laboratoire pharmaceutique algrien turnover million year ended st december result year yet determined estimated loss million turnover million million loss related period acquisition recorded group accounts book fair value fair value adjustment value net assets acquired property plant equipment cash cash equivalents liabilities goodwill fair value loss arising increased investment lpa distribution total consideration novamin technology inc th december gsk acquired share capital novamin technology inc privately held us company cash consideration million purchase price included million intangible assets million goodwill million net liabilities provisional valuations may change future company specialty oral care ingredient treatment dentine hypersensitivity goodwill arising acquisition represents potential additional growth combination companys technology specific gsk oral care products transaction accounted purchase method accounting novamin technology inc turnover million loss tax million year nil turnover nil loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets deferred tax provision goodwill total consideration acquisitions made beginning year estimated group turnover would increased million year acquisitions fully integrated gsk business practicable separately identify impact acquisitions group profit year acquisitions year include million invested shionogiglaxosmithkline holdings lp joint venture group share million invested shenzhen glaxosmithkline neptunus biologicals co ltd associate group initial share certain stiefel laboratoire novamin bms businesses laboratories pharmaceutique technology cash flows genelabs pakistan ucb sa az tika inc algrien inc total cash consideration cash cash equivalents acquired net cash consideration contingent consideration net purchase consideration gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued acquisitions continued sirtris pharmaceuticals inc th june group acquired issued share capital sirtris pharmaceuticals inc biopharmaceutical company based massachusetts usa cash consideration million company focused discovering developing proprietary orally available small molecule drugs potential treat diseases associated ageing including metabolic diseases type diabetes sirtris drug candidates designed mimic certain beneficial health effects calorie restriction activation sirtuins recently discovered class enzymes sirtris believes control ageing process transaction accounted purchase method accounting goodwill arising acquisition reflects potential enabling gsk enhance metabolic neurology immunoinflammation research efforts establishing worldleading presence sirtuin field aided existence company highly experienced development team encompasses aspects sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration bristol myers squibb egypt th october group acquired egyptian mature products business bristol myers squibb bms cash consideration million amount million deferred payment made alternative supply arrangements established group acquired branded products occupy leading market positions four therapeutic disease areas egypt including duricef antibiotic capozide capoten ace inhibitors theragranh iron supplement kenacomb topical steroid total sales combined mature products pharmaceuticals business million group also take ownership bmss high quality manufacturing facility giza greater cairo continue supply acquired products group ability export generic versions acquired products markets outside egypt thereby creating opportunity drive sales growth middle east north africa region fact reflected goodwill arising acquisition business turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment inventory goodwill total consideration gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements acquisitions disposals continued sirtris bms egypt acquired beginning combined group turnover year would million combined group profit year would million shionogi euclid sr glaxosmithkline cash flows sirtris bms egypt partners lp holdings lp total cash consideration cash cash equivalents acquired net cash payment acquisitions euclid sr partners lp additional million invested euclid sr partners lp associate group share shionogiglaxosmithkline holdings lp additional million invested shionogiglaxosmithkline holdings lp joint venture group share acquisitions reliant pharmaceuticals inc th december group acquired issued share capital reliant pharmaceuticals inc pharmaceutical company based usa cash consideration million company specialises development marketing speciality medicines combat heart disease includes us rights lovaza treatment adult patients high levels triglycerides transaction accounted purchase method accounting goodwill arising acquisition reflects potential product growth throughout usa puerto rico expected synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration gsk annual report pp stnemetats laicnanif notes financial statements acquisitions disposals continued domantis limited th january group acquired issued share capital domantis limited drug discovery company based uk cash consideration million company developing next generation antibody therapies transaction accounted purchase method accounting goodwill arising acquisition reflects potential combining worldleading technology domantis development programme already place within gsk put group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax provision liabilities goodwill total consideration praecis pharmaceuticals inc th february group acquired issued share capital praecis pharmaceuticals inc biopharmaceutical company based usa cash consideration million company developed efficient method identifying drug leads targeting human disease using proprietary technology transaction accounted purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax related period since acquisition included group accounts book fair value fair value adjustment value net assets acquired intangible assets property plant equipment assets including cash cash equivalents deferred tax asset liabilities goodwill total consideration reliant domantis praecis total cash flows cash consideration cash cash equivalents acquired net cash payment acquisitions reliant domantis praecis acquired beginning year combined group turnover year would million combined group profit year would million gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments business combinations pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted majority intangible commitments denominated us dollars weakening foreign currencies year led decrease commitments reported number commitments made licensing agreements including arrangements chroma therapeutics limited concert pharmaceuticals inc idenix pharmaceuticals inc prosensa bv seattle genetics inc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified st december actuarial funding valuation table shows commitment excludes normal ongoing annual funding requirement approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases post balance sheet events th february gsk received complete response letter fda regarding new drug application horizant extended release tablets restless legs syndrome letter indicated questions remained precluded approval horizant restless legs syndrome time gsk evaluating letter considering appropriate next steps groups intangible assets include million relation compound yet possible determine amount impairment may recorded future periods pending completion full analysis situation gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures borrowings together cash generated operations glaxosmithkline plc reports sterling pays dividends onlent contributed equity certain subsidiaries used sterling profits role corporate treasury manage pay dividends make acquisitions gsk make share monitor external internal funding requirements repurchases financial risks support strategic objectives treasury total capital equity net debt group increased activities governed policies procedures approved million million increase board directors recently st october million principally represents retained profit treasury management group tmg chaired chief financial year offset actuarial losses defined benefit pension plans officer meets monthly basis review treasury activities reduction net debt net debt reduced compared members receive management information relating treasury primarily consequence gsks decision suspend activities internal auditors review treasury internal control share repurchases groups positive cash generation environment regularly along issuance billion bond emtn programme billion commercial paper sufficient gsk uses variety financial instruments finance operations repay maturing shortterm debt finance groups derivative financial instruments manage risks acquisitions year whilst also increasing groups overall operations derivatives principally comprising forward cash position st december foreign currency contracts interest rate currency swaps liquidity risk used swap borrowings liquid assets currencies required group purposes manage exposure funding risks manage net borrowing requirements portfolio changes foreign exchange rates interest rates longterm borrowings including bonds together shortterm finance us billion commercial paper programme gsk hold issue derivatives speculative purposes commercial paper programme backed billion treasury policies specifically prohibit activity committed facilities facilities last renewed october transactions financial instruments undertaken consider level committed facilities adequate manage risks arising underlying business activities given current cash holdings information speculation facilities please refer note financial statements capital management net debt also benefit strong positive cash flow operating units manage capital ensure entities group able operate going concerns optimise return european medium term note programme shareholders appropriate balance debt equity billion st december billion board reviews groups dividend policy funding notes issue programme also us shelf requirements annually registration statement st december billion billion notes issue programme tmg capital structure group consists net debt monitors cash flow forecast monthly basis see note net debt shareholders equity see consolidated statement changes equity longterm borrowings mature dates longterm debt ratings remained stable since continue expect investment opportunities arise february currently rated stable outlook allow group invest support strategic priorities standard poors stable outlook moodys ensure sufficient flexibility take advantage shortterm debt ratings p standard opportunities currently expect make significant share poors moodys respectively repurchases investment opportunities continue assessed strict financial criteria well committed facilities also substantial cash gsk operates global basis primarily subsidiary liquid investments amounted billion companies established markets trade st december also benefit strong positive cash significant levels patent trademark protection flow operating units pharmaceutical products compete largely product efficacy differentiation rather price selling margins sufficient cover normal operating costs operations cash generative operating cash flow used fund investment research development new products also used make routine outflows capital expenditure tax dividends repayment maturing debt extent determined board share repurchases policy borrow centrally using variety capital market issues borrowing facilities meet anticipated funding requirements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued market risk interest rate risk management policy interest rate risk management limits amount floating interest payments prescribed percentage trading profit use interest rate swap redenominate one external borrowings interest rate coupon required gsk duration swap matches duration principal instrument interest rate derivative instruments accounted fair value cash flow hedges relevant assets liabilities foreign exchange risk management foreign currency transaction exposures arising internal external trade flows hedged exposure overseas operating subsidiaries transaction risk minimised matching local currency income local currency costs purpose internal trading transactions matched centrally manage intercompany payment terms reduce foreign currency risk exceptional foreign currency cash flows hedged selectively management corporate treasury manage cash surpluses borrowing requirements subsidiary companies centrally using forward contracts hedge future repayments back originating currency seek denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling certain borrowings swapped currencies required borrowings denominated swapped foreign currencies match investments overseas group assets may treated hedge relevant assets forward contracts also used major currencies reduce exposure investment overseas group assets see net investment hedges section note details tmg reviews ratio borrowings assets major currencies monthly credit risk group considers maximum credit risk million million total groups financial assets exception investments bear credit risk see details groups total financial assets gsks greatest concentration credit risk billion billion invested us treasury treasury repo money market funds bear credit exposure us government treasuryrelated credit risk credit risk remained high global credit crisis gsk continued maintain conservative approach counterparty risk throughout period report relationship banks credit ratings presented annually tmg approval aggregate credit risk respect financial instruments group may one counterparty limited reference longterm credit ratings assigned counterparty moodys standard poors table sets credit ratings counterparties liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table though isda contracts amount risk net asset position counterparty credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb total bank balances deposits us treasury treasury repo money market funds corporate debt instruments government securities rd party financial derivatives total credit ratings tables assigned moodys investor services standard poors respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency data source available ratings converted global ratings equivalent moodys investor services standard poors using published conversion tables figures restated reflect equivalent global sovereign ratings appropriate rather local ratings providers gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures following methods assumptions used estimate fair values continued centrally managed cash reserves amounted billion cash cash equivalents approximates st december available within months group carrying amount invests centrally managed liquid assets bank deposits aaaaaa liquid investments based quoted market prices rated us treasuries us treasury repo money market funds case marketable securities based principal amounts short term corporate debt instruments minimum shortterm case nonmarketable securities short credit rating ap bank deposits repricing periods global counterparty limits assigned gsks banking investments investments traded active market investment counterparties based longterm credit ratings determined reference relevant stock exchange quoted moodys standard poors corporate treasurys usage bid price investments determined reference limits monitored daily corporate compliance current market value similar instruments reference officer cco operates independently corporate discounted cash flows underlying net assets treasury breach limits would reported shortterm loans overdrafts approximates carrying cfo immediately cco also monitors credit rating amount short maturity instruments counterparties changes ratings occur notifies longterm loans based quoted market prices corporate treasury changes made investment case eurobonds fixed rate borrowings levels authority limits appropriate approximates carrying amount case floating wholesale retail credit risk rate bank loans loans usa line pharmaceutical companies forward exchange contracts based market data group sells products small number wholesalers exchange rates balance sheet date addition hospitals pharmacies physicians groups currency swaps based market data balance sales three largest wholesalers amount approximately sheet date groups us pharmaceutical sales st december interest rate swaps based net present value group trade receivables due three discounted cash flows wholesalers totalling million million group exposed concentration credit risk respect receivables payables approximates wholesalers one encounters carrying amount financial difficulty could materially adversely affect lease obligations approximates carrying amount groups financial results fair value investments gsk shares groups credit risk monitoring activities relating st december employee share ownership plan wholesalers includes review quarterly financial information esop trusts held gsk shares carrying value standard poors credit ratings development gsk internal million million fair value risk ratings establishment periodic review credit limits million million based quoted market however group believes credit risk provision price shares represent purchases esop trusts satisfy required excess normal provision bad doubtful future exercises options awards employee incentive debts see note trade receivables outside schemes carrying value lower cost expected usa customer accounts trade proceeds shares recognised deduction receivables balance reserves st december gsk held treasury shares cost million million fair value financial assets liabilities deducted retained earnings table presents carrying amounts fair values groups financial assets liabilities committed facilities st december st december group committed facilities back commercial paper programme billion billion billion fair values financial assets liabilities included billion days duration renewable annually amount instrument could exchanged st december undrawn committed facilities totalled current transaction willing parties forced billion billion billion billion liquidation sale gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued carrying fair carrying fair value value value value cash cash equivalents availableforsale investments liquid investments government bonds total liquid investments investments loans receivables trade receivables noncurrent assets scope ias heldfortrading financial assets derivatives designated accounting hedges derivatives total financial assets financial liabilities measured amortised cost borrowings bonds designated hedging relationship bonds commercial paper bank loans overdrafts loans private financing obligations finance leases total borrowings trade payables noncurrent liabilities scope ias heldfortrading financial liabilities derivatives designated accounting hedges derivatives total financial liabilities net financial assets financial liabilities gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level financial assets fair value st december level level level total heldfortrading financial assets derivatives designated accounting hedges derivatives availableforsale financial assets liquid investments investments financial liabilities fair value st december level level level total heldfortrading financial liabilities derivatives designated accounting hedges derivatives movements year financial instruments measured using level valuation methods presented investments st january losses recognised profit loss gains recognised comprehensive income additions disposals transfers tofrom level exchange st december losses relating level financial assets included operating income attributable assets held end year gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued trade receivables noncurrent assets scope ias following table reconciles financial assets within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning assets include tax receivables pension surplus balances prepayments outside scope ias trade receivables note noncurrent assets note analysed financial assets scope ias assets following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days amounts past due greater days total million million balance million million relates receivables due state hospital authorities certain european countries given profile customers including large wholesalers government backed agencies credit risk identified trade receivables past due balances allowance made trade payables noncurrent liabilities scope ias following table reconciles financial liabilities within trade payables noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities liabilities include payments account tax social security payables outside scope ias trade payables note noncurrent liabilities note analysed financial liabilities scope ias liabilities gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued debt interest rate repricing table following table sets exposure group interest rates debt effect interest rate swaps maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases effect effect interest interest debt rate swaps total debt rate swaps total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing sensitivity analysis sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations place st december financial instruments affected market risk include borrowings deposits derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes relevant foreign exchange interest rates foreign exchange sensitivity table shows groups sensitivity foreign exchange rates us dollar euro yen financial instruments excluding obligations finance leases certain nonderivative financial instruments net debt present material exposure three currencies major foreign currencies gsks financial instruments denominated gsk considered movements currencies last three years concluded movement rates reasonable benchmark table financial instruments considered sensitive foreign exchange rates functional currency entity holds intercompany loans fully hedged maturity currency swap excluded analysis increasedecrease reduction increasedecrease reduction income equity income equity appreciation us dollar appreciation euro appreciation yen depreciation stated currencies would equal opposite effect movements income statement relate primarily hedging instruments us dollar legal provisions trade payables trade receivables whilst hedging instruments provide economic hedges related provisions financial instruments therefore included table combined sensitivity hedging instruments provisions would insignificant provisions included movements equity relate foreign exchange positions used hedge group assets denominated us dollar euro yen therefore depreciation currency swap would give rise corresponding appreciation group asset foreign exchange sensitivity group assets financial instruments included gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related disclosures continued interest rate sensitivity table shows groups sensitivity interest rates floating rate sterling us dollar euro financial instruments currencies gsk historically issued debt held investments gsk considered movements interest rates last three years concluded increase reasonable benchmark debt maturity less one year floating rate calculation movement interest rates deemed material effect equity increasedecrease increasedecrease income income increase sterling interest rates increase us dollar interest rates increase euro interest rates interest rates could decreased currently less maximum increasedecrease income would therefore limited million million million sterling us dollar euro interest rates respectively million million million interest rate movements obligations finance leases foreign currency derivatives trade payables trade receivables financial instruments net debt present material exposure groups balance sheet based increase decrease interest rates contractual cash flows nonderivative financial liabilities derivative instruments following analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held st december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates st december finance charge trade obligations obligations interest finance finance payables st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade obligations obligations interest finance finance payables st december debt debt leases leases net debt total due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report pp stnemetats laicnanif notes financial statements financial instruments related disclosures continued following table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates st december receivables payables receivables payables less one year one two years two three years three four years four five years greater five years gross contractual cash flows derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities cash flow hedges cross currency swaps principal amount nil million fair value hedges interest rate swaps principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated accounting hedges foreign exchange contracts principal amount million million embedded derivatives derivatives designated accounting hedges total derivative instruments analysed current noncurrent total gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements financial instruments related employee share schemes disclosures continued group operates share option schemes whereby options granted employees acquire shares ads glaxosmithkline derivative financial instruments plc grant price savingsrelated share option schemes principal amount foreign exchange contracts share award schemes addition gsk operates performance calculated based outstanding positions balance sheet share plan whereby awards granted employees acquire date calculated net currency buysell side position shares ads glaxosmithkline plc cost subject majority contracts periods months less achievement group specified performance targets share value plan whereby awards granted employees st december group held outstanding foreign acquire shares ads glaxosmithkline plc cost exchange contracts consisting primarily currency swaps three year vesting period granting restricted share awards total credit fair value million million debit replaced granting options certain employees represent hedges intercompany loans deposits cost scheme readily equates potential gain designated accounting hedges changes fair value made employee taken profit loss period offset exchange gains losses related intercompany lending borrowing grants share option schemes normally exercisable cash flow hedges three ten years date grant grants restricted shares share awards normally exercisable group entered two cross currency swaps end three year vestingperformance period grants designated cash flow hedge converting fixed euro savingsrelated share option schemes normally exercisable interest euro debt within groups japanese subsidiary three years saving options share option schemes payable annually fixed yen payments bond swaps granted market price ruling date grant matured rd june risk hedged accordance uk practice majority options variability cash flows arising currency fluctuations savingsrelated share option schemes granted price ineffectiveness recorded hedge amounts market price ruling date grant share options recognised comprehensive income reclassified awarded directors effect grant income statement offset exchange gains losses cet subject performance criteria period underlying bond result revaluation relevant reporting date fair value hedges group designated interest rate swap fair value hedge risk hedged variability fair value bond arising interest rate fluctuations gains losses fair value hedges disclosed note finance costs net investment hedges foreign exchange contracts designated net investment hedges respect foreign currency translation risk principally arising consolidation groups net investment us dollar euro yen foreign operations addition euro loan capital issued billion billion previous years designated monetary net investment hedge respect foreign currency translation risk principally arising consolidation groups net investment euro operations net investment hedge ineffectiveness disclosed note finance income gsk annual report pp stnemetats laicnanif notes financial statements employee share schemes continued option pricing purposes valuing options awards arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years years savingsrelated share option share award schemes years years years weighted average share price grants year ordinary shares ads volatility determined based three five year share price history appropriate fair value performance share plan grants take account market conditions expected lives options determined based weighted average historic exercises options options outstanding share option share option savingsrelated schemes shares schemes ads share option schemes weighted weighted weighted weighted weighted weighted number exercise fair number exercise fair number exercise fair price value price value price value st january options granted options exercised options lapsed st december options granted options exercised options lapsed st december options granted options exercised options lapsed st december range exercise prices weighted average market price exercise weighted average remaining contractual life years years years gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements employee share schemes continued order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares ads glaxosmithkline shares ads programme established give additional cash benefit exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options normally become exercisable three years date grant may certain circumstances vest earlier set within various scheme rules change effective exercise price outstanding options year share option share option savingsrelated options exercisable schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december gsk annual report pp stnemetats laicnanif notes financial statements employee share schemes continued glaxosmithkline share award schemes performance share plan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period awards granted directors members cet prior subject single performance condition compares gsks tsr period tsr companies comparator group period awards granted onwards directors members cet award based achievement adjusted free cash flow targets three year measurement period remaining award based relative tsr performance comparator group described pages half tsr element award measured three years half four years awards made eligible employees prior performance conditions consist two parts applies award first part performance condition compares gsks eps growth increase uk retail prices index three year measurement period second part performance condition compares gsks tsr period tsr companies comparator group period awards granted onwards first part performance condition continues based eps second part performance condition based strategic operational business measures three year measurement period specific employees business area shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december share value plan group operates share value plan whereby awards granted form shares certain employees cost awards vest three years performance criteria attached shares weighted ads weighted number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements employee share schemes continued deferred investment award plan group operates deferred investment award plan whereby awards granted form notional shares certain senior executives cost awards typically vest threeyear period commencing fourth anniversary date grant award initially vesting subsequent two years performance criteria attached shares weighted ads weighted number shares ads issuable number fair value number fair value st january awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares open market finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves held value proceeds receivable employees exercise deemed permanent diminution value reflected transfer retained earnings trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beecham midterm incentive plan trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report pp stnemetats laicnanif notes financial statements principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group st december details given principal country operation location headquarters business sector business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holdings one limited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline mercury limited ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limited ph h brentford glaxo operations uk limited ph p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph r brentford glaxosmithkline uk limited ph p brentford setfirst limited phch h brentford wellcome foundation limited ph p cambridge domantis limited ph r brentford smithkline beecham overseas limited ph h brentford smithkline beecham holdings uk limited ph h brentford viiv healthcare limited ph h brentford viiv healthcare uk limited ph brentford viiv healthcare trading services limited ph e f austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch st amand les eaux glaxosmithkline biologicals sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h p r greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare products limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch verona glaxosmithkline manufacturing spa ph p gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements principal group companies continued europe location subsidiary sector activity luxembourg mamer glaxosmithkline international luxembourg sarl phch f h netherlands zeist glaxosmithkline bv ph utrecht glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk services spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alges glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limited ph p r ireland cork glaxosmithkline trading services limited ph e dublin glaxosmithkline consumer healthcare ireland limited ch dublin glaxosmithkline ireland limited ph dungarvan stafford miller ireland limited ch p dungarvan glaxosmithkline dungarvan limited ch p romania brasovi europharm holding sa phch bucharest glaxosmithkline gsk srl ph r russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa coral gables stiefel laboratories inc ph h p hamilton corixa corporation ph p philadelphia glaxosmithkline llc phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f cambridge sirtris pharmaceuticals inc ph r research triangle park viiv healthcare company ph americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval id biomedical corporation ph h quebec city id biomedical corporation quebec ph p r mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch shanghai glaxosmithkline biologicals shanghai ltd ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ch p r gsk annual report pp stnemetats laicnanif notes financial statements principal group companies continued asia pacific location subsidiary sector activity india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limited ii ch p malaysia petaling jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd ph h singapore glaxo wellcome manufacturing pte ltd ph h p r singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited ph ch thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty limited phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch usa location associate sector activity usa madison quest diagnostics incorporated iii clinical testing middle east africa south africa johannesburg aspen pharmacare holdings limited iii phch p r exempt provisions section companies amendment act ireland ii consolidated subsidiary undertaking accordance section companies act grounds dominant influence iii equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc key business sector ph pharmaceuticals ch consumer healthcare business activity development e exporting f finance h holding company insurance marketing p production r research service full details group subsidiary associated undertakings attached companys annual return filed registrar companies glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings january neolab filed action invalidate group involved significant legal administrative combination patent federal court germany revocation proceedings principally product liability intellectual property actions combination patent germany also tax antitrust governmental investigations well related filed mylan dura gmbh march hexal ag december private litigation group makes provision proceedings ivax october four revocation actions regular basis summarised note accounting principles heard together rd february court advised policies note provisions respect parties decision issued within weeks number legal proceedings group involved following hearing basic patent covering combination possible make reasonable estimate expected product seretide expires september subject financial effect result ultimate resolution supplementary protection certificate extends protection proceedings cases group may disclose september information respect nature facts cases july sandoz hexal initiated revocation action provision typically made intellectual property claims include district court hague groups dutch challenges validity enforceability groups patents combination patent relating seretide hearing originally various products processes well assertions non scheduled th february rescheduled infringement patents loss cases could th november basic patent covering combination result loss patent protection product issue product seretide expires september subject consequences loss could significant decrease supplementary protection certificate extends protection sales product could materially affect future results september operations group revocation action basic patent covering seretide legal expenses incurred provisions related legal claims combination ireland filed high court dublin charged selling general administration costs provisions behalf ivax july trial took place th march made taking appropriate legal specialist advice th may high court handed decision reasonable estimate made likely outcome th june finding patent invalid obviousness dispute group established actuarially determined decision related solely irish combination patent provision product liability claims incurred yet reported seretide binding decision group filed described note provisions st december appeal decision october trial date groups aggregate provision legal disputes set appeal including tax matters described note taxation billion ultimate liability legal claims may vary action revocation french seretide combination amounts provided dependent upon outcome patent filed sandoz tribunal de grande instance litigation proceedings investigations possible settlement paris th october trial date yet set negotiations groups position could change time basic patent covering combination product seretide therefore assurance losses result expires september subject supplementary outcome legal proceedings exceed protection certificate extends protection amount provisions reported groups financial accounts september material amount happen could argatroban material adverse impact results operation group december encysive pharmaceuticals inc mitsubishi kasei reporting period judgements incurred corporation group filed action us district court settlements entered significant matters southern district new york barr laboratories described inc infringement mitsubishis pharmaceutical composition intellectual property patent covering argatroban pursuant license mitsubishi encysive developed argatroban treatment heparin advairseretide induced thrombocytopenia holds new drug application october group filed complaint patent approved us fda encysive licensed us marketing dispute chamber regional court dsseldorf germany rights argatroban group mitsubishi patent neolab uk infringement german patent expires june barr filed abbreviated new drug claiming compositions containing combination salmeterol application anda fda certification invalidity fluticasone propionate used seretide known viani unenforceability noninfringement mitsubishi patent germany complaint based neolabs stated intention twoweek trial case held january letter market salmeterolfluticasone combination product parties awaiting decision fda approval anda germany event occur trial took place stayed earlier may resolution patent patent dispute chamber regional court dsseldorf infringement action january resulted permanent injunction neolab neolab appealed appeal hearing scheduled th july gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued combivir patents listed orange book combivir include composition arzerra matter tclamivudine combination lamivudine azt october group filed action us district court lamivudine crystal form patents expire southern district florida declaration us patent respectively september group received socalled cabilly ii patent owned jointly notice teva filed anda fda alleging genentech inc city hope invalid unenforceable combination patent invalid infringed gsks product arzerra ofatumumab arzerra approved fda chronic lymphocytic leukaemia november group filed action district court orphan indication october february group district delaware teva pharmaceuticals usa inc voluntarily dismissed case filed new case us infringement combination patent fda approval tevas district court northern district california anda stayed earlier march resolution suit currently pending patent infringement action favourable teva case discovery phase october teva filed certification avodart groups patent covering crystal form lamivudine invalid january group received notice barr laboratories infringed group file suit patent filed anda fda allegation invalidity july group received notice lupin ltd filed three patents listed orange book cover certification fda alleging combination patent active ingredient avodart use treat benign prostatic invalid infringed product lupin also filed certification hyperplasia bph february group filed action groups patent covering crystal form lamivudine us district court district delaware barr invalid infringed infringement patents basic compound patent expires two patents expire fda approval august group filed suit lupin barrs anda stayed earlier july resolution district court district delaware infringement patent infringement action parties agreed settle combination patent group file suit lupin matter terms settlement subject review crystal form patent march action federal trade commission must receive final court approval lupin stayed mutual consent pending resolution case teva neither teva lupin challenged benlysta basic compound patent covers lamivudine one active february uk court appeal upheld earlier high ingredients combivir patent expires may court decision revoking hgs uk patent ep claim revocation brought eli lilly patent coreg cr claims cytokine blys antibody binds blys group filed suit april us district court benlysta belimumab gsk licence patent eastern district pennsylvania crystal form patent party litigation proceedings equivalent patent covering use coreg cr treating congestive heart european patent upheld october final appeal failure october group filed motion dismiss european patent office following opposition action gave mutual covenant sue patents proceeding filed eli lilly uk decision affect mutual obtain final approval market generic product european patents arising european patent th april based upon data exclusivity granted hgs gsk considering appeal uk decision fda product matter concluded uk supreme court decision affect gsk hgss hiberix infanrix hexa menitorix freedom market sell benlysta rd august novartis sued group belgium boniva patent infringement relation hiberix infanrix hexa group participated marketing boniva pursuant menitorix vaccine products relation phase development copromotion agreement roche expired january vaccine projects hibmency menacwy parallel infringement september roche laboratories commenced proceedings also filed novartis uk infanrix hexa actions us district court district new jersey menitorix hiberix european patent office granted eight generic drug manufacturers case roche groups request accelerated review reconsider validity alleged infringement roche patents relating boniva tablets patent december novartis claims relevant defendants filed anda fda groups products held invalid uk belgian certification invalidity unenforceability noninfringement infringement trials dismissed least one roche patents two manufacturers levitra challenged basic compound patent expires final fda approval andas stayed earlier group participates marketing levitra pursuant november resolution relevant patent infringement copromotion agreement bayer healthcare july bayer action august roche obtained new patent brought suit teva us district court district monthly dosing regimen boniva brought suit delaware teva pharmaceuticals inc infringement anda filers challenging patents new patent patent relating levitra teva filed anda fda expires cases ongoing certification patent covering active ingredient levitra expires invalid unenforceable infringed stay fda approval effect earlier decision case adverse bayer november gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued treximet lovaza october group received letter par march group received notice teva pharmaceuticals pharmaceuticals fda accepted anda treximet usa inc par pharmaceutical inc apotex inc filed included certification patents owned pozen andas certification two patents covering lovaza inc relating treximet invalid unenforceable andor invalid unenforceable infringed patents expire infringed pozens patents licensed group november group licensee patents pronova pozen filed suit par three patents biopharma norge owner patents sued teva par district court eastern district texas november apotex us district court district delaware fda group received letter alphapharm designated approval andas stayed earlier may agent mylan pharmaceuticals fda accepted decision favourable one generics anda treximet included certification pozens patents relating treximet invalid unenforceable andor malarone infringed pozen filed suit alphapharm mylan january august group filed suit us district court infringement patents district court district delaware glenmark generics inc eastern district texas delaware delaware case since usa infringement patents related malarone dismissed pozen also sued teva pharmaceuticals group received notification glenmark filed usa inc dr reddys patents court anda malarone certification alleging treximet data exclusivity precludes approval generic groups patents invalid unenforceable infringed product april group party patents expire cover combination lawsuits brought pozen atovaquone proguanil hydrochloride use preventing malaria fda approval glenmarks anda stayed valtrex earlier january judgment adverse gsk july apotex inc filed complaint declaratory judgment district court middle district north paxilseroxat carolina apotexs valacyclovir product infringe usa number manufacturers distributors generic formulation patent owned group valtrex apotex filed paxil filed applications fda market generic versions para iv certification challenging patent gsk prior expiration groups patent paroxetine file suit challenging certificate gsk filed response hyrdrochloride hemihydrate actions one remains declaratory judgment complaint august pending namely action apotex us district court contest noninfringement allegation october apotex eastern district pennsylvania patents composition filed motion judgment matter pending decision matter process manufacture claims antitrust motion november ranbaxy launched first generic counterclaim asserted apotex discussed product valacyclovir antitrust case set trial april vesicare group markets vesicare license astellas europe generic products containing paroxetine hydrochloride pharma inc september astellas filed suit teva market european countries groups pharmaceuticals usa inc federal district court netherlands patent infringement action farmaceutisch southern district new york infringement patent analytisch laboratorium duiven bv fal fals counterclaims covering active ingredient vesicare astellas received unfair competition settled july notice teva pharmaceuticals filed anda following litigation canada apotex several certification basic patent expires patents related paroxetine apotex launched generic product invalid unenforceable fda approval tevas anda stayed canada october apotex alleged earlier february decision case result litigation enjoined launching favourable teva product receipt regulatory approval action apotex recover damages related delay occasioned product liability injunctions ongoing preclinical clinical trials conducted development potential products determine safety efficacy requip xl products use humans following approval regulatory january group received letters impax bodies notwithstanding efforts drugs vaccines laboratories inc actavis south atlantic llc indicating introduced marketplace unanticipated safety issues andas requip xl accepted fda may become evident group currently defendant letters included allegation patent licensed number product liability lawsuits related groups group skyepharma covering extended release formulation pharmaceutical consumer healthcare products infringed products additional andas significant matters described pages filed torrent pharmaceuticals lupin ltd certifications formulation patent infringed group bring suits companies gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued claims lawsuits alleging treatment paxil caused homicidal suicidal behaviour exhibited users avandia product class certification denied january group named product liability lawsuits behalf purported personal injury class action lawsuit cases remain individuals purported class action cases asserting consumer pending federal state courts cases filed philadelphia fraud andor personal injury claims behalf purchasers coordinated mass tort program users avandia federal cases part multidistrict respect lawsuits filed state federal courts litigation proceeding pending us district court eastern usa canada alleging paxil addictive causes district pennsylvania cases also filed state courts dependency withdrawal reactions virtually us actions cases filed philadelphia coordinated mass tort resolved california court granted plaintiffs program matters discovery phase first trial motion certify class consumer fraud lawsuit seeking scheduled june additionally purported nationwide class economic damages focused discontinuation symptoms action suit filed february us district court canada quebec court denied plaintiffs motion certify eastern district pennsylvania behalf third party payers class patients allegedly experienced discontinuation seeking economic damages various state unfair trade practices symptoms decision appeal uk public funding consumer protection laws plaintiffs indicated granted hundreds patients pursue common filing amended complaint future issues litigation alleging paroxetine caused finally one purported class action filed israel suffer withdrawal reactions dependency trial briefing whether certify class action underway scheduled commence january ten class actions pending canada early stage poligrip baycol number product liability lawsuits claims filed group bayer corporation principal us subsidiary group state federal courts usa bayer ag signed allocation agreement including purported class actions alleging zinc poligrip bayer corporation agreed pay settlements causes copper depletion permanent neurologic injury compensatory damages judgments party retaining first lawsuit alleging neurologic injuries zinc poligrip responsibility attorneys fees punitive damages filed august federal cases part denture federal cases consolidated multidistrict litigation cream adhesive multidistrict litigation us district court proceeding us district court district minnesota southern district florida established june multidistrict litigation process winding group procter gamble defendants less plaintiffs remaining date two statewide class actions litigation included mdl purported class actions asserting certified medical monitoring case pennsylvania economic loss claims state consumer protection laws consumer fraud deceptive business practices act case claims medical monitoring one exception state court illinois medical monitoring action dismissed case arkansas state court cases consolidated court summary judgment supreme court illinois mass tort program philadelphia purported class action likewise dismissed consumer fraud claim summary judgment asserting consumer fraud claims recently filed canada december nationwide class thirdparty payers th february group announced voluntarily certified pennsylvania state court case settled withdrawing zinccontaining formulations poligrip trial another class action group named thimerosal defendant certified oklahoma case decertified deadline appealing decertification order group along number pharmaceutical passed claims death serious injury companies named defendant numerous individual settled thousands others alleging muscle aches personal injury lawsuits state federal district courts pains voluntarily involuntarily dismissed usa alleging thimerosal preservative used manufacture vaccines causes neurodevelopmental disorders paxil paxil cr injuries including autism group received numerous lawsuits claims alleging two cases purported class actions although use paxil paroxetine caused variety injuries determination whether cases many lawsuits claims allege use paxil permitted proceed class action number purported pregnancy resulted birth child birth defects class actions jurisdictions withdrawn health issues lawsuits claims allege patients dismissed plaintiffs seek remedies including compensatory punitive took paxil committed attempted commit suicide statutory damages well cost fund medical acts violence finally third group lawsuits claims monitoring research allege use paxil caused patients suffer symptoms discontinuing treatment paxil date report limited number cases approached trial dates vaccine manufacturers cases filed philadelphia alleging injury pregnancy manufacturers thimerosal containing medicinal products coordinated philadelphia mass tort program successful excluding testimony plaintiffs expert october first trial resulted adverse jury verdict witnesses causation specifically grounds plaintiffs amount million kilker v glaxosmithkline punitive failed establish hypothesised link thimerosal damages awarded posttrial motions pending group neurodevelopmental disorders generally accepted reliable also purported class action litigation canada concerning use within relevant scientific community paxil pregnancy gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued average wholesale price united states department justice number states additionally february office special masters putative classes private payers several years united states court federal claims rejected first three investigating andor bringing civil litigation regarding allegations approximately autism claims filed national numerous pharmaceutical companies including gsk vaccine injury compensation program nvicp grounds violated federal state fraud abuse laws result claimants failed produce reliable scientific evidence linking way average wholesale price awp wholesale acquisition vaccinations medical conditions including autism cost wac determined reported various drugs group party proceedings findings reimbursed medicare medicaid insurance used evidence pending lawsuits programmes group reached million civil group three decisions upheld appeal united settlement federal government resolve allegations states court federal claims two three nvicp claimants relating pricing marketing zofran kytril appealed rulings us court appeals group also amended existing corporate integrity agreement federal circuit third claimant elected appeal requirement settlement group received rejected decision nvicp claimant final approval million nationwide private payer class option filing action either group andor action settlement relating groups price reporting mdl physician administered vaccine question proceeding us district court district massachusetts date action commenced number states respective attorneys general remaining approximately nvicp claimants also counties new york state filed civil ultimately option pursuing personal injury lawsuits lawsuits state federal courts gsk many vaccine manufacturers including group drug companies claiming damages restitution due early determine whether announcement nvcip awp andor wac price reporting pharmaceutical products decisions likely lead increase number civil cases covered states medicaid programmes states seek filed group date report recovery behalf states payers cases cases scheduled trial group defendant behalf instate patients consumers group separately resolved awp claims state medicaid sales marketing regulation programmes twothirds states marketing promotion doj settlement separate negotiations litigation concerning february group received subpoena us awp issues continuing eight states well new attorneys office colorado regarding groups sales york counties july alabama state court jury returned promotional practices relating nine largest selling products million verdict group one case filed period january particular state alabama october alabama supreme government inquired alleged promotion drugs court reversed jury verdict rendered judgment gsks offlabel uses well groupsponsored continuing medical favour court expressly found gsk defrauded education programmes speaker events special issue boards alabama medicaid programme january alabama advisory boards speaker training programmes clinical studies supreme court declined alabamas petition reconsideration related grants fees travel entertainment although reversal original subpoena issued us attorneys office november kentucky state court jury returned colorado scope inquiry nationwide compensatory damages verdict group government also inquiring groups response another case filed state kentucky jury found october letter fdas division drug marketing group liable violating states consumer protection laws advertising communication requesting information liable states medicaid fraud false advertising groups alleged promotion wellbutrin sr offlabel use statutes january judge case awarded state group cooperating investigation providing kentucky additional statutory penalties requested information group considering whether appeal following united nations report alleging bribes nominal pricing paid iraqi government officials connection un oil group responded two letter requests us senate food programme group received subpoena committee finance dated april february sec february respect groups participation documents information relating nominal price exception programme us department justice also initiated best price reporting requirements medicaid drug investigation december uk serious fraud office rebate programme january committee released issued formal notice group requiring production findings pharmaceutical manufacturers inappropriately documents related groups participation programme used nominal price exception contrary committees group cooperating investigations provided interpretation congressional intent may group documents responsive subpoena notice advised us department justice investigating continues respond follow questions requests certain groups nominal pricing bundled sales arrangements determine whether arrangements qualify exception best price reporting requirements violate civil statutes laws gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued cidra puerto rico manufacturing site october group announced plans cease march group received broad letter request operations manufacturing facilities located cidra us department justice seeking range documents relating puerto rico th july cidra site ceased operations groups nominal pricing arrangements since commenced decommissioning activities remaining possible bundled sales group continuing cooperate operational staffs released th september investigation produce documents group also th october us district court eastern received subpoenas requests documents information district north carolina entered order vacating consent delaware michigan related groups nominal price decree group fda agreed regarding arrangements group cooperating investigations groups manufacturing operations site group producing responsive documents addition completed decommissioning activities currently pursuing governmental investigations allegations concerning nominal opportunities sell site third party pricing made certain government payers part awp litigation group entered nominal october us federal government executed search price arrangements since december warrant cidra facility seized records relating manufacturing operations site b programme group defending action filed federal court april group received subpoena us us district court northern district california attorneys office boston requesting production records county santa clara one county seeks regarding manufacturing cidra site covering information represent putative class hospitals clinics entities similar seized us government puerto california eligible receive discounted ceiling rico subsequently group received additional prices pharmaceuticals federal programme known subpoenas government related cidra facility b programme plaintiffs allege group group cooperating us attorneys office numerous pharmaceutical manufacturers producing records responsive subpoenas addition setting ceiling prices higher allowed law july group learned us district court contract governs programme therefore district massachusetts unsealed complaint brought overcharged entities california eligible former employee federal false claims act participate b programme lawsuit dismissed claiming monetary damages result alleged failure reinstated august following appeal cidra facility comply fda good manufacturing actively litigated trial court level part processes gmps manufacture various products plaintiffs claim defendants miscalculated average group also named two purported consumer fraud class manufacturer prices amps best prices bps action lawsuits one filed california state court medicaid rebate program form part us district court district puerto rico alleging ceiling price formula resulted inflated ceiling prices paxil products manufactured according gmp defendants asserted continue assert plaintiffs sought economic statutory punitive damages plaintiffs entitled challenge calculation amps along request injunctive relief summer bps part lawsuit group reached tentative agreement settle paxilseroxat matters settlement covers nationwide classes consumer following groups settlement lawsuit filed purchasers third party payers provides claims procedure new york state attorney generals office alleging failure class members receive payment splitdefective disclose data use paxil children adolescents paxil cr tablets settlement received final trial court approval similar cases purported class actions september objectors settlement filed appeals filed private plaintiffs seeking recover amounts paid appeals dismissed february accordingly paxil purchased use patients age settlement become final effective accordance following class settlement consumers us terms settlement agreement consumer district court district minnesota approved fraud class action lawsuits dismissed prejudice million class settlement ensuing lawsuits seeking related third party payer suit filed philadelphia court recovery behalf insurance companies thirdparty common pleas marked settled discontinued payers payments prescriptions paxil children ended th october adolescents group denied liability settlements similar purported class action filed us district court district minnesota behalf federal state local government entities paid prescriptions paxil minors also remains similar purported class action canada seeking economic damages behalf individuals third party payers governmental entities purchased paxil use patients age gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes financial statements legal proceedings continued secondary wholesaler july rxusa wholesale inc secondary wholesaler antitrust filed suit group many pharmaceutical paxilseroxat manufacturers wholesalers us district court trial date remaining patent infringement eastern district new york complaint alleges action brought group apotex apotexs defendants engaged conspiracy refuse supply counterclaim remains set th april us district pharmaceutical products rxusa violation federal court eastern district pennsylvania matter state antitrust laws groups motion dismiss group seeks substantial damages apotexs alleged complaint granted plaintiff filed appeal infringement one groups patents paroxetine wellbutrin xl hydrochloride apotex turn seeks damages group amount substantially larger damages actions filed biovail gsk purported sought group alleged violations federal antitrust classes direct indirect purchasers allege unlawful laws well involving advertising state antitrust monopolisation antitrust violations related consumer protection laws federal antitrust enforcement biovails wellbutrin xl patents filing laws damages sought apotex would trebled biovail citizen petitions groups motion dismiss event adverse jury verdict group amended complaint indirect purchasers granted nd december court ordered group respect claims class apotex engage mediation attempt reach settlement representatives many claims asserted indirect patent infringement claim counterclaim purchasers case proceeded discovery respect remaining claims well ones brought eu sector inquiry purported class direct purchasers january european commission announced inquiry flonase certain aspects competition pharmaceutical sector initiated inspections premises number innovator purported direct indirect purchaser class actions generic pharmaceutical companies including group filed us district court eastern district commission published preliminary report november pennsylvania alleging group illegally maintained monopoly based information provided innovator generic power market flonase charged plaintiffs supra pharmaceutical companies report suggests defensive competitive prices additionally suit filed roxane patenting strategies may lead obstacles innovation laboratories inc generic competitor seeking lost profits innovator companies employ measures hinder generics coming groups alleged actions unlawfully delaying roxanes entry onto market final report issued july market predicate allegations contradicting preliminary report final report filing group allegedly sham citizen petitions conceded delays generic entry much fault subsequent litigation group successfully narrowed regulatory environment innovator companies defensive claims purported class indirect purchasers strategies report commission stated motions dismiss complaint amended complaints attack legitimate patenting practices identified areas follow groups motion dismiss roxanes complaint recently scrutiny commission recommended regulatory denied discovery regard parties scheduled reform improvement conclude q wellbutrin sr commercial corporate december january february lawsuits securities class actions several purported class actions filed november attorneys purporting represent class us district court eastern district pennsylvania purchasers glaxosmithkline shares ads filed group behalf direct indirect purchasers amended consolidated complaint group senior wellbutrin sr complaints allege violations us officers us district court southern district new antitrust laws sham litigation fraud patent york alleged group individual defendants office group obtaining enforcing patents covering violated us securities laws artificially inflated price wellbutrin sr complaints followed introduction glaxosmithklines stock misleading investors safety generic competition wellbutrin sr april district avandia amended consolidated complaint also alleges appellate court rulings generic manufacturer several current former senior officers members infringe groups patents class direct purchasers group engaged insider trading motion dismiss certified decision yet made complaint filed behalf group court regard certification indirect purchaser class individual defendants may district court entered discovery substantially completed groups order dismissing case defendants plaintiffs filed motion summary judgment remains pending appeal us court appeals second circuit august court appeals affirmed district courts dismissal matter concluded gsk annual report pp stnemetats laicnanif notes financial statements legal proceedings continued third case filed us district court district arizona november sought establish nationwide th july class action suit brought behalf collective action behalf entire groups us current former employees stiefel laboratories inc pharmaceutical sales representatives ground filed us district court southern district representatives exempt employees us fair florida complaint alleges stiefel officers labor standards act plaintiffs sought double damages directors violated us employee retirement income security act overtime allegedly worked groups pharmaceutical sales erisa federal state securities laws inducing stiefel representatives three year period november employees sell shares employee stock plan back court granted groups motion summary judgment stiefel company greatly undervalued price without dismissed lawsuit ground sales disclosing employees stiefel sold representatives exempt employees outside january defendants motion dismiss granted part sales exemption us fair labor standards act plaintiffs denied part specifically court determined asked court reconsider amend judgment based erisa claims individual stiefel defendants well rationale advanced us department labor federal securities claims individual defendants brief department filed case involving another stiefel could go forward court dismissed florida company st february court reaffirmed securities act common law breach fiduciary duty claims dismissal action plaintiffs subsequently filed notice holding erisa preempts state common law well appealing decision us court appeals malpractice claim stiefels former accountants ninth circuit wage hour claims environmental matters december two purported class actions filed gsk notified potential responsibility relating group behalf entire groups us past operations past waste disposal practices pharmaceutical sales representatives actions certain sites primarily usa matters filed transferred us district court central subject litigation including proceedings initiated district california initially alleged representatives us federal state governments waste disposal site exempt employees california law andor remediation costs tort actions brought private parties us fair labor standards act consequently entitled overtime pay among things gsk advised may responsible party approximately sites appear national plaintiffs subsequently amended complaints priority list created comprehensive environmental assert class action limited solely pharmaceutical sales response compensation liability act superfund representatives working california asserting claims proceedings seek require operators hazardous californias wage hour laws waste facilities transporters waste sites generators suits seek variety compensatory punitive statutory hazardous waste disposed sites clean damages group moved summary judgement dismissing sites reimburse government cleanup costs claims putative class representatives ground instances gsk involved alleged generator hazardous exempt employees court held waste although superfund provides defendants appeals pending united states court appeals jointly severally liable cleanup costs proceedings ninth circuit cases involving manufacturers frequently resolved basis nature quantity virtually factual legal arguments therefore waste disposed generator site gsks deferred ruling summary judgement motion stayed proportionate liability cleanup costs substantially activity case appellate court rules determined sites referred least one companies pending cases gsks potential liability varies greatly site site cost investigation study remediation sites could time substantial gsk routinely accrues amounts related share liability matters gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp directors statement responsibilities directors statement responsibilities disclosure information auditors relation companys financial statements directors office date report confirmed directors responsible preparing parent company financial statements remuneration report accordance far aware relevant audit applicable law regulations information companys auditors unaware company law requires directors prepare financial statements financial year law directors elected taken steps ought prepare parent company financial statements accordance taken director make aware applicable law united kingdom accounting standards relevant audit information establish companys united kingdom generally accepted accounting practice auditors aware information company law directors must approve parent company confirmation given interpreted accordance financial statements unless satisfied give true provisions section companies act fair view state affairs company period going concern basis preparing financial statements directors required making enquiries directors reasonable expectation company adequate resources continue select suitable accounting policies apply operational existence foreseeable future reason consistently continue adopt going concern basis preparing make judgements accounting estimates financial statements reasonable prudent combined code state regard parent company financial board considers glaxosmithkline plc applies main statements applicable uk accounting standards principles combined code corporate governance followed subject material departures disclosed financial reporting council described corporate explained financial statements governance pages complied provisions except described directors responsible keeping adequate accounting records sufficient show explain companys required listing rules financial services authority transactions disclose reasonable accuracy time auditors considered directors statement financial position company enable ensure compliance relation points combined code parent company financial statements comply specified review companies act also responsible safeguarding assets company hence taking reasonable steps prevention detection fraud irregularities sir christopher gent parent company financial statements year ended chairman st december comprising balance sheet year th february ended st december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended st december included annual report published hard copy printed form made available website directors responsible maintenance integrity annual report companys website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different gsk annual report pp stnemetats laicnanif independent auditors report members glaxosmithkline plc audited parent company financial statements matters required report glaxosmithkline plc year ended st december exception comprise company balance sheet uk gaap nothing report respect following matters related notes ah financial reporting framework companies act requires us report applied preparation applicable law opinion united kingdom accounting standards united kingdom generally accepted accounting practice adequate accounting records kept parent company returns adequate audit respective responsibilities directors received branches visited us auditors parent company financial statements part explained fully directors responsibilities statement directors remuneration report audited set directors responsible agreement accounting records returns preparation parent company financial statements certain disclosures directors remuneration specified law satisfied give true fair view responsibility made audit parent company financial statements accordance received information explanations applicable law international standards auditing require audit uk ireland standards require us comply auditing practices boards ethical standards auditors matters report including opinions prepared reported separately group financial statements companys members body accordance glaxosmithkline plc year ended st december chapter part companies act company passed resolution accordance section purpose giving opinions accept assume companies act senior statutory auditors responsibility purpose person name stated report shown whose hands may come save expressly agreed prior consent writing scope audit financial statements audit involves obtaining evidence amounts disclosures financial statements sufficient give reasonable pricewaterhousecoopers llp assurance financial statements free material chartered accountants statutory auditors misstatement whether caused fraud error includes london assessment whether accounting policies appropriate th february parent companys circumstances consistently applied adequately disclosed reasonableness significant accounting estimates made directors overall presentation financial statements opinion financial statements opinion parent company financial statements give true fair view state companys affairs st december h ave properly prepared accordance united kingdom generally accepted accounting practice h ave prepared accordance requirements companies act opinion matters prescribed companies act opinion part directors remuneration report audited properly prepared accordance companies act information given directors report financial year parent company financial statements prepared consistent parent company financial statements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp company balance sheet uk gaap st december notes fixed assets investments debtors e cash bank current assets creditors amounts due within one year f net current liabilities net assets capital reserves called share capital g share premium account g reserves h profit loss account h equity shareholders funds approved board th february sir christopher gent chairman glaxosmithkline plc registered number gsk annual report pp stnemetats laicnanif notes company balance sheet uk gaap presentation financial statements expenditure description business expenditure recognised respect goods services received glaxosmithkline plc parent company gsk major global supplied accordance contractual terms provision healthcare group engaged creation discovery made obligation exists future liability respect development manufacture marketing pharmaceutical past event amount obligation products including vaccines overthecounter otc medicines reliably estimated healthrelated consumer products investments subsidiary companies preparation financial statements investments subsidiary companies held cost less financial statements prepared going concern provision impairment basis drawn accordance uk generally accepted impairment investments accounting principles uk gaap uk accounting carrying value investments reviewed impairment presentation st december comparative figures indication investment might impaired st december appropriate comparative figures provision resulting impairment review charged reclassified ensure consistent presentation current income statement year concerned year information share based payments permitted companies act profit issuance company subsidiaries grant loss account company presented annual report companys options represents additional capital contributions accounting convention standards company subsidiaries additional investment balance sheet prepared using historical cost subsidiaries results corresponding increase shareholders convention complies applicable uk accounting standards equity additional capital contribution based fair value grant issued allocated underlying grants accounting principles policies vesting period preparation balance sheet conformity generally accepted accounting principles requires management taxation make estimates assumptions affect reported current tax provided amounts expected paid amounts assets liabilities disclosure contingent applying tax rates enacted substantially enacted assets liabilities date balance sheet balance sheet date actual amounts could differ estimates company accounts taxation deferred balance sheet prepared accordance accelerated reason timing differences originated companys accounting policies approved board reversed balance sheet date deferred tax assets described note b recognised extent considered recoverable future taxable profits b accounting policies deferred tax measured average tax rates foreign currency transactions expected apply periods timing differences foreign currency transactions recorded exchange rate expected reverse deferred tax liabilities assets ruling date transaction forward rate hedged discounted forward exchange contract foreign currency assets liabilities translated rates exchange ruling balance financial guarantees sheet date forward rate liabilities relating guarantees issued company behalf subsidiaries held fair value amortised life dividends paid received guarantee dividends paid received included accounts period related dividends actually paid received c operating profit fee relating audit company charged operating profit gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp notes company balance sheet uk gaap fixed assets shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments e debtors amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings f creditors amounts due within one year bank overdraft amounts owed group undertakings creditors company guaranteed debt issued one subsidiary companies receives annual fee subsidiary aggregate company issued guarantees billion debt instruments amount due subsidiary companies relation guarantee fees recovered life bonds disclosed within debtors see note e gsk annual report pp stnemetats laicnanif notes company balance sheet uk gaap g share capital share premium account share ordinary shares p premium number share capital authorised st december st december share capital issued fully paid st january issued share option schemes purchased cancelled st december issued share option schemes st december st december st december number shares issuable outstanding options number unissued shares option st december issued share capital shares held esop trust shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trust disclosed note employee share schemes h reserves profit reserves loss account total st january profit attributable shareholders dividends shareholders ordinary shares purchased cancelled capital contribution relating share based payments st december profit attributable shareholders dividends shareholders capital contribution relating share based payments st december profit glaxosmithkline plc year million million dividends million million gave retained profit million profit million cost shares purchased cancelled nil million million profit loss account reserve st december stood million million million unrealised million gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information shareholder information section includes financial record shareholder information presenting historical information prepared accordance ifrs quarterly trend adopted european union also ifrs issued five year record iasb full product development pipeline section also discusses shareholder return form dividends share product development pipeline price movements provides information shareholders share price dividends nature trading market share price movements dividends shown annual general meeting graphs details price movements dividends investor relations registrar pages taxation information shareholders glossary terms index share price dividends per share us pence us l uu kk ss hh aa rr ee pp rr ii cc ee l uu ss aa dd rr pp rr ii cc ee uu ss l uukk ddiivviiddeennddss ppeerr sshhaarree l uuss ddiivviiddeennddss ppeerr aaddss analysis shareholdings st december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bank new york mellons holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value th february bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date th february number holders shares usa holdings shares number registered holders adr holdings adr certain shares adr held brokers nominees result number holders record registered holders usa representative number beneficial holders residence beneficial holders gsk annual report p noitamrofni redloherahs shareholder information quarterly trend unaudited analysis group results pharmaceutical sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information quarterly trend unaudited analysis group results pharmaceutical sales therapeutic area provided quarter sterling financial year income statement total months q q q q cer cer cer cer cer turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement results major restructuring total turnover cost sales selling general administrative research development operating income operating profit finance income finance costs profit disposal interest associate share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interests profit attributable shareholders adjusted earnings per share pence p p p p p diluted earnings per share pence p p p p p calculation results major restructuring described note financial statements presentation financial statements gsk annual report p noitamrofni redloherahs shareholder information quarterly trend pharmaceutical turnover total group q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix stiefel products pharmaceutical turnover includes copromotion income gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information quarterly trend pharmaceutical turnover usa q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover includes copromotion income gsk annual report p noitamrofni redloherahs shareholder information quarterly trend pharmaceutical turnover europe q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover includes copromotion income gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information quarterly trend pharmaceutical turnover rest world q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antivirals hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia products avandia avandamet bonvivaboniva antibacterials augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover includes copromotion income gsk annual report p noitamrofni redloherahs shareholder information quarterly trend consumer healthcare turnover total group q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlicks ribena consumer healthcare turnover usa q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlicks ribena gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information quarterly trend consumer healthcare turnover europe q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlicks ribena consumer healthcare turnover rest world q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlicks ribena gsk annual report p noitamrofni redloherahs shareholder information five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board pharmaceutical turnover therapeutic area respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials oncology emesis vaccines pharmaceutical turnover geographic area usa europe rest world emerging markets japan asia pacific canada rest world pharmaceutical turnover includes copromotion income consumer healthcare turnover otc medicines oral healthcare nutritional healthcare gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share financial results major restructuring turnover operating profit profit taxation profit taxation pence pence pence adjusted earnings per share adjusted diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted return capital employed return capital employed calculated total profit taxation percentage average net assets year balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity minority interests total equity gsk annual report p noitamrofni redloherahs shareholder information number employees usa europe rest world asia pacific including china japan middle east africa latin america canada rest world manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates day year feb jan dec nov oct sept high low st december federal reserve bank new york ceased publishing noon buying rates bank england pm buying rates used subsequent calculations pm buying rate th february us gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp product development pipeline key inlicense alliance relationship third party bla biological license application month first submission maa marketing authorisation application europe month first regulatory approval maa first eu nda new drug application usa approval letter phase evaluation clinical pharmacology usually conducted volunteers alcr month approvable complete response letter received indicates phase ii determination dose initial evaluation efficacy conducted ultimately approval given subject resolution small number patients outstanding queries phase iii large comparative study compound versus placebo andor established po month eu positive opinion treatment patients establish clinical benefit safety ta fda tentative approval maa ndabla regulatory milestones shown table achieved future submission dates included list achieved regulatory review milestones compound type indication phase maa ndabla biopharmaceuticals monoclonal antibody alzheimers disease monoclonal antibody metabolic disease monoclonal antibody amyotrophic lateral sclerosis domain antibody targeted malignant melanoma multicomponent vaccine apn recombinant human angiotensin acute respiratory distress syndrome converting enzyme iboctadekin doxil il immunomodulator topoisomerase ii ovarian cancer inhibitor iboctadekin rituximab il immunomodulator anticd follicular lymphoma monoclonal antibody otelixizumab anticd monoclonal antibody sc type diabetes monoclonal antibody stroke ii monoclonal antibody rheumatoid arthritis ii monoclonal antibody severe asthma ii arzerra ofatumumab anticd human monoclonal antibody follicular lymphoma relapsed patients ii benlysta belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus ii antibody sc mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ii ofatumumab anticd human monoclonal antibody multiple sclerosis ii arzerra ofatumumab anticd human monoclonal antibody chronic lymphocytic leukaemia first line therapy iii use relapsed patients arzerra ofatumumab anticd human monoclonal antibody diffuse large b cell lymphoma relapsed patients iii arzerra ofatumumab anticd human monoclonal antibody follicular lymphoma refractory patients iii benlysta belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody iv denosumab antireceptor activator nuclear kappa rank bone metastatic disease iii ligand human monoclonal antibody denosumab antirank ligand human monoclonal antibody hormone ablativechemotherapy bone loss cancer patients iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis iii otelixizumab anticd monoclonal antibody iv type diabetes iii syncria glucagonlike peptide agonist type diabetes iii prolia denosumab antirank ligand human monoclonal antibody postmenopausal osteoporosis submitted podec na arzerra ofatumumab anticd human monoclonal antibody chronic lymphocytic leukaemia refractory patients approved pojan aoct cardiovascular metabolic prolyl hydroxylase inhibitor anaemia muopioid receptor inverse agonist obesity sodium dependent glucose transport sglt type diabetes inhibitor sirt activator sarcopaenia also copd psoriasis sirt activator type diabetes also haematologic cancers ii high affinity nicotinic acid receptor hma dyslipidaemia ii agonist oxytocin antagonist premature ejaculation ii gastrinreleasing peptide gpr receptor type diabetes ii agonist glycogen phosphorylase inhibitor type diabetes ii sirt activator type diabetes also copd haematologic cancers ii losmapimod p kinase inhibitor cardiovascular disease also copd pain depression ii retosiban oxytocin antagonist threatened preterm labour ii rilapladib lppla inhibitor atherosclerosis ii avandamet xr ppar gamma agonist metformin type diabetes extended release iii na avandia simvastatin ppar gamma agonist statin type diabetes iii na darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approved aaug alfeb sep avandia ppar gamma agonist prevention disease progression approved aapr ajul gsk annual report p noitamrofni redloherahs product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla infectious diseases plasmodium electron transport chain inhibitor malaria topoisomerase ii inhibitor treatment bacterial infections novel class antibacterial agent treatment bacterial infections relenza neuraminidase inhibitor iv treatment influenza ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivax malaria ii neurosciences crf antagonist depression anxiety dopamine antagonist drug dependency sodium channel blocker bipolar disorder muscarinic acetylcholine agonist dementia nknk antagonist schizophrenia ht antagonist depression anxiety ii histamine h antagonist dementia schizophrenia ii crf antagonist depression anxiety ii orexin antagonist sleep disorders ii ht antagonist dementia ii pro antisense oligonucleotide duchenne muscular dystrophy ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii horizant voltagegated calcium channel modulator migraine prophylaxis ii horizant voltagegated calcium channel modulator neuropathic pain ii losmapimod p kinase inhibitor pain also cardiovascular disease copd depression ii losmapimod p kinase inhibitor depression also cardiovascular disease copd pain ii orvepitant nk antagonist depression anxiety ii almorexant orexin antagonist insomnia iii horizant voltagegated calcium channel modulator restless legs syndrome submitted crfeb retigabine neuronal potassium channel opener epilepsy partial seizures submitted soct soct lamictal xr sodium channel inhibitor epilepsy partial generalised tonicclonic seizures oncedaily approved na ajan lamictal xr sodium channel inhibitor epilepsy partial seizures oncedaily approved na amay oncology akt protein kinase inhibitor cancer braf protein kinase inhibitor cancer pi kinase inhibitor cancer akt protein kinase inhibitor cancer sirt activator haematologic cancers also type diabetes ii mitogenactivated protein kinase inhibitor cancer ii mek thrombopoietin receptor agonist thrombocytopaenia ii foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancers ii cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelated thrombocytopaenia ii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma unresectable disease ii votrient pazopanib multikinase angiogenesis inhibitor breast cancer adjuvant therapy ii votrient pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer first line adjuvant therapy ii votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii revoladepromacta thrombopoietin receptor agonist chronic liver disease induced thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis c induced thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient pazopanib multikinase angiogenesis inhibitor sarcoma iii votrient pazopanib multikinase angiogenesis inhibitor inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor avodart alpha reductase inhibitor reduction risk prostate cancer submitted ssep duodart avodart alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fixed dose combination submitted sdec tajan alpha blocker revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approved podec anov tyverbtykerb egfr dual kinase inhibitor breast cancer first line therapy approved pofeb ajan votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer approved pofeb aoct ophthalmology pazopanib multikinase angiogenesis inhibitor oral agerelated macular degeneration also cancer indications pazopanib multikinase angiogenesis inhibitor eye drops agerelated macular degeneration ii see note financial statements post balance sheet events gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla respiratory immunoinflammation p kinase inhibitor inhaled copd p kinase inhibitor iv acute lung injury acute respiratory distress syndrome chemokine receptor cxcr antagonist copd sirt activator copd psoriasis also type diabetes sarcopaenia ccx ccr antagonist crohns disease pde inhibitor inhaled copd ii muscarinic acetylcholine antagonist copd ii muscarinic acetylcholine antagonist copd ii longacting beta agonist chemokine receptor cxcr antagonist cystic fibrosis ii glucocorticoid agonist asthma ii transient receptor potential vanilloid trpv nonallergic rhinitis ii antagonist intranasal novel glucocorticoid agonist inhaled asthma ii muscarinic antagonist beta agonist copd ii motilin receptor agonist delayed gastric emptying ii antiinflammatory macrolide conjugate oral inflammatory bowel disease ii ccx ccr antagonist crohns disease ii lipoxygenaseactivating protein flap asthma ii inhibitor losmapimod p kinase inhibitor oral copd also cardiovascular disease pain depression ii relovair longacting beta agonist glucocorticoid asthma ii agonist relovair longacting beta agonist glucocorticoid copd iii agonist longacting beta agonist copd iii paediatric vaccines hexavalent combination conjugated neisseria meningitis c haemophilus influenzae vaccine type b diphtheria tetanus pertussis poliomyelitis disease prophylaxis heptavalent combinatio conjugated neisseria meningitis c haemophilus influenzae ii vaccine type b diphtheria hepatitis b tetanus pertussis poliomyelitis disease prophylaxis pneumoniae paediatric recombinant conjugated streptococcus pneumoniae disease prophylaxis ii next generation mosquirix recombinant malaria prophylaxis plasmodium falciparum iii na nimenrix menacwytt conjugated neisseria meningitis groups c w disease prophylaxis iii menhibrix hibmencytt conjugated neisseria meningitis groups c haemophilus submitted saug influenzae type b disease prophylaxis hiberix conjugated paediatric booster haemophilus influenzae type b approved anov aaug synflorix conjugated streptococcus pneumoniae disease prophylaxis infants approved amar na children vaccines alzheimers disease conjugated treatment alzheimers disease cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv disease prophylaxisimmunotherapy nthipneumo recombinant streptococcus pneumoniae haemophilus influenzae disease prophylaxis adults dengue fever attenuated tetravalent dengue fever prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpes zoster prevention ii new generation flu vaccine inactivated split trivalent seasonal influenza prophylaxis elderly iii simplirix recombinant genital herpes prophylaxis iii flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis submitted sjul sjun prepandemic quebec canada arepanrix flu pandemic hn inactivated split adjuvanted pandemic influenza prophylaxis emergency use approved pojan aoct monovalent quebec canada cervarix recombinant cervical dysplasia cancer prophylaxis caused approved asep aoct hpv influenza hn hn inactivated split monovalent pandemic influenza hn prophylaxis approved anov monovalent vaccine quebec emergency use flu pandemic pandemrix hn inactivated split adjuvanted pandemic influenza prophylaxis approved sep flu pandemic monovalent dresden gsk annual report p noitamrofni redloherahs product development pipeline achieved regulatory review milestones compound type indication phase maa ndabla antigen specific cancer immunotherapeutic asci wt recombinant treatment acute myelogenous leukaemia ii magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii dermatology stiefel late stage assets duac low dose clindamycinbenzoyl peroxide gel acne vulgaris iii tazarotene foam retinoid foam acne vulgaris iii calcipotriene vitamin analog mild moderate plaque psoriasis submitted sdec itraconazole tablets oral antifungal onychomycosis submitted smar veltin antibioticretinoid gel acne vulgaris submitted soct hiv viiv healthcare hiv integrase inhibitor hiv infections ii hiv integrase inhibitor hiv infections ii idx nonnucleotide reverse transcriptase hiv infections ii inhibitor pf ccr antagonist hiv infections ii uk nonnucleotide reverse transcriptase hiv infections ii inhibitor selzentrycelsentri ccr antagonist hiv infection use treatment naive patients approved anov optionbased alliances third parties include assets phase phase ii development company disease area phase anacor pharmaceuticals antibacterial chemocentryx inflammatory disease ii concert pharmaceuticals hiv protease inhibitor galapagos autoimmune disease neurosearch neuroscience anxiety pain oncomed pharmaceuticals oncology prosensa therapeutics neuroscience ranbaxy laboratories respiratory theravance gastrointestinal two assets gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information ordinary shares company listed london stock dividends per ads exchange new york stock exchange nyse form table sets dividends per ads us dollars american depositary shares ads details listed debt last five years translated us dollars applicable listed refer note net debt exchange rates share price year us st january high year low year st december increasedecrease dividend calendar quarter exdividend date record date payment date table sets middle market closing prices companys share price increased compares q th february th february th april increase ftse index year q th may th may th july share price th february q th july th july th october q th october th october th january market capitalisation market capitalisation based shares issue excluding financial reporting calendar treasury shares glaxosmithkline st december billion date gsk fifth largest company publication date market capitalisation ftse index results announcements smithkline beecham plc floating rate quarter april quarter july unsecured loan stock quarter october loan stock listed exchange redeemed preliminaryquarter february entirety par ie every loan stock held st june annual reportsummary februarymarch loan stock holders required surrender results announcements certificates compulsory redemption made automatically due time cheque respect results announcements issued london stock exchange redemption value posted th may available news service shortly afterwards issued media made available website sent taxation us securities exchange commission nyse general information concerning uk us tax effects financial reports share ownership set taxation information shareholders gsk publishes annual report shareholder needing full detail report summary document dividends available date publication website summary glaxosmithkline pays dividends quarterly continues increase sent shareholders shareholders may elect receive cash returns shareholders dividend policy dividends annual report writing registrars alternatively shareholders remain essential component total shareholder return may elect receive notification email publication gsk committed increasing dividend longterm financial reports registering wwwshareviewcouk details dividends declared amount payment copies previous financial reports available gsks website dates given note financial statements dividends printed copies obtained registrars uk dividends per share gsk response center usa table sets dividends per share last five years corporate responsibility report year pence late march gsk publish website corporate responsibility report covering performance areas including community investment ethics integrity access medicines rd environment health safety gsk annual report p noitamrofni redloherahs shareholder information nature trading market annual general meeting following tables set periods indicated high queen elizabeth ii conference centre th may low middle market closing quotations pence shares broad sanctuary westminster london stock exchange high low last reported london swp ee sales prices us dollars ads nyse pence per share agm companys principal forum communication high low private shareholders addition formal business quarter ended st march presentation chief executive officer february performance group future development january opportunity questions board chairmen boards committees take questions matters relating december committees november october investors holding shares nominee service september arrange nominee service appointed corporate quarter ended st december representative proxy respect shareholding order quarter ended th september attend vote meeting quarter ended th june adr holders wishing attend meeting must obtain proxy quarter ended st march bank new york mellon enable quarter ended st december attend vote business transacted adr holders quarter ended th september may instruct bank new york mellon way quarter ended th june shares represented adr voted completing quarter ended st march returning voting card provided bank accordance year ended st december instructions given year ended st december year ended st december documents display memorandum articles association company documents referred annual report us dollars per ads available inspection registered office company high low quarter ended st march exchange controls limitations february affecting security holders january currently uk laws decrees regulations restricting december import export capital affecting remittance november dividends payments holders companys shares october nonresidents uk limitations relating september nonresidents uk english law companys quarter ended st december memorandum articles association right quarter ended th september holder vote respect companys shares quarter ended th june quarter ended st march quarter ended st december quarter ended th september quarter ended th june quarter ended st march year ended st december year ended st december year ended st december th february internet information company including details share price available gsks website wwwgskcom information made available website constitute part annual report gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp shareholder information duplicate publications adr programme administrator queries relating receipt duplicate copies gsks publications adr programme administered addressed registrars bny mellon shareowner services po box investor relations pittsburgh pa investor relations may contacted follows wwwbnymelloncomshareowner tel us toll free uk tel outside usa great west road brentford middlesex tw gs email shrrelationsbnymelloncom tel administrators also provide global buydirect direct ads usa purchasesale dividend reinvestment plan adr holders one franklin plaza po box philadelphia pa gsk response center tel us toll free tel us toll free tel outside usa provision details intended registrar invitation inducement engage investment activity companys registrars advice share dealing obtained stockbroker independent financial adviser equiniti limited aspect house spencer road lancing west sussex bn da wwwshareviewcouk tel inside uk tel outside uk equiniti also provides following services nominee dealing account individual savings account isa g laxosmithkline corporate sponsored nominee hareview service share dealing service dividend reinvestment plan share dealing service shareholders may trade shares either held certificates corporate sponsored nominee internet telephone shareview dealing share dealing service provided equiniti financial services limited internet deals log www shareviewcoukdealing telephone deals call inside uk nominee isa service either wwwshareviewcouk dealing call telephone services available monday friday market trading hours glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel gsk annual report p noitamrofni redloherahs taxation information shareholders summary certain uk tax us federal income tax subject us federal income tax net income basis respect consequences certain holders shares adr shares adr holds shares adr capital assets citizens uk usa set complete resident uk uk tax purposes hold analysis possible tax consequences purchase shares purposes trade profession vocation ownership securities intended general guide carried uk branch agency summary holders advised consult advisers respect tax also address tax treatment holders subject consequences purchase ownership shares adr special tax rules banks taxexempt entities insurance consequences state local tax laws usa companies dealers securities currencies persons hold implications current ukus income tax convention shares adr part integrated investment including straddle comprised share adr one us holders adr generally treated owners positions persons directly indirectly underlying shares purposes current usauk double voting stock gsk taxation conventions relating income gains income tax convention estate gift taxes estate gift tax convention taxation dividends purposes us internal revenue code gross amount dividends received treated foreign source amended code dividend income us tax purposes eligible dividend received deduction allowed us corporations dividends adr uk shareholders payable us dollars dividends shares payable sterling summary applies uk resident shareholder holds dividends paid pounds sterling included income shares capital assets us dollar amount calculated reference exchange rate taxation dividends day dividends received holder subject certain exceptions shortterm hedged positions individual eligible uk resident individual shareholders generally subject uk us holder subject us taxation maximum rate income tax full amount dividends paid grossed respect qualified dividends received amount one ninth dividend tax credit tax credit may set individuals income tax liability respect taxation capital gains gross dividend repayable shareholders tax generally us holders subject uk capital gains tax liability less associated tax credit tax year subject us tax capital gains realised sale subsequent tax years additional rate income disposal shares adr gains longterm tax dividends imposed taxpayers whose income capital gains subject reduced rates taxation individual uk resident shareholders corporation holders shares adr held one year taxpayers note dividends paid st july generally entitled exemption corporation tax new information reporting backup withholding rules shareholders doubt position dividends payments proceeds sale shares consult professional advisers adr paid within usa certain usrelated financial intermediaries subject information reporting may taxation capital gains subject backup withholding unless us holder corporation uk shareholders may liable uk tax gains disposal exempt recipient provides taxpayer identification shares adr disposals individuals capital gain number certifies loss exemption occurred taxed flat rate subject availability nonus holders generally subject information reporting exemption relief annual exempt amount backup withholding may required provide corporation taxpayers may entitled indexation allowance certification nonus status connection payments applies reduce capital gains extent received amounts withheld allowed refund gains arise due inflation indexation allowance may reduce credit holders us federal income tax liability provided chargeable gain create allowable loss required information furnished irs inheritance tax estate gift taxes individual shareholders may liable inheritance tax estate gift tax convention us shareholder transfer shares adr tax may charged amount generally subject uk inheritance tax value shareholders estate reduced result transfer way gift disposal less full stamp duty market value uk stamp duty sdrt subject certain exemptions payable issue transfer shares adr custodian gift disposal subject uk inheritance depository rate price issued amount tax us estate gift tax estate gift tax convention consideration provided transferred sale value would generally provide tax paid usa credited transferred consideration tax payable uk sdrt would payable transfer adr uk stamp duty stamp duty payable transfer adr provided uk stamp duty stamp duty reserve tax sdrt subject instrument transfer executed remains certain exemptions payable purchase shares rate times outside uk stamp duty transfer adr purchase price would payable rate consideration us shareholders transfer sale underlying shares would subject certain exceptions result liability uk stamp duty case may summary applies shareholder citizen resident sdrt rate usa domestic corporation person otherwise gsk annual report business review pp governance remuneration pp financial statements pp shareholder information pp glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid shareholders funds shareholders equity share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity glaxosmithkline holds majority shareholding andor exercises control treasury share treasury stock turnover revenue gsk annual report p noitamrofni redloherahs index performance overview interest rate risk management accounting principles policies internal control framework acquisitions disposals inventories adjustments reconciling profit tax operating cash flows investments associates joint ventures annual general meeting investor relations annual remuneration key accounting judgements estimates assets held sale key performance indicators associates joint ventures legal proceedings board major restructuring programmes business review movements equity cash cash equivalents nature trading market chairman ceo summary net debt combined code new accounting requirements commitments nonexecutive director terms conditions committee reports nonexecutive directors remuneration competition notes financial statements consolidated balance sheet operating profit consolidated cash flow statement intangible assets consolidated income statement investments consolidated statement changes equity noncurrent assets consolidated statement comprehensive income noncurrent liabilities consumer healthcare operating income contingent liabilities provisions corporate executive team outlook corporate governance pensions postemployment benefits critical accounting policies performance overview dialogue shareholders pharmaceutical turnover directors senior management post balance sheet events directors senior management remuneration presentation financial statements directors interests principal group companies directors interests contracts product development pipeline directors statement responsibilities products dividends property plant equipment donations eu political organisations eu quarterly trend political expenditure reconciliation net cash flow movement net debt earnings per share registrar economy regulation employee costs related party transactions employee share schemes remuneration policy employees remuneration report exchange rates report directors executive director terms conditions research development finance costs responsibility finance income risk factors financial instruments related disclosures segment information financial position resources share capital control financial review share capital share premium account financial review share options financial statements glaxosmithkline plc prepared share price dividends uk gaap shareholder information financial trends strategy five year record taxation foreign exchange management taxation information shareholders global manufacturing supply total equity glossary terms trade payables goodwill trade receivables governance policy trademarks improving access medicines treasury operations incentive plans us law regulation independent auditors report world economy intellectual property world market gsk annual report head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel g sk changing registered number printed uk paper used annual report production document made post consumer waste pulp bleached using totally chlorine free process feel better live longer glaxosmithkline annual report wwwgskcom